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Summary
Scanned ion beam therapy provides highly tumor-conformal treatments. So far, only tumors
showing no considerable motion during therapy have been treated as tumor motion and dy-
namic beam delivery interfere, causing dose deteriorations. One proposed technique to mitigate
these deteriorations is beam tracking (BT), which adapts the beam position to the moving tumor.
Despite application of BT, dose deviations can occur in the case of non-translational motion.
In this work, real-time dose compensation combined with beam tracking (RDBT) has been im-
plemented into the control system to compensate these dose changes by adaptation of nominal
particle numbers during irradiation. Compared to BT, significantly reduced dose deviations
were measured using RDBT. Treatment planning studies for lung cancer patients including the
increased biological effectiveness of ions revealed a significantly reduced over-dose level (3/5
patients) as well as significantly improved dose homogeneity (4/5 patients) for RDBT. Based
on these findings, real-time dose compensated re-scanning (RDRS) has been proposed that po-
tentially supersedes the technically complex fast energy adaptation necessary for BT and RDBT.
Significantly improved conformity compared to re-scanning, i.e., averaging of dose deviations
by repeated irradiation, was measured in film irradiations. Simulations comparing RDRS to BT
revealed reduced under- and overdoses of the former method.
Zusammenfassung
Strahlentherapie mit gescannten Teilchenstrahlen ermöglicht sehr tumorkonforme Dosisvertei-
lungen. Bis jetzt sind jedoch nur Tumore, die sich während der Bestrahlung nicht merklich
bewegen, behandelt worden. Tumorbewegung und dynamische Strahlapplikation verursachen
Interferenzen, die die resultierende Dosisverteilung beeinträchtigen. Bei einer vorgeschlagenen
Technik zur Abschwächung des Bewegungseinflusses, der bewegungskompensierten Bestrahlung
(BKB), wird der Strahl der Tumorbewegung nachgeführt. Trotz Verwendung dieser Technik kön-
nen bei nichttranslationaler Bewegung Dosisabweichungen auftreten.
In dieser Arbeit wurde dosis- und bewegungskompensierte Bestrahlung (DBKB) implementiert,
das diese Dosisabweichungen durch Anpassung der nominellen Teilchenzahlen in Echtzeit kom-
pensiert. Im Vergleich zu BKB wurde eine signifikante Verringerung von Fehldosierungen ge-
messen. Bestrahlungsplanungsstudien für Lungentumore ergaben eine signifikante Verringerung
der Überdosierungen (3/5 Patienten) und eine signifikante Verbesserung der Dosishomogenität
(4/5 Patienten). Basierend auf dieser Methode wurde dosiskompensierte Mehrfachbestrahlung
(DKMB) vorgeschlagen, das ohne die technisch komplexe schnelle Strahlenergieanpassung, die
für BKB und DBKB benötigt wird, auskommt. Signifikant bessere Konformität von DKMB im
Vergleich zu konventioneller Mehrfachbestrahlung wurde in Filmbestrahlungen gemessen. Au-
ßerdem zeigte DKMB in Simulationen geringere Unter- und Überdosierungen als BKB.
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The development of radiotherapy techniques is mainly driven by the aim to deliver dose distri-
butions as conformal as possible to the tumor. Transferring the high tumor conformity nowadays
achievable in stationary treatments to the treatment of moving tumors is technically challenging.
This work focuses on the treatment of mobile tumors.
Reports about cancer incidence and mortality are published by Husmann most recently for
2006 et al. (Husmann et al., 2010). Data with regard to lung cancer are reported here. For men
as well as for women lung cancer had the third highest incidence rate (47.100 or 11% of all
incidences in Germany). In the same year 210.930 people in Germany died from cancer (19%
or 40.771 cases among them because of lung cancer). Among men lung cancer is even the most
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frequent cause of cancer death in Germany. These numbers indicate a relatively poor prognosis
for lung cancer patients.
The three most common treatment options for cancer are surgery, radiotherapy and
chemotherapy. They are also used in combination. Radiotherapy is the therapeutic applica-
tion of ionizing radiation. It is further divided into internal radiotherapy where the radiation
source is inside the body (e.g., brachytherapy where needles are used to place a radioactive
source directly inside the tumor.) and external radiotherapy where an external source, e.g.,
an accelerator, is employed to deliver radiation to the body. This work will focus on exter-
nal radiotherapy thus if not stated otherwise radiotherapy in the following refers to external
radiotherapy.
The aim of curative radiotherapy is to sterilize a, typically local, tumor by depositing sufficient
dose to the tumor tissue. Ionizing radiation can damage cells. If the damage is severe enough
the cell will subsequently die and a tumor can be sterilized. Not only tumor but also normal cells
are damaged by radiation causing side effects. To reduce the probability for side effects the dose
to the healthy tissue surrounding the tumor should be kept as low as possible. To understand the
rationale for radiotherapy some knowledge concerning the interaction of radiation and matter
as well as radiobiology is indispensable. Thus, these two topics are addressed in this chapter
before different radiotherapy methods are introduced. The last part of this chapter is dedicated
to organ motion in radiotherapy.
1.1 Interaction of radiation and matter
For this work radiation therapy employing ions is investigated. The majority of radiotherapy
treatments is carried out with photons. There are distinctive differences but also similarities in
the physical principles of these two therapy approaches. Thus, the following sections outline
the interaction of these radiation types with matter. An overview about photon interactions
with matter with focus on radiotherapy applications can be found, e.g., in Alpen (Alpen, 1998).
A comprehensive overview concerning the interaction of particles with matter is given by the
Particle Data Group (Nakamura and Particle Data Group, 2010).
1.1.1 Interaction of photons and matter
While passing through matter photons lose energy or are absorbed undergoing different pro-
cesses. The intensity I of a monoenergetic photon beam with initial intensity I0 after passing a
homogeneous material of thickness d can be described by an exponential function:
I = I0 · e
−µd . (1.1)
10
The linear attenuation coefficient µ depends on photon energy and material. In practice the
coefficient is often normalized to the material density ρ to make it independent from the mate-
rial’s physical state. The normalized quantity is called the mass attenuation coefficient. Different
physical processes contribute to the total mass attenuation coefficient. They are outlined in the
following.
Coherent scattering
Coherent scattering, also referred to as Rayleigh scattering, does not transfer energy to the
medium. Electron oscillations are induced by interactions between photons and electrons. The
subsequently emitted photons have the same energy as the incident photons but a different
direction. Hence this process enlarges the angular dispersion of the incident photon beam. The
linear attenuation coefficient σcoherent of this process is negligible for photon energies above
100keV. It thus plays no relevant role for radiotherapy.
Photoelectric effect
The photoelectric effect is the absorption of a photon by an atom. The absorbed photon energy
is released by emission of an electron from one of the atomic shells. The energy Ee− of the
emitted electron equals the photon energy hν reduced by the electron’s binding energy Eb:
Ee− = hν − Eb, (1.2)
where hmeans the Planck constant and ν is the frequency of the impinging photon. The electron
hole in the atomic shell is refilled by an electron from an outer orbital. The energy difference
between the orbitals can be emitted via a photon or an Auger electron. The linear attenuation
coefficient τphotoelectric for the photoelectric process is largest for small photon energies. Its
dependence on photon energy can approximately be described by (hν)−3 but has sharp peaks at
the binding energies of the electron orbitals.
Compton scattering
Compton scattering describes a process where an impinging photon is scattered at a loosely
bound electron and transfers a part of its energy to the electron. The energy of the quasi-free
electron is given by the energy difference of the incident and the scattered photon:
Ee− = hν − hν
′, (1.3)
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where ν and ν ′ mean the frequency of the incident and scattered photon, respectively. The
Compton scattering linear attenuation coefficient σCompton is almost independent of atomic
number and decreases with increasing photon energy. In the energy range between 100keV
and 10MeV Compton scattering is the dominant photon interaction process in soft tissue mate-
rial.
Pair production
Pair production is only possible if the photon energy hν exceeds twice the rest energy of an
electron with mass me: hν > 2mec
2. In the nucleus field of an atom the photon can be absorbed
and an electron positron pair can be produced. While the excitation state of the nucleus remains
unchanged energy and momentum are partly transferred to the nucleus. Since the amount of
energy transferred to the nucleus is very small the energy of the electron Ee− and the positron
Ee+ can be written as:
Ee− + Ee+ = hν − 2mec
2. (1.4)
The linear attenuation coefficient κpair for pair production increases with the square of the
atomic charge: κpair ∝ Z
2. Especially for high energetic photons Z in this equation has to be
corrected for the screening effect taking into account that the atomic charge of the nucleus is
partly screened by shell electrons.
Total mass attenuation coefficient
The total mass attenuation coefficient µ/ρ is the sum of the contributions from the single pro-
cesses:
µ
ρ
=
1
ρ

σcoherent+τphotoelectric+σCompton+ κpair

. (1.5)
The mass attenuation coefficients of water represent biological tissue very well when scaled
to the respective density. The mass attenuation coefficients for water are shown in Figure 1.1
on the facing page.
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Figure 1.1.:Mass attenuation coefficients in water for a range of photon energies. The coeffi-
cients for energy scattered µs/ρ and energy absorbed µa/ρ are shown separately.
The dominating process contributing to energy absorption between 100keV and
10MeV is Compton scattering. Figure from (Alpen, 1998).
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1.1.2 Interaction of ions and matter
The interaction of ions and more generally charged particles with matter has been quantum
mechanically described by Bethe (Bethe, 1930). At moderately relativistic energies the mean
rate of energy loss is given by the Bethe equation:
−

dE
d x

=
4πNez
2
eff
mec
2β2

e2
4πε0
2
1
2
ln

2mec
2β2γ2Tmax
I2

− β2

, (1.6)
where Ne is the absorber’s electron density, zeff is the effective projectile’s charge in units of the
electron charge, c is the vacuum speed of light, β is the projectile speed in units of c, γ is the
relativistic Lorentz factor γ = 1/
p
1− β2, I is the mean excitation energy of the absorber and
Tmax is the maximum kinetic energy that can be transferred per collision. The electron density
of the absorber material can be given either in electrons/cm3 or in electrons/g. In analogy
to introducing the mass attenuation coefficient in Section 1.1.1 the latter definition of electron
density has the advantage of providing a mean energy loss independent of absorber density. The
mean energy loss in that case is given in units of MeVcm2/g. The absorber atoms are excited or
ionized by the energy transferred from the projectiles.
The main dependencies can easily be seen from this equation. The mean energy loss increases
with the square of the projectile’s charge. Going to low projectile energies the mean energy loss
increases with 1/β2. This behavior can be understood if considering that at lower energies the
interaction time a projectile spends in the Coulomb field of an atom increases.
Several corrections need to be applied to this equation if the projectile’s energy is very high
or very low. For therapy applications only the low energy corrections are of interest. In this case
Tmax can be approximated by (Nakamura and Particle Data Group, 2010):
Tmax = 2mec
2β2γ2. (1.7)
The Bethe equation (Equation 1.6) can then be approximated by:
−

dE
d x

=
4πNez
2
eff
mev
2

e2
4πε0
2
ln

2mev
2
I

+ corrections

, (1.8)
where v is the projectile velocity.
The Bethe equation is proportional to z2eff. A more precise description, taking into account
higher orders of zeff is needed especially for low energies. At low energies also atomic bindings
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become relevant. For a detailed discussion of low energy corrections to the Bethe equation the
reader is referred to ICRU report 49 (ICRU, 1993b).
The rationale for the introduction of the effective charge are electron capture processes re-
ducing the projectile’s charge. They are important if the projectile velocity is in the order of the
velocity of the absorber’s outer shell electrons. A correction has been found by Barkas (Barkas,
1963):
zeff = z

1− e−125βz
− 2
3

. (1.9)
Several descriptions for the regime of extremely small projectile energies have been
found (Andersen and Ziegler, 1977; Lindhard et al., 1963).
The energy loss for an ion is shown in Figure 1.2.
Figure 1.2.: Energy loss of ions. The Bethe equation describes the particle in a moderate energy
regime quite well. For low energies electron capture lowering the effective projectile
charge and eventually nuclear interactions become important.
The Bethe equation only describes the electronic energy loss. At extremely low energies ions
lose energy primarily via nuclear reactions. The energy loss for protons (electronic energy loss)
and carbon ions (electronic and nuclear energy loss) can be seen in Figure 1.3 on the next page.
1.1.3 Energy loss of electrons
Both kinds of radiation, photons as well as ions cause ionization of the absorber material. The
produced electrons subsequently lose their kinetic energy when travelling through the material.
Thus, the main energy transfer to the medium for both types of radiation happens via energy
loss of the electrons. Electrons lose energy primarily via ionization and Bremsstrahlung. The
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Figure 1.3.: Energy loss for protons and carbon ions. For carbon ions also the nuclear energy
loss is given that is the dominating process only at extremely low energies. Figure
from (Schardt et al., 2010).
energy loss for both processes depends on the electron energy Ee− . These dependency can be
approximated by (Nakamura and Particle Data Group, 2010):
−

dE
d x

ion
∝ ln
 
Ee−

(1.10)
for ionization as well as
−

dE
d x

BS
∝ Ee− (1.11)
for Bremsstrahlung. Thus, for high energies Bremsstrahlung is the dominating process while
for low energies the energy loss is dominated by ionization events. For the therapeutic energy
regime the main energy loss mechanism for electrons is ionization. The mean free path length
of an electron depends on its energy. It has a minimum around 100eV where the mean free
path length is in the order of 1nm. As will be shown in Figure 1.6 on page 20, this length is
characteristical for the critical target in radiotherapy, the cell’s deoxyribonucleic acid (DNA).
From the approximation in Equation 1.7 on page 14 that is valid for therapeutic energies it
can be seen that the maximal electron energy is only dependent on the projectile velocity and
not e.g., its mass or charge. The maximal electron energy determines the maximal range of the
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electrons and thus the radius of the dose distribution around a particle track. A parameterization
for the track radius has been found by Kiefer and Straaten (Kiefer and Straaten, 1986):
rmax = γT
δ
max, (1.12)
with γ= 0.062µm (MeV/u)−1.7 and δ = 1.7.
Implications for therapeutic beam application
For therapeutic applications the depth dose profile of the therapeutic radiation beam is of out-
standing importance. Photons deposit the highest local dose shortly after entering the material
(see Figure 1.4 on the following page). This can be explained when considering that the photon
intensity is more and more attenuated (see Equation 1.1 on page 10). The short build up period
before reaching the maximal local dose is due to the non-isotropic emission of electrons from
primary ionizations, mainly Compton electrons. They are emitted preferably in beam direction.
In contrast to the photon depth dose profile, ions are characterized by an inverted depth dose
profile where the highest local dose deposition happens at the very end of the particle track, the
so called Bragg-Peak region (see Figure 1.4 on the following page). This can be understood if
taking into account that the mean energy loss increases with 1/v 2 for slow particles and at the
very end of the track decreases again as the effective charge diminishes (see Section 1.1.2).
The interaction mechanism for dose deposition for photons as well as for different ions is
primarily via secondary electrons. Nevertheless the therapeutic efficacy of photons and ions
differs. Moreover the efficacy for different ion types differs. These differences are caused by
the different dose distributions. Differences are apparent on the macroscopic as well as on
the microscopic scale. The macroscopic depth dose profiles for photons and ions have already
been introduced above. The dose distribution of different ions on the microscopic scale have
been simulated by Krämer and Kraft (Krämer and Kraft, 1994). Results of these simulations
are shown in Figure 1.5 on page 19. The key to understanding the differences in the biological
efficacy of different types of radiation lies in radiobiology. Thus, in the following section some
fundamental concepts of radiobiology are introduced.
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Figure 1.4.: Depth dose profiles of photons with different energy spectra compared to carbon
ions at different energies. The dose deposition of ions is concentrated to the distal
end of the particle track, the so called Bragg-Peak. The depth of the Bragg-Peak
can be varied by changing the ion energy. The depth dose distribution for photons
shows an exponential decrease after a build up depending on the energy spectrum
of the photons.
18
Figure 1.5.:Microscopic track structure comparing protons and carbon ions at different energies.
While protons and high energetic carbon ions are sparsely ionizing irradiation carbon
ions at low energies show a high density of ionization events close to the particle
track. Thus, they are considered as densely ionizing radiation. The size of a DNA is
provided for comparison. Figure courtesy of Michael Krämer.
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1.2 Radiobiology
Photons in the energy regime used for radiotherapy as well as ions are ionizing radiation. The
beam’s energy is in both cases mainly deposited by ionization events. The electrons produced
can cause subsequent ionizations. These ionizations damage biological structures like a cell’s
DNA. DNA is the carrier of genetic information in living organisms. It is therefore considered
to be the critical target in radiotherapy. In eukaryotic cells1 most of the DNA is within the cell
nucleus. A single DNA strand comprises the backbone made of phosphate and sugar residues as
well as bases attached to the sugar/phosphate group. In DNA four different bases can be found:
adenine (A), cytosine (C), guanine (G) and thymine (T). The sequence of these bases along a
strand encodes the genetic information. DNA normally appears as a double helix formed by
two single strands. Base pairs are formed along the double helix each consisting of one base
from each of the two strands. Pairs are always formed by either A and T or C and G. Thus,
for an existing single strand the partner single strand to form a double helix is predetermined.
This means there is redundancy in the cell’s genetic information. This redundancy is important
e.g., for repair processes and DNA replication. The genetic information is distributed among
chromosomes, each consisting of one long DNA double helix. The length of the DNA double
strand of a single chromosome can easily be several centimeters. It only fits into a cell nucleus
because it is packed on several structural levels (see Figure 1.6).
Figure 1.6.: Different levels of DNA organization. The DNA double helix is packed on several
levels. Thus, several double strands each with a length in the order of cm fit within
the cell nucleus. Figure from (Hall and Giaccia, 2006).
1 Eukaryotic cells have a cell nucleus e.g., most human cells.
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Several types of DNA damage can be caused by ionizing radiation. The most important ones
are shown in Figure 1.7. The space between the two strands is around 2nm (see Figure 1.6 on
the facing page). Thus electrons with a mean free path on this length scale are most effective in
introducing more double strand breaks. Cells have developed several countermeasures in case
Figure 1.7.: DNA damage caused by ionizing radiation. Single-strand breaks and base damage
are considered as elementary lesions. Two elementary lesions closer than ≈ 20 base
pairs form a simple clustered lesion, e.g., a double-strand break. Complex clustered
lesions (not drawn) are formed by three or more elementary lesions.
DNA damage is detected. Different repair mechanisms are available which are very effective
in repairing especially less complex lesions. In case of irreparable damage a controlled path-
way to self-inactivation, called apoptosis, is activated. In this case the remainder of the cell is
removed by cells of the immune system. Apoptosis usually is the preferred pathway of tumor
cell inactivation in radiotherapy. Other pathways like necrosis, i.e., uncontrolled destruction
of the cell, typically cause more severe reactions of the immune system, e.g., inflammations.
Cells are typically effective in repairing elementary lesions (i.e., single-strand breaks and base
changes) or even double-strand breaks, i.e., two single-strand breaks within ≈ 20 base pairs.
As more complex damages2 are involved, the probability for induction of an irreparable lesion
eventually leading to cell death is increased. At the same dose level the probability to induce
complex damages varies depending on the local energy deposition pattern. The critical measure
is the linear energy transfer (LET). It is defined as the energy locally deposited per unit path
2 A complex damage is defined as a damage comprising three or more elementary lesions.
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length and typically given in keV/µm. Photons, protons as well as fast ions3 are considered to
be sparsely ionizing radiation with a low LET while slow ions are considered densely ionizing
radiation with a high LET. To quantify an increased biological effectiveness the measure relative
biological effectiveness (RBE) is introduced. It is defined as follows:
RBE=
Dphoton
Dtest

iso-effect
(1.13)
where Dphoton denotes the absorbed photon dose necessary to obtain a certain iso-effect and
Dtest is the absorbed dose of a test radiation, e.g., ions at a defined energy, leading to the same
iso-effect.
Assuming a given fluence of one ion species, with increasing LET the probability to induce cell
killing4 increases but at the same time also the locally deposited dose increases. For LET values
below a certain threshold the increase in dose is over-compensated by the increased cell killing.
Therefore, for this LET regime the RBE increases with increasing LET. Around this threshold,
typically lying between 100keV/µm and 200keV/µm, the deposited dose is most effective in
inducing cell killing while at even higher LET the increase in local dose deposition outweighs
the additional cell killing. The RBE consequently decreases again with further increasing LET.
This effect is known as overkill effect. The RBE dependence on LET for carbon ions is shown in
Figure 1.8 on the next page.
The RBE dependencies are complex. Besides the introduced dependency on LET the RBE
also depends on other factors like projectile, tissue or cell type, end point and dose level. The
dependence on end point and dose is illustrated in Figure 1.9 on the facing page.
1.2.1 Radiobiological modeling
For radiotherapy a quantitative understanding of the biological radiation response is needed. A
complete simulation of dose deposition and subsequent biological processes eventually leading
to cell death is currently not achievable. This is due to the huge complexity and the limited
understanding of the vast amount of biological processes. Thus, current radiotherapy relies
on models. After introducing the linear-quadratic model often used to describe cell survival
curves (Hall and Giaccia, 2006), one radiobiological model, the local effect model (LEM), de-
veloped by Scholz et al. (Scholz and Kraft, 1996), will be introduced.
3 If not stated otherwise here and in the following ions refers to ions of interest for external radiotherapy. These
are usually elements of the periodic table’s first two periods.
4 The following is also true for many other end points.
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Figure 1.8.: RBEα dependence on LET. RBEα denotes the initial RBE. A rise of the RBE with in-
creasing LET can be seen but around an LET of 200keV/µm, the RBE peaks and
drops again if LET is further increased. The xrs5 cell line is a repair deficient cell line.
Figure from (Schardt et al., 2010). Experimental data from (Weyrather et al., 1999).
Figure 1.9.: Typical dose response curves for photon and heavy ion irradiation. Depending
on the end point (here survival of 0.1 and survival of 0.01, respectively) the RBE
changes. Thus, the RBE for high doses is lower than the RBE for small doses. Figure
from (Schardt et al., 2010).
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Linear-quadratic model
The dose response for cell killing is often described using an exponential function with a linear-
quadratic exponent. For high doses experimental data suggest that a purely linear-quadratic
model overestimates the cell killing. Some models thus introduce a threshold dose Dt above
which the response curve is purely exponential:
S =
eαD+βD
2
: D ≤ Dt
Ste
s(D−Dt) : D > Dt ,
(1.14)
where α and β are the linear-quadratic parameters, St is the survival at Dt and s is the curve’s
slope at Dt . The linear-quadratic model with this extension will in this work be referred to as
the linear-quadratic-linear model. Depending on the chosen parameters the dose response curve
exhibit a more or less pronounced shoulder shape 1.10 on the next page.
Local effect model
The basic idea of LEM is to separate the physical part and the biological part. As mentioned
above the biological part is very difficult to simulate. LEM includes the biological effects by
taking dose response curves for photon radiation into account. LEM assumes that the biological
response to a local dose deposition does not depend on the primary radiation quality (e.g., pho-
ton or ion radiation). This assumption is justified by the final interaction mechanisms described
in Section 1.1. For photons as well as ions the final step in dose deposition is interaction of
secondary electrons with the target material. The different response to the same overall dose
apparent when introducing the RBE formalism thus has to be caused by differences in local dose
deposition. The local dose distribution is purely physical and can be modeled reasonably well.
For the calculation of cell survival the cell nucleus containing the DNA is the critical structure.
LEM models the local dose deposition in small subvolumes of the cell nucleus based on Monte
Carlo simulations and determines the survival level by integration over the nucleus’ volume tak-
ing into account photon dose response curves. These curves need to be extrapolated as in ion
radiation local doses close to the ion track can be extremely large.
Different improvements have been implemented to improve LEM. One main extension was the
consideration of clustered single strand breaks effectively leading to additional double strand
breaks (Elsässer and Scholz, 2007). A further development was the implementation of an energy
dependent track radius leading to a further improved description of measured data. The most
recent LEM implementation is based on an analysis of the distribution pattern of double strand
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Figure 1.10.: Dose response curves after x-ray irradiation. Different cell lines exhibit different
combinations of α and β values. Thus, the shape of the dose response curve differs.
Repair deficient cell lines, here xrs5, show a nearly straight survival curve while
other cell lines show a more pronounced shoulder. Figure from (Schardt et al.,
2010). Data from (Weyrather et al., 1999).
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breaks. These distributions are analyzed with respect to their proximity (Elsässer et al., 2010;
Friedrich et al., 2012). Thus, this approach provides a more mechanistic description of the
biological effects in response to ion radiation.
1.2.2 Radiation response
There are several factors modifying the radiation response. A genetic predisposition is sug-
gested, e.g., by the study of Flint-Richter and Sadetzki (Flint-Richter and Sadetzki, 2007). Other
factors include cellular status like oxygenation level and cell cycle state. An assessment of these
factors and a prediction of the individual sensitivity is very challenging and currently not in
clinical routine for radiotherapy.
Fractionation
Another factor modifying the radiation response is depending on the delivery scheme. When
the therapeutic dose is not delivered at once but within a fractionation scheme, the biological
response is altered.
Applying the linear-quadratic model the effect E, e.g., logarithmic cell killing, of a single dose
D can be written as:
E1 = αD+ βD
2. (1.15)
Typically one fraction is applied per day. After one day repair processes can be considered to
be completed. In that case for a fractionated treatment with n fractions and fraction dose d the
effect En can be written assuming n independent treatments:
En = n

αd + βd2

(1.16)
= α (nd)

1+
d
α/β

. (1.17)
The biologically effective dose (BED) is often used to compare different fractionation schemes
and is defined as:
En
α
= nd

1+
d
α/β

. (1.18)
Equation 1.15 can be written as:
E1
α
= D

1+
D
α/β

. (1.19)
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Figure 1.11.: Dose response for late responding tissue and early responding tissue. Late respond-
ing tissue shows a more pronounced shoulder as the α/β is relatively small and thus
the quadratic dose term is important already at low doses. Tumors typically behave
like early responding tissue. Figure from (Hall and Giaccia, 2006).
Comparing Equation 1.19 on the preceding page and Equation 1.18 on the facing page, it can
be easily seen that the biological effect of a dose D = nd is always largest for a single dose ap-
plication. Thus, fractionation results in a smaller effect after application of the same cumulative
dose. Depending on the shape of the dose response curve the effect of fractionation is more or
less pronounced.
Tissue effects can be categorized in early effects that are typically already apparent during
the course of radiotherapy and late effects that appear after months or even years. Survival
of tumor cells is clonogenic survival, i.e., a tumor cell is considered dead if it is not able to
proliferate5. Clonogenic survival tends, like early responding tissue, to exhibit a large α/β
ratio implicating a less pronounced bending. Organ functioning, in contrast, is rather related
to functional survival showing a more pronounced shoulder in radiation response due to a
relatively small α/β ratio (Hall and Giaccia, 2006). Thus, normal tissue surrounding the tumor
and organs at risk (OARs) close to the tumor typically exhibit a relatively small α/β . This is
illustrated in Figure 1.11. The main rationale for fractionation is the differential response to
fractionation of typical tumor compared to typical normal tissues and OAR: Late responding
5 Precisely, cells able to form colonies with more than 50 cells are considered clonogenic survivors.
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tissue profits stronger from fractionation than early responding tissue and most tumors do. This
tendency for different α/β ratios can already be seen from Equation 1.18 on page 26. Thus,
fractionation allows to reduce the probability for late effects while largely maintaining tumor
response.
1.3 Photon therapy
After the discovery of x-rays by Röntgen in 1895 the first photon treatment was already con-
ducted in 1897 (Freund, 1897). First photon treatments used x-ray tubes and radioactive
sources (e.g., radium sources) providing photons in the keV range. Increasing the photon en-
ergy allows more effective treatment of deeper seated tumors (see photon depth dose curves in
Figure 1.4 on page 18). The effort to increase photon energy lead to the introduction of 60Co
sources emitting photons with 1.17MeV and 1.33MeV and eventually linear accelerators. In
these linear accelerators electrons are accelerated and hit a target. The emitted bremsstrahlung
is used for therapy. State of the art are medical linear accelerators delivering photon spectra in
the megavolt (MV)6 regime. Until today, for the majority of radiotherapy treatments photons
are used.
Not only the photon energy spectrum but also the application technique itself has a major
impact on tumor conformity. The medical advances in photon therapy have been reviewed by
Bucci et al. (Bucci et al., 2005). In conventional photon therapy treatment fields could only
be conformed to the lateral tumor shape, resulting in substantial dose delivery to healthy tis-
sue. The introduction of 3D imaging techniques, e.g., computed tomography (CT) and positron
emission tomography (PET), allowed to assess the tumor shape in all three dimensions and sub-
sequently better conform the photon fields to the 3D contour of the tumor. In combination with
dedicated treatment planning algorithms, this method is called 3D conformal therapy. However,
the amount of conformity was still limited as only single static fields were used.
Intensity modulated radiotherapy (IMRT) has strongly improved achievable dose distributions
in photon therapy (IMRT Collaborative Working Group, 2001). In IMRT, many small beamlets
with varying intensities are delivered from different beam angles. The beamlets are shaped
by multileaf collimators (MLC). A sketch of an intensity modulated beam application using
a MLC is shown in Figure 1.12 on the facing page. This technique introduces new degrees
of freedom that lead, in combination with dedicated treatment plan optimization, to much
conformer dose distributions with superior OAR sparing if compared to conventional and 3D
conformal photon therapy. The dosimetric advancement of IMRT in comparison to conventional
therapy is exemplary shown in Figure 1.13 on the next page. Different implementations of
IMRT are available. Most commonly, the linear accelerator is mounted on a gantry that allows
to deliver the treatment beam from different angles.
6 For linear accelerators the photons energy spectrum is usually described by a voltage unit not an energy unit.
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Figure 1.12.: Principle of IMRT. The multileaf collimator is used to conform the photon field to
the target extent. Different positions of the single leafs allow for an intensity mod-
ulated radiation field. Figure from (Schlegel and Mahr, 2001).
Figure 1.13.: Comparison of dose distributions for conventional therapy using two treatment
fields and IMRT therapy. In conventional therapy treatment fields can only be con-
formed to the lateral tumor extent. Field intensities are constant. IMRT in contrast
uses more field angles and varying intensities per field. The dose distribution can
be adapted to the tumor shape in all three dimensions. Clearly superior tumor con-
formity can be achieved with IMRT. Tumor coverage is achieved for both techniques
but normal tissue sparing is much better for IMRT (see the iso dose lines). Figure
from (Bucci et al., 2005).
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Two particular implementations are introduced here as they will be of importance later in this
work.
TomoTherapy TomoTherapy is an implementation where the linear accelerator for IMRT treat-
ment is mounted on a ring (Mackie et al., 1993). Like a CT, the accelerator can move
around the patient enabling beam delivery from all possible beam angles (360°). Together
with a linear couch motion, spiral beam delivery can be achieved. Thus, also large treat-
ment fields can be irradiated at once. The system can be seen in Figure 1.14 on the facing
page.
Cyberknife The Cyberknife system comprises a linear accelerator mounted on a robotic
arm (Kilby et al., 2010). Thus, this system offers a large freedom in the choice of treat-
ment ports. Of special importance for the treatment of moving tumors is the Synchrony
extension of the Cyberknife system. The Synchrony system provides adaptation of the ther-
apeutic beam position to the changing tumor position. Two basic requirements have to be
met for fast beam adaptation. A flexible beam delivery unit allowing for fast beam posi-
tion adaptations and a motion monitoring system assessing tumor motion. The flexibility
of beam delivery is guaranteed by the robotic arm. Motion monitoring is achieved by a
combination of external motion monitoring using a camera system and infrared markers
as well as internal motion monitoring using x-ray fluoroscopy. The system is shown in
Figure 1.15 on the next page. Tumor motion as well as its monitoring and techniques to
mitigate its influence will be discussed in more detail in Section 1.5.
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Figure 1.14.: TomoTherapy treatment unit. The system comprises a linear accelerator mounted
on a ring around a movable patient couch. The setup is comparable to a CT mount-
ing. Full 360° treatment angles are available. Together with couch motion spiral
beam delivery can be used, e.g., for large treatment fields. Figure courtesy of Ac-
curay Inc.
Figure 1.15.: Cyberknife Synchrony system. The linear accelerator is mounted on a robotic arm.
Motion monitoring for mobile tumors is performed with a combination of external
imaging using infrared markers and a camera system (ceiling-mounted, left device)
and internal imaging using x-ray fluoroscopy (two ceiling mounted x-ray tubes and
two detector panels integrated to the floor). Figure courtesy of Accuray Inc.
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1.4 Ion therapy
Even though photon therapy techniques nowadays are very advanced the unfavorable photon
depth dose profile limits achievable tumor conformity. Ion beams, in contrast, have a finite
range with the highest local energy deposition at the very end of the particle range, the Bragg
peak, which depth can be controlled via the particle energy (see Figure 1.4 on page 18).
Based on this physical advantage Wilson proposed already in 1946 the usage of ions for tumor
treatment (Wilson, 1946). It is remarkable that state of the art concepts like increased biological
effectiveness, range modulator wheels, and carbon therapy have already been mentioned by
Wilson. The first ion beam therapies were already performed in 1954 at Berkeley Lab (Tobias
et al., 1958). First treatments have been performed using protons but from 1957 on also other
ions (primarily Helium ions) have been employed exploring the efficacy of heavier ions.
As in photon treatment, also in ion treatment several improvements lead to more conformal
dose depositions. Improvements concern, e.g., the choice of the projectile ions as well as more
sophisticated beam delivery methods.
1.4.1 Projectile ion
Already in Berkeley heavier ions have been used for therapy. Heavier ions provide preferable
physical as well as biological properties. Physical properties include reduced lateral scattering
of heavier ions. According to Molière (Molière, 1948) the scattering angle’s root mean square
is approximately inversely proportional to the projectile’s momentum. Thus, the use of heav-
ier ions like carbon enables sharper lateral penumbras of the dose distribution. These are of
particular importance if an OAR is close to the tumor.
Besides this physical advantage, heavier ions also provide increased biological effectiveness.
This increased effectiveness is caused by a different track structure of heavier ions. While pho-
tons as well as protons and fast heavier ions are considered as sparsely ionizing low LET radi-
ation, heavier ions at low energies are densely ionizing high LET radiation. In Section 1.2 the
relation between RBE and LET has been described. When choosing the therapeutic ion species,
ions for which the Bragg peak region coincides with the most effective LET region, are to be
preferred (Krämer et al., 2003). Due to the z2eff dependence of the Bethe equation (see Equa-
tion 1.6 on page 14), light ions reach the most effective LET only in the very distal part of the
Bragg peak resulting in a relatively low average RBE in the spread out Bragg peak (SOBP). Very
heavy ions in contrast reach the most effective LET region already in the entrance channel.
It is important to realize that an increased biological effectiveness is only advantageous for
therapy if it is differential, i.e., if the increase is more pronounced in the tumor tissue than in
the normal tissue. While for protons only the very distal Bragg exhibits an elevated RBE and
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thus the average RBE of the SOBP is virtually the same as for the plateau region7 ions heavier
than oxygen have the highest RBE in the proximal part of the Bragg peak or, for even heavier
ions, already in the plateau of the depth dose distribution (Krämer et al., 2003).
Carbon ions are biologically most effective in the Bragg peak region and thus physical and
biological advantages coincide. For a typical treatment situation with carbon ions the average
LET in the tumor region is larger than the LET in the entrance channel where typically normal
tissue is affected.
Besides the choice of the projectile ion, also the application technique has a large influence
on resulting dose distributions.
1.4.2 Application technique
First treatments in Berkeley were performed by shooting the proton beam through the complete
patient head (Tobias et al., 1958). Passive beam delivery uses the Bragg peak region of the
beam for dose coverage of the tumor (Koehler et al., 1975, 1977). In this technique, the beam
delivered by the accelerator is scattered. This broad beam’s energy spectrum is subsequently
widened by a range modulator, e.g., a modulator wheel8 or a ridge filter, to deliver a SOBP
covering the tumor extent (typically plus margins) in longitudinal direction. The weights of the
different energies in the SOBP are optimized such that a typically constant (RBE weighted) dose
level is delivered to the whole SOBP. Conformity to the distal tumor border is achieved by a
compensator while a collimator is used for collimation in the lateral plane. The proximal border
of the tumor can not be directly shaped in this approach as the width of the SOBP is fixed by
the energy modulator to the largest longitudinal tumor extent. For lateral positions where the
longitudinal tumor extent is smaller the target dose is pulled to the tissue proximal to the target.
A sketch of a static delivery system is shown in Figure 1.16 on the following page
One of the major improvements was the introduction of beam scanning (Haberer et al., 1993;
Pedroni et al., 1995). In contrast to passive beam delivery techniques, beam scanning is consid-
ered as active beam delivery. Instead of passive beam shaping material a large number of small
pencil beams (full width at half maximum (FWHM) typically several mm) delivered by an ac-
celerator are used to conform the dose distribution to the tumor extent. These pencil beams can
be positioned laterally by magnetic deflection or patient couch movement as well as in depth by
choosing a suitable energy. An example of a scanning delivery system is shown in Figure 1.17
on page 35.
In longitudinal direction the tumor is divided into iso-energy slices with, e.g., 3mm|H2O spac-
ing. An iso-energy slice (IES) is the entity of beam positions with a common energy. Obviously
7 Clinically, a constant proton RBE of 1.1 is used.
8 A modulator wheel is a fast rotating wheel with variable thickness. Depending on the wheel position the energy
adaptation changes resulting in a broadening of the energy spectrum.
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Figure 1.16.: Passive beam delivery system. The thin beam delivered by the accelerator is broad-
ened by a scattering system. The width of the SOBP can be adjusted by the range
modulator (here a ridge filter) widening the energy spectrum. A range shifter shifts
the spectrum to the desired depth. Lateral and distal conformity are achieved by a
collimator and a compensator, respectively. The proximal field border can not be
shaped as the width of the SOBP is fixed by the range modulator. Thus, the dose
distribution is pulled to the proximal part of the target volume. The transversal
beam shape as well as the longitudinal dose distribution are additionally shown.
Figure from (Schardt et al., 2010).
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Figure 1.17.: Scanning beam delivery system. Two pairs of scanning magnets are employed to
scan the pencil beam over one IES. A beam monitor system feeds beam position
and intensity back to the TCS. The TCS steers the magnets via their power supplies
to switch to the next beam position as soon as the nominal particle number from
the treatment plan is reached. The beam energy matching the next IES to form
the SOBP is actively requested from the synchrotron control system. Scanning sys-
tems are also used in combination with cyclotrons. In this case, energy changes
are typically achieved by inserting absorber material into the beam line. Figure
from (Schardt et al., 2010).
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the definition of IES depends on the field angle. The IES concept takes into account particle
range instead of geometrical depth. Hence positions belonging to the same IES might have very
different geometrical depths but rather share the same radiological or water equivalent depth.
The water equivalent depth of a position given in mm|H2O is the depth particles stopping at
that position would have reached in water. By overlaying beams with different energies a SOBP
can be formed for scanned beam systems. An example is shown in Figure 1.18. Lateral tumor
Figure 1.18.: SOBP for a scanned beam. Several Bragg peaks with different energies are overlaid
to deliver a flat RBE weighted dose to the target area. Also shown is the corre-
sponding absorbed dose that is not flat in the target area as the RBE is not constant
throughout the SOBP but depends e.g., on LET. Figure courtesy of Michael Scholz.
conformity within one iso-energy slice is achieved by overlaying many pencil beams of the same
energy. The Bragg Peak of each pencil beam represents one beam position.
Different scanning flavors exist, e.g., spot scanning (Pedroni et al., 1995) and raster scan-
ning (Haberer et al., 1993; Furukawa et al., 2007). While in spot scanning the beam is switched
off between two beam positions raster scanning works in continuous mode, i.e., beam is not
switched off between beam positions. Compared to their FWHM the spacing of beam positions
is smaller for raster scanning what makes dose distributions more robust. Lateral deflection
relative to the patient is typically achieved by magnets or a combination of magnets and patient
couch motion. The SOBP covering the tumor extent in the longitudinal direction is formed by
overlaying many IESs. Scanning methods allow improved tumor conformity when compared to
passive beam delivery as each IES can be laterally shaped. Especially the proximal tumor border
coverage is typically more conformal as the width of the SOBP for scanning techniques is not
fixed for the whole lateral tumor extent.
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1.4.3 Treatment planning
The goal of treatment planning is to find machine parameters that ensure delivery of the pre-
scribed dose to the tumor. At the same time, OAR dose constraints have to be met. While this
basic principle is true for all kinds of radiotherapy techniques, in the following the focus will be
on scanned particle beam techniques.
Scanning techniques in particle treatments have a large number of degrees of freedom. Typical
treatment plans can easily comprise several thousand or ten thousand beam positions. For
each beam position, an individual particle number to deliver has to be determined such that a
predescribed, typically flat, overall (RBE weighted) dose distribution to the tumor is obtained.
Treatment planning is based on patient imaging data. In particle therapy, CT data is used be-
cause it represents photon attenuation that can be converted into water-equivalent depth. Other
imaging methods like magnetic resonance imaging (MRI) or PET provide complementary infor-
mation and are often used to support, e.g., tumor delineation. Once the images are obtained,
tumor and OARs are delineated and tumor dose as well as OAR dose constraints are defined. For
tumor delineation, different volumes are defined by the international commission on radiation
units and measurements (ICRU) in different reports. ICRU report 50 defines the gross tumor
volume gross tumor volume (GTV), the clinical target volume (CTV), and the planning target
volume (PTV) for photon treatments as follows (ICRU, 1993a):
GTV "The Gross Tumor Volume (GTV) is the gross palpable or visible/demonstrable extent and
location of the malignant growth."
CTV "The Clinical Target Volume (CTV) is a tissue volume that contains a GTV and/or subclinical
microscopic malignant disease, which has to be eliminated. This volume thus has to be
treated adequately in order to achieve the aim of therapy: cure or palliation."
PTV "The Planning Target Volume (PTV) is a geometrical concept, and it is defined to select ap-
propriate beam sizes and beam arrangements, taking into consideration the net effect of all
the possible geometrical variations and inaccuracies in order to ensure that the prescribed
dose is actually absorbed in the CTV."
These three volumes are shown for a lung cancer patient in Figure 1.19 on the next page.
In ICRU report 62, a supplement to report 50, the ICRU defined the internal margin
(IM) (ICRU, 1999):
IM "The Internal Margin, commonly asymmetric around the CTV, is intended to compensate
for all movements and all variations in site, size, and shape of the organs and tissues
contained or adjacent to the CTV. They may result, e.g., from respiration, different fillings
of the bladder, different fillings of the rectum, swallowing, heart beat, movements of the
bowel."
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Figure 1.19.: CT slice of a lung tumor patient. GTV (black), CTV (red), and PTV (blue) contours
delineated. Definitions of GTV, CTV, and PTV are given in the Section 1.4.3.
Based on this definition, the term internal target volume (ITV) is commonly used to describe
the volume encompassing CTV and IM.
Another report addressing specifically proton therapy has been published by the ICRU (ICRU,
2007). As far as volumes are concerned the concepts of GTV and CTV remain unchanged as
they are independent on modality. The PTV in contrast does depend on modality. Especially the
longitudinal margin is crucial for proton (and other ion) therapy due to their depth dose profile.
The distinctive Bragg peak structure implies an increased susceptibility to range uncertainties
if particle dose distributions are compared to photon dose distributions. Drawing of the ITV
contour is considered to be optional. It might not be drawn but has to be taken into account
when drawing the PTV (ICRU, 2007).
After delineation, the number of fields as well as the field angles are chosen to spare OARs as
well as possible. Because of their superior depth dose distribution, for particle treatments often
two fields are sufficient.
In the next step the number of particles to be delivered at each beam position is opti-
mized. Dedicated treatment planning software has been developed for that purpose. At
GSI Helmholtzzentrum für Schwerionenforschung GmbH (GSI) TReatment planning for Par-
ticles (TRiP) was developed (Krämer and Scholz, 2000; Krämer et al., 2000). Optimization
has to include RBE calculation. As already mentioned, RBE depends on many different factors.
Within TRiP, LEM (see Section 1.2.1) is used for RBE modeling (Krämer and Scholz, 2006).
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Figure 1.20.: Comparison of dose distributions achievable with IMRT (left) and scanned carbon
ions (right), respectively. While both methods show a homogeneous target cov-
erage the integral dose delivered to the patient is larger with IMRT. Especially the
dose level to organs at risk close to the target e.g., the brain stem is superior if
scanned carbon ions are used.
1.4.4 GSI particle therapy pilot project
At GSI a pilot project using carbon radiotherapy has been conducted between 1997 and 2008.
The pilot project has been conducted in a collaboration between GSI, Heidelberg university hos-
pital, the German cancer research center (DKFZ), and the research center Rossendorf/Dresden.
In total 440 patient treatments have been performed. Mostly, tumors in the head and neck re-
gion have been treated. The usual fractionation scheme has been 20 fractions on consecutive
days. Later also prostate and spinal cord tumors have been treated. The treatments have been
performed using a dedicated raster scanning system (Haberer et al., 1993). Treatment planning
was performed with TRiP (Krämer and Scholz, 2000; Krämer et al., 2000).
For online verification of dose delivery, an in-beam PET system has been developed (Enghardt
et al., 2004). In nuclear reactions between projectile ions and target atoms β+ emitters are
produced. By reconstructing the vertices of consecutive e+ − e− annihilations, the expected
dose distribution could be verified after each fraction.
A comparison of dose distributions achievable with IMRT versus scanned carbon ions is shown
in Figure 1.20.
Based on the successful pilot project the Heidelberg Ion-Beam Therapy Centre (HIT) has
started clinical operation in 2009 (Haberer et al., 2004; Combs et al., 2010). The centro
nazionale di adroterapia oncologica (CNAO) in Pavia, Italy started patient treatments with
scanned ions in October 2011 (Amaldi, 2004).
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1.5 Organ motion in radiotherapy
The organs of a patient are subject to temporal changes. That is not only true for the organs
but also for a patient’s tumor. As treatment planning is, like described above, based on acquired
imaging information, changes in the patient anatomy not accounted for in treatment planning
are likely to impair the quality of the delivered dose distribution compared to the optimized
treatment plan. Hence, assessing and, if necessary, considering organ motion in treatment
planning is an essential task.
In the following different types of organ motion are described. The sources for organ motion
can be categorized in patient positioning related motion and motion caused by the patient’s
anatomy or physiology. The latter cause of motion is commonly subdivided with regard to its
time scale into interfractional and intrafractional motion. An overview is given by Langen and
Jones (Langen and Jones, 2001).
1.5.1 Types of organ motion
Different types of organ motion are shown in Figure 1.21 and will be described in the following.
Figure 1.21.: Different types of organ motion. In a) a lung tumor is shown in two extreme mo-
tion states. This is an example for intrafractional motion. In b) two CT scans of a
prostate patient are compared. Interfractional position changes are visible. In c)
density variations between two CT scans are shown. Figure from (Engelsman and
Bert, 2011).
Patient positioning related motion
Patient positioning related motion can occur on the interfractional as well as the intrafractional
time scale. Patient positioning introduces an uncertainty of tumor position with respect to the
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treatment field and can thus be considered as organ motion. While the daily variations in patient
positioning between different fractions are typically random uncertainties, other uncertainties
like different positioning in imaging and therapy (e.g., sitting versus lying patient position) can
also introduce systematic displacements. Although typically patient fixation systems are applied
residual patient movement within one fraction might play a role on the intrafractional time
scale.
Interfractional motion
Interfractional motion introduces anatomic changes between different fractions of the treatment
course while it is negligible within one fraction. Thus, the time scale of interfractional motion
typically is hours or even days.
One type of interfractional motion is caused by physiological processes like gut and bladder
filling or bowel movement. Organs subject to this kind of interfractional motion are, e.g., organs
of the abdomen like prostate, intestine, and bladder.
Changes in the breathing motion pattern between fractions are observed. Sonke et al. report
that the motion trajectory of lung tumors is often reproducible but the base line of the motion
might be subject to considerable interfractional changes (Sonke et al., 2008).
Not only position or motion of the tumor but the extent of the tumor entity itself might be
subject to changes during the course of radiotherapy. Tumor shrinkage has been observed e.g.,
for lung tumors by Erridge et al. (Erridge et al., 2003).
Density differences between different fractions are not necessarily due to organ motion but
may e.g., be caused by air cavities being filled with liquid. Especially for particle beams these
changes are of importance as they have a large impact on beam range (see Figure 1.21 on the
facing page).
Intrafractional motion
Intrafractional motion plays a role on a much shorter time scale compared to interfractional
motion. Typical time scales are seconds or minutes. The main causes of intrafractional motion
are breathing and heart beat. Lung tumors and organs close to the diaphragm are especially
prone to this kind of organ motion.
The amount of intrafractional lung tumor motion has been investigated by Liu et al. (Liu
et al., 2007). They found that lung tumor motion is most prominent in the superior-inferior
(SI) direction. The average motion amount in their patient cohort was found to be 0.50 cm,
0.12 cm, and 0.21 cm in the superior-inferior (SI), lateral, and anterior-posterior (AP) direction,
respectively. Identified factors significantly influencing the motion amount in this study were
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T staging of the tumor (Edge et al., 2009), GTV size, and fractional tumor location in the SI
direction.
1.5.2 Motion acquisition
4DCT
Like described in section 1.4.3, typically CT information is used for particle therapy treatment
planning. If the tumor site is subject to intrafractional motion, acquisition of a CT leads to a
blurred image. More precise information about the moving tumor is provided by time resolved
computed tomography (4DCT) (Low et al., 2003; Rietzel et al., 2005b). For this technique a
motion signal is recorded during the CT scan. The motion trace is divided into a set of motion
states each representing a different anatomical state within the (cyclic) patient motion. CT
image projections are sorted into different bins according to the motion state they have been
acquired in. Thus, a series of quasi-static 3D images each representing a different motion state
of the whole motion cycle can be reconstructed.
Motion monitoring
The assessment of intrafractional motion is relevant, e.g., for 4DCT image sorting as well as
the application of motion mitigation techniques (these techniques will be described in Sec-
tion 1.5.3). Different techniques are available and are reviewed by Evans et al. (Evans, 2008).
The acquired motion signals can be categorized in direct measurements and surrogate sig-
nals. Direct tumor position measurements are, e.g., fluoroscopy and tracking of electromagnetic
transponders implanted in or nearby the tumor. Surrogate signals demand knowledge concern-
ing a correlation function to obtain the tumor position.
Implanted fiducial markers can facilitate precise tumor localization for fluoroscopy (Shirato
et al., 2003). But as the implantation poses an additional risk for the patient and possibly
comprises image acquisition (e.g., CT) or dose delivery (especially for particles), fluoroscopy
without implantation of fiducial markers has been proposed and is already in use (Schweikard
et al., 2005; Cui et al., 2007). Electromagnetic transponder systems are, e.g., used for photon
prostate treatments (Willoughby et al., 2006).
Methods using a surrogate signal are, e.g., camera systems, systems attached to the patient
measuring respiratory movement, or systems measuring respiratory air. Camera systems ac-
quire images either of the patient surface or of infrared markers attached to the patient (Bert
et al., 2005; Schweikard et al., 2004). Alternatively, a motion signal can be obtained e.g., by
a belt measuring expansion and contraction of the body (Li et al., 2006). Systems measuring
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the patient’s respiratory airflow are another option to obtain a surrogate signal for tumor mo-
tion (Kubo and Hill, 1996). All these methods are implantation-free, provide a motion signal
with high frequency and deliver no additional dose to the patient. Their main drawback is the
indirect tumor motion measurement that requires knowledge of the correlation between tumor
position and surrogate signal.
Direct measurements and acquisition of surrogate signals can be combined. The Cyberknife
Synchrony system performs beam tracking (BT) for photon therapy and is already in clinical use.
Its motion monitoring system combines direct (fluoroscopy) and surrogate (infrared camera sys-
tem) motion signals. Thus, the frequency of fluoroscopic imaging can be kept low. Fluoroscopy
is used to update the correlation model of the surrogate system. The accuracy of this system has
been assessed by Seppenwoolde et al. (Seppenwoolde et al., 2007).
1.5.3 Mitigation of organ motion influence
Mitigation of patient positioning related motion influence
Different countermeasures to mitigate the influence of organ motion on the treatment outcome
are in clinical use or currently under investigation.
By implementing precise und reliable patient positioning and patient fixation techniques, the
influence of interfractional as well as intrafractional positioning related motion can be mini-
mized. For intra-cranial lesions patient fixation employing head masks is commonly used. The
positioning accuracy using different head mask systems has been investigated in different stud-
ies (Karger et al., 2001; Tryggestad et al., 2011). In conclusion, margins of 1mm to 2mm are
recommended to account for positioning uncertainties if the investigated mask systems are used.
Mitigation of interfractional motion influence
Repeated imaging is essential to assess interfractional motion. Based on the new imaging in-
formation dose delivery can be adapted. This is called adaptive radiotherapy (ART). Several
concepts are currently investigated. One of those is the "plan of the day" approach. Several
treatment plans are optimized typically before the treatment course. From this treatment plan
library the best matching treatment plan is chosen after each re-imaging (Murthy et al., 2011).
Also a re-optimization of the treatment plan based on the new imaging data is investigated.
Especially this approach demands fast treatment plan optimization and a sophisticated clini-
cal workflow. ART for lung tumors has been reviewed by Sonke and Belderbos (Sonke and
Belderbos, 2010).
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Mitigation of intrafractional motion influence
Different motion mitigation techniques to mitigate the influence of intrafractional motion are
currently investigated or are already in clinical use. Intrafractional motion is particularly chal-
lenging if the dynamics of beam delivery is on the same scale as the intrafractional motion.
This is the case for the current implementations of the advanced dose treatment techniques
IMRT and beam scanning. The common time scale of motion and beam delivery is the cause
for interference effects leading to over- and underdoses within the irradiated area. This effect is
commonly referred to as interplay (Phillips et al., 1992; Jiang et al., 2003; Bert et al., 2008).
If beam delivery is not dynamic, e.g., in passive particle therapy, the interplay effect does not
occur and homogeneous dose delivery to the tumor volume is achievable by irradiation of an
ITV encompassing the tumor motion (ICRU, 2007). However, this approach results in increased
dose deposition to the healthy tissue surrounding the tumor. Motion mitigation techniques in
passive particle therapy thus do not aim at mitigating dose deteriorations inside the tumor but
at reducing the required margins.
Re-scanning is also known as re-painting. It is applicable to beam scanning dose delivery and
is based on statistical averaging of interplay patterns. This effect has already been described in
1992 by Phillips et al. (Phillips et al., 1992).
An ITV encompassing the tumor in all possible motion states is the minimal target contour.
The prescribed dose is not delivered in one but in multiple scans. The overall number of par-
ticles delivered to a beam position is distributed over these scans. In the simplest approach,
N scans are used and a fraction of 1/N of the nominal particle number is delivered per scan.
Radiographic films irradiated with different numbers of re-scans are shown in Figure 1.22 on
the next page.
Different flavors of re-scanning have been investigated by Seco et al. (Seco et al., 2009). From
their studies and earlier investigations by Furukawa et al. (Furukawa et al., 2007) it is known
that one of the main concerns for re-scanning is insufficient averaging due to synchronization
effects between beam delivery and respiratory breathing cycle. This problem can be overcome
by distributing the re-scans over the respiratory cycle. Thus, unwanted synchronized starts of
the re-scans in respect to the respiratory motion can be avoided.
Zenklusen et al. proposed a more sophisticated method of distributing the total particle num-
ber of each beam position over the different re-scans (Zenklusen et al., 2010). Instead of equally
distributing the particles over all re-scans a fixed amount of particles is delivered to each beam
position per re-scan. If its nominal particle number is reached the beam position is omitted
in further re-scans. This method not only reduces the impact of synchronization by effectively
changing the scan path between re-scans, but also can lower the technical demands regarding
the irradiation time of a beam position. This is because in their approach the particle number
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Figure 1.22.: Normalized film response for re-scanning irradiations. Target area is drawn with
red solid lines. The IMs are indicated by dotted lines. Figure from (Bert et al.,
2009a).
per beam position and re-scan is fixed while it scales with the beam positions overall particle
number in case of equally distributing particle numbers over all re-scans.
Gating reduces the motion influence by delivering the treatment plan only in a subsample
of the complete motion trajectory the so called gating window. Typically, a motion window
around end-exhale is chosen as it is the most reproducible motion state showing a comparably
small motion (Balter et al., 1998; Ritchie et al., 1994). Gating is applicable to both, scanned
and passive beam delivery. The motion influence is reduced to the residual motion within
the gating window. Thus, for scanned beams the dose distortions due to the interplay effect
can be expected to be less severe, while passive beam delivery profits from reduced margins
that only need to encompass the tumor under consideration of its residual motion within the
gating window. For scanning techniques, several methods have been proposed to reduce the
interplay effects due to residual tumor motion. While Furukawa et al. for National Institute of
Radiological Sciences (NIRS) as well as Zenklusen et al. for Paul Scherer Institut (PSI) proposed
a combination of gating and re-scanning (Furukawa et al., 2007; Zenklusen et al., 2010), Bert et
al. proposed an increased overlap of adjacent pencil beams in lateral as well as longitudinal
direction to mitigate the influence of the residual motion (Bert et al., 2009b). Gating requires
motion monitoring as the beam has to be turned on and off depending on the current tumor
position.
At NIRS gating functionality has been implemented and has been used with passive carbon
beams for therapy of mobile tumors (Minohara et al., 2000). A sketch of a typical gating time
sequence is shown in Figure 1.23 on the following page.
45
Figure 1.23.: Time sequence of gating . In (a) the breathing motion of a patient is shown. The
gating window is marked by a solid line (b). Whenever the motion is within the
gating window a "Gate-on" signal is triggered (c). Whenever a "Gate-on" coincides
with a beam extraction window of the synchrotron accelerator (flat top (d)), beam
is extracted (e). Figure from (Minohara et al., 2000).
The idea of BT is to adapt the position of the delivered beams to the actual tumor position
in real-time. BT intrinsically does not require an increase of treatment margins. Precise motion
monitoring and image registration maps are needed for BT.
BT has been proposed by Keall et al. for IMRT (Keall et al., 2001). In photon therapy, longitu-
dinal tumor position changes can typically be ignored as the photon depth dose profile changes
only gradually. Clinically, BT is used in the Cyberknife Synchrony system (see Section 1.3). BT
is also applicable for particle beams. The Bragg peak structure of particles poses an additional
challenge because dose distributions are also very sensitive against longitudinal changes.
A BT system has been implemented at GSI (Grözinger et al., 2004; Bert et al., 2007). Lat-
eral compensation is performed by employing the scanner magnets. Energy with the required
speed changes can not be achieved by the current synchrotron system but are obtained by a
polymethyl methacrylate (PMMA) double wedge absorber system that is mounted on fast lin-
ear motors proximal to the target (Saito et al., 2009). In their implementation, compensation
parameters for the lateral plane as well as the longitudinal direction are pre-calculated for each
beam position in each motion state (Bert and Rietzel, 2007). A sketch of the GSI implementation
of BT is shown in Figure 1.24 on the next page.
The impact of intrafractional motion on treatment outcome can not only be reduced by ded-
icated beam application methods as introduced above. By changing the motion itself it’s influ-
ence can become smaller or more predictable.
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Figure 1.24.: BT system implemented at GSI. Scanner magnets are used for lateral adaptation of
pencil beam positions. A dedicated double wedge system is used for fast energy
adaptation (Saito et al., 2009). Figure from (Grözinger, 2004).
Breathing is the main cause of motion for many tumor sites subject to intrafractional motion.
Different methods have been developed to mitigate the influence of breathing. To reduce the
motion amplitude and consequently the required treatment margins abdominal press can be
used. The use of abdominal press in photon lung cancer therapy is reported by,e.g., Negoro et
al. (Negoro et al., 2001) and Hof et al. (Hof et al., 2003). Breath-hold techniques are reported
by (Hanley et al., 1999; Wong et al., 1999). This technique is used to immobilize the tumor.
Breath-holds can be induced either automatically by a dedicated device with valves or voluntary
by the patient. Reproducibility and stability of the tumor position are main concerns using this
technique (Kimura et al., 2004; Yoshitake et al., 2009).
Expected uncertainties during treatment delivery, e.g., patient motion, can enter the treat-
ment planning process. The aim is to optimize a treatment plan that is robust against these
expected uncertainties. Plan robustness can be increased, e.g., by the choice of the treatment
field entrance angles. If an OAR is close to the tumor the treatment port in particle therapy is
typically chosen such that the OAR is at the lateral rather than the distal edge of the tumor. Thus,
uncertainties in particle range do not result in a shift of the treatment field into the OAR. The
rationale is that typically the longitudinal Bragg-Peak position is more prone to uncertainties
than the lateral Bragg-Peak position is.
Also during optimization of the treatment plan robustness can be an objective. Inaniwa et
al. have implemented a robust algorithm into their scanned carbon treatment planning
code (Inaniwa et al., 2011). The algorithm explicitly takes range and setup uncertainties into
account.
These methods for intrafractional motion mitigation can be combined. Combination of gat-
ing and re-scanning has been proposed by Furukawa et al. (Furukawa et al., 2007, 2010a).
Van de Water and colleagues investigated BT for scanned proton beams. They concluded that
this method is very susceptible for positioning uncertainties and recommended to combine re-
scanning and BT to gain robustness (van de Water et al., 2009).
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1.6 Aim of this work
This work focuses on the motion mitigation technique BT. BT is a technique that can use the
whole accelerator duty cycle (in contrast to gating) and at the same time does not require
intrinsic motion mitigation technique specific margins (like re-scanning and gating). BT thus
has the potential to combine excellent tumor conformity and short irradiation times for moving
tumors. On the other hand it is technically challenging. Especially important are precise motion
detection and reliability of patient data, e.g., 4DCT and image registration.
But even if precise and reliable motion information can be provided, BT only works perfectly
for translational motion. If other motion components like rotational or deformational compo-
nents are present, even though the Bragg peak position is adapted the tissue beam path might
change. These path changes alter the overall dose distribution. An example for rotational
motion is shown in Figure 1.25.
ϕ
Motion State Reference Motion State m
Figure 1.25.: Target volume in two different motion states in case of rotational motion. The
shade of color represents the deposited dose. Although BT ensures delivery of
Bragg peak dose to the correct position, the overall dose deposition is changed
due to the changed tissue beam path. The arrows represents the beam direction
while the dashed arrow shows the nominal beam direction for the reference state.
Figure adapted from (Bert and Rietzel, 2007).
The exact transition of the patient through the 4DCT phases, i.e., the period and phase of the
breathing motion at any time of a whole treatment fraction, is unknown a priori. Dose changes
thus can not be considered beforehand, i.e., in treatment planning. Bert and Rietzel (Bert and
Rietzel, 2007) proposed a method to compensate these dose changes during beam application.
Such a method has to evaluate dose changes at individual beam positions, accumulate these
dose changes and eventually compensate them by adapting the nominal particle numbers. All
these steps have to be performed in real-time during beam delivery.
In this work such a method, called real-time dose compensation combined with beam track-
ing (RDBT), has been implemented into the therapy control system (TCS) at GSI. The imple-
mentation of that method and its experimental verification are described in Chapter 2.
For an assessment of the clinical efficacy of RDBT treatment planning studies have been con-
ducted. They have been based on 4DCT data of lung cancer patients. The study compares the
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motion mitigation techniques lateral beam tracking (LBT), BT, and RDBT and is presented in
Chapter 3.
Finally, a new method based on RDBT is proposed that has the potential to supersede the
technically complex fast energy adaptation system needed for BT and RDBT. This method along
with initial measurements and simulations are presented in Chapter 4.
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2 Implementation and experimental
verification
The content of this chapter has in similar form been published (Lüchtenborg et al., 2011).
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2.1 Introduction
In this chapter the implementation of a real-time dose compensation extension for beam track-
ing (BT) into the therapy control system (TCS) at GSI Helmholtzzentrum für Schwerionen-
forschung GmbH (GSI) is described. Several experiments employing moving detectors have
been performed to verify the implementation with the goal to show the benefit gained from the
implemented dose compensation method. This has been done by comparing dose delivery on
a static target and a moving target for BT as well as for real-time dose compensation combined
with beam tracking (RDBT). Target volumes with simple geometric shapes, like box and sphere,
were used in combination with a large (24°) purely rotational target motion. The scope of this
work was verification of the implemented dose compensation technique rather than application
to a scenario that resembles typical tumor motion. By choosing large rotational motion the ef-
fect of dose changes is expected to be also large. The chosen rotation angles rather represent a
worst-case scenario than a typical tumor motion but are expected to facilitate the experimental
comparison of RDBT and BT. The possible clinical benefit of RDBT for a more typical tumor
motion range is assessed by means of treatment planning studies in Chapter 3.
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2.2 Material & methods
The theoretical basis for dose compensation is described in Section 2.2.1, it’s implementation is
described in Section 2.2.1. In Section 2.2.3 the measurements for dosimetric assessment of the
implemented method are described.
2.2.1 Dose compensation - theoretical basis
BT treatment plans are typically optimized for one reference motion state from tumor imag-
ing (e.g., one time resolved computed tomography (4DCT) state). Due to the tumor motion
the anatomical structure underlying a beam position is in general not any longer at the posi-
tion assumed in treatment planning, i.e., the position in the reference motion state. BT aims
at changing beam parameters such that the Bragg Peak dose is again delivered to the same
anatomical structure. Therefore, the beam parameters (i.e., beam position in perpendicular
plane and beam energy determining beam range) are adapted according to the current motion.
The required adaptation vectors can be obtained from image registration (Brock et al., 2006;
Rietzel and Chen, 2006). The components of the BT system implemented at GSI are shown in
Figure 2.1 on the next page.
However, BT can preserve the overall dose only for the special case of pure translational
motion. In the presence of other motion components like rotations and deformations, parts
of the tissue will receive more or less dose than in treatment planning because its position
relative to the beam axis is changed despite BT (see Figure 1.25 on page 48). RDBT considers
these dose changes by accumulating the dose changes for all beam positions during treatment
delivery. Once a beam position is irradiated, its cumulative dose change is compensated by
adapting the nominal particle number applied to that beam position. Overdose compensation is
carried out by reducing the number of particles delivered to a beam position. Thus, the overdose
compensation of a beam position is limited by its nominal particle number and can in some cases
only be reduced but not completely avoided. In contrast, the clinically more crucial underdoses
can always be compensated by increasing the number of particles delivered to a beam position.
The general workflow of the RDBT method is shown in Figure 2.2 on page 54. In addition
to choosing the position adaptation values ∆(x , y, z)m
i
matching the actual beam position i and
motion state m, dose changes to all following beam positions caused by the irradiation of the
current beam position are calculated. As the applied particle number itself is fed back to the
dose compensation calculation procedure, RDBT is considered a closed-loop approach. The term
dose change here always means the difference between the (motion state m dependent) actual
deposited dose to a beam position i and the dose that would have been deposited according
to 3D reference treatment planning. Like mentioned earlier, even if the treatment planning
4DCT data is still valid at time of dose delivery, dose changes will occur simply due to the
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Figure 2.1.: Setup of the GSI BT system. Target motion is measured by laser triangulation and
used to determine, based on 4D treatment planning, position adaptation parame-
ters. For compensation of lateral shifts the scanner magnets are used while a double
wedge is used to compensate depth changes. Figure adapted from (Saito et al.,
2009).
a priori unknown motion state a beam position is actually irradiated in. Furthermore, while
in this experimental setup the intrinsic assumption that the 4DCT is still valid at application
time is obviously true, this assumption might not be valid in patient cases. The influence of
anatomy changes between imaging and therapy on different motion mitigation techniques has
to be investigated in dedicated treatment planning studies (see Chapter 3).
Implementation of the dose compensation functionality into GSI’s treatment planning system
TReatment planning for Particles (TRiP) (Krämer et al., 2000) has been based on the method
proposed by Bert and Rietzel (Bert and Rietzel, 2007) which is summarized in the following.
The method can be subdivided into two parts. The first part is calculation of dose compensa-
tion parameters Dik
m
and can be done off-line during treatment planning and is therefore not
time-critical. The second part, in contrast, is highly time-critical. During irradiation of one
raster position (few ms) the resulting dose changes to all following beam positions have to be
calculated from precalculated dose compensation parameters and measured motion state.
Dose compensation parameter optimization
The basic idea of dose compensation is to adapt the particle number applied to a beam position
considering motion induced dose changes caused by earlier irradiated beam positions. At irra-
diation time of a beam position only the particle number of so far not irradiated beam positions
can still be changed. Thus, it is sufficient to precalculate only dose compensation parameters
concerning later irradiated beam positions.
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Figure 2.2.: This figure illustrates the basic workflow of RDBT. RDBT is an extension of BT. For
a currently irradiated beam position i parameters ∆xm
i
, ∆ym
i
, ∆zm
i
are read from
4D treatment planning considering the motion information and the nominal Bragg
peak position x i, yi, zi are adapted accordingly. The dose changes at beam positions
k, where i + 1 ≤ k ≤ N are calculated. Necessary adaptation of particle number for
beam position i + 1 is communicated to the therapy control system controlling the
irradiation. While the BT part (left branch, bright yellow) can be considered as an
open-loop approach, the dose compensation extension (right branch, dark green) is
a closed-loop system as the result of the irradiation is fed back to the∆N calculation
to adapt future dose application.
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iMotion State m
1
k
N
Figure 2.3: Treatment plan in motion state m.
Scanning starts in the most distal
slice at beam position 1 and passes
beam positions i and k. The last
beam position is N . Scan path is
represented by the dashed arrows.
Consider that this is a 2D represen-
tation of the treatment plan. There-
fore, each vertical row represents
one IES.
Assuming a target volume consisting of beam positions 1 ≤ i, k ≤ N and a motion described
by 4DCT states 1 ≤ m ≤ M (see Figure 2.3), the motion state dependent dose delivered to
beam position k while irradiating beam position i can be defined as Dik
m
. This quantity assumes
deposition of the nominal particle number to beam position i. For each beam position i the Dik
m
for i ≤ k ≤ N are calculated with TRiP and stored for each motion state m in a look-up table.
Hence, the look-up table is dependent on the scan path, i.e., the sequence of the beam positions.
As dose deviations are mainly caused by the beam plateau proximal to the Bragg peak, the plan
is preferably executed starting at the most distal energy slice. Because the motion state a beam
position is irradiated in is not known a priori, dose compensation parameters for all motion
states need to be provided in real-time. In the current implementation of RDBT the number of
beam positions in a treatment plan is limited by the memory size of the look-up table.
Real-time dose compensation
It is assumed that beam position i is currently irradiated. All calculations described in this
section are performed by the TCS for all beam positions 1 ≤ i ≤ N . At irradiation time of a
beam position i the motion state m is known from motion monitoring. Thus, the actual dose
difference for every beam position k > i can be calculated. Hereby, one needs to take into
account that the particle number delivered to beam position i is already adapted. Thus, the
dose change to beam position k can be calculated as follows:
∆d ik
m(i)
=
eDik
m(i)
− Dikref

, (2.1)
with ref denoting the reference motion state of the 4DCT and eDik
m(i)
representing the dose actu-
ally deposited at beam position k during irradiation of raster position i. The dose deposited at
position i itself typically is also modified by the dose compensation. As the look-up table entries
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Dik
m
were determined assuming deposition of nominal particle number to beam position i, the
actual dose can be calculated by multiplying Dik
m
by the fraction of the planned dose actually
deposited at beam position i. ∆Di denotes the cumulative dose change of beam position i from
irradiation of beam positions 1≤ p < i:
∆Di =
i−1∑
p=1
∆d
pi
m(p)
. (2.2)
eDik
m(i)
can now be written as
eDik
m(i)
= Dik
m(i)

1−
∆Di
Diiref

. (2.3)
It should be stated here that in case ∆Di ≥ Diiref the dose received by beam position i already
exceeds the planned dose delivery. As a reduction of the already delivered dose is not possible
even applying no particles to that beam position will result in a local over- dose.
As the current GSI scanning system does not allow to skip single beam positions, currently
instead of no particles a predefined minimal fraction of the nominal number of particles is
delivered in case of an accumulated overdose that can not be completely compensated.
Combining Equation 2.1 on the previous page and Equation 2.3 yields
∆d ik
m(i)
=

Dik
m(i)

1−
∆Di
Diiref

− Dikref

, (2.4)
for the dose change deposited at beam position k during irradiation of beam position i. To
correctly represent the real situation the term 1−∆Di/Diiref is checked and if necessary set to
the predefined minimal fraction of the nominal particle number. The individual dose change
counters∆Dk existing for each beam position are incremented by∆d ikm(i) for all k > i . The dose
change ∆Di+1 for beam position i + 1 is needed by the TCS for adapting the nominal particle
number. In order to avoid conversions including daily changing ionization chamber calibration
factors it is advantageous to pass a unit-independent quantity. Therefore, not ∆Di+1 but the
relative quantity ∆Di+1/D(i+1)(i+1)ref is passed to the TCS. The TCS finally changes the nominal
particle number N i+1nom to
N i+1adapt = N
i+1
nom
 
1−
∆Di+1
D
(i+1)(i+1)
ref
!
. (2.5)
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2.2.2 Dose compensation - Implementation into therapy control system
The existing BT software of the TCS has been extended by a dose compensation functionality.
Thus, RDBT is now experimentally available.
The TCS software is organized in a loop structure. It is essential that the loop time of the soft-
ware is considerably shorter than the irradiation time of a beam position which is in the order
of some milliseconds. This is crucial if the particle number of a beam position and thereby its
irradiation time is lowered by the dose compensation itself. In the current setup the dose com-
pensation software is running on a RIO4 VME processor board (CES, Switzerland) providing
a 1GHz GHz processor and 512MB on-board memory. 448MB are usable for dose compensa-
tion. In combination with 25 motion states this allows for a maximal treatment plan size of
3064 beam positions. With this implementation, loop times in the order of 30µs have been
measured. In the following way the software workflow has been structured to minimize com-
putational load during time-critical phases and to pass computed compensation values as fast
as possible to the TCS:
During irradiation of beam position i the most time-critical task is to pass the cumulative dose
change of beam position i+1 to the TCS before irradiation of raster position i+1 starts. There-
fore in the current implementation first of all ∆Di+1 is calculated and the respective relative
dose change is passed as described above. Then, the dose changes for the beam positions of
the current IES are calculated and the respective counters are updated. To reduce the workload
during the time-critical raster position irradiation, all calculations concerning beam positions in
the remaining IESs of the treatment plan are shifted to the accelerator extraction pause prior to
the next IES. These pauses before each IES are obligatory as the beam energy changes are ac-
tively requested from the synchrotron accelerator. Typically, they last for a few seconds (≈ 2.2 s
at GSI), providing more than enough time to make up for the calculations shifted during irra-
diation of the IES. In Figure 2.4 on the next page the software workflow comprising the most
important software tasks is summarized.
Log file analyses showed that these loop times are short enough to guarantee a proper exe-
cution of all necessary steps even for beam positions where the nominal particle number and
consequently the irradiation time was decreased.
2.2.3 Dose compensation - dosimetric assessment
Measurements
Experiments to assess the technical performance of the implemented dose compensation func-
tionality have been performed. As mentioned above, dose changes only occur for nontransla-
tional motion components, so a rotational motion realized by a dedicated rotational table has
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II) evaluate motion signal
III) determine position tracking parameters
IV) control scanner magnets
V) control range modulator
VI) calculate dose change for RP i+1
VII) pass cumulative dose change for RP i+1
motion sensor
SCP
4D treatment
planning
4D treatment
planning
dx, dy
dz
dN
end of iso-energy-slice?
VIII) calculate dose changes for RPs i+2,…,n
IX) calculate dose changes for 
voxels n+1,…,N caused by irradiation of the 
RPs in the just finished iso-energy slice
YES NO
I) read actual raster position (RP)
SCP
Figure 2.4.: RDBT Software workflow. The TCP decides, based on ionization chamber measure-
ments, when magnets switch to the next beam position based on ionization cham-
ber measurement. The RDBT software therefore needs to perform with a loop time
fast compared to typical beam position irradiation times (few ms). After the actual
beam position number (I) and the motion signal (II) are read, BT parameters are cal-
culated (III), and scanner magnets (lateral) (IV) and range modulator (longitudinal)
(V) are controlled accordingly. Now the dose changes for all following beam posi-
tions i + 1, . . . , N remain to be calculated. As passing the cumulative dose change
of beam position i + 1 is highly time-critical the respective dose change is calculated
first (VI) and immediately passed (VII). Afterwards, the dose changes for all remain-
ing beam positions of the current IES i+2, . . . , n are calculated (VIII). The calculation
of dose changes to beam positions in other iso-energy slices n+1, . . . , N is shifted to
the mandatory extraction pause after each IES (IX). That ensures that the loop starts
over as fast as possible.
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(a) Rotation by −14°. (b) Not rotated reference
phase.
(c) Rotation by 10°.
Figure 2.5.: Figure 2.5b shows the water phantom in its reference state while Figure 2.5a (−14°
rotation) and 2.5c (10° rotation) show the extreme motion states. Filled red circles
represent the position of the ionization chambers. The center of rotation is 45mm
downstream the entrance window.
been used in the experiments. The table was rotating between −14° and 10° (see Figure 2.5). A
laser triangulation system (Sick Vertriebs GmbH, Düsseldorf, Germany, Model OD100-35P840)
was used for motion feedback. To induce additional need for energy changes a ramp-shaped
absorber made from polymethyl methacrylate (PMMA) was positioned proximal to the motion
table. The absorber did not move during beam delivery thus introducing a position-dependent
bolus thickness since BT was used. A sketch of the setup can be seen in Figure 2.6 on the
next page. The large rotation as well as the additional ramp-absorber have been introduced to
clearly demonstrate the dose change effect rather than to resemble the clinical situation where
the tumor motion possibly comprises a mixture of translational, rotational, and deformable
components.
A computed tomography (CT) reflecting the not rotated setup including the ramp-absorber
was constructed and considered as reference state. The amplitude of the laser sensor signal
representing the complete rotation (between −14° and 10°) was equidistantly divided into 25
motion states. For each motion state the rotational angle representing the motion state’s center
was determined and corresponding transformations for the reference CT state were analytically
calculated. 4DCT phases were obtained by applying the transformation to the reference CT
state.
An array of ionization chambers in a water tank that was used in clinical routine for patient
treatment plan verifications at GSI (Karger et al., 1999) was employed as detector system. The
setup was aligned using the in-room laser system that in the past was also used for patient
alignment. Treatment planning was performed according to Bert and Rietzel (Bert and Rietzel,
2007) and is shortly summarized here. After delineation of the target contours, TRiP was used
to optimize the number of carbon ions deposited at each beam position. The overall target dose
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Figure 2.6.: Setup for experimental verification. The BT system (see Figure 2.1 on page 53) was
employed to adapt beam positions to the changing target position. The motion
table introduced rotational motion. Additional necessity for energy changes was
caused by the ramp absorber.
Figure 2.7.: Nominal dose distributions for all target geometries. Prescribed dose has been
1000mGy.
was set to 1Gy. IES spacing was set to 3mm water-equivalent (3mm|H2O) and a 3mm ripple
filter was used (Weber and Kraft, 1999). For all plans irradiation sequence starts at the most
distal IES. Within one slice the beam position spacing was set to 3mm in horizontal as well as
vertical direction. The spot size was from 7.3mm to 7.6mm (depending on IES) full width at
half maximum (FWHM). Three different volumes of interest (VOIs) were used:
• SPHERE: A sphere with 22mm radius,
• BOX: A box of 50× 15× 45mm3 (in beam’s eye view horizontal 50mm, vertical 15mm,
longitudinal 45mm),
• 2BOX: A plan consisting of two boxes (proximal box 50× 15× 10mm3, distal box
20× 15× 5mm3).
Nominal dose distributions for all geometries can be seen in Figure 2.7. In addition, dose
60
compensation parameters Dik
m
were calculated for 1 ≤ i ≤ N , i ≤ k ≤ N , 1 ≤ m ≤ 25 . RDBT
was compared to BT by experiments each consisting of three measurements:
• REF: Irradiation scheme where the nominal treatment plan was applied. target was in
reference phase (i.e., 0°) and not moving. Neither BT nor RDBT were used,
• POS: Irradiation scheme using BT. The target was rotating between −14° and 10°,
• FULL: Irradiation scheme using RDBT. The target was rotating between −14° and 10°.
All relevant delivery data, e.g., particle number for every beam position, beam position, and
target motion state, were logged during treatment. Thus, it was possible to reconstruct dose
distributions for each individual measurement by using TRiP4D (Bert and Rietzel, 2007; Richter
et al., 2011). The treatment planning code TRiP4D is an extension of the TRiP98 code developed
by Krämer et al. (Krämer et al., 2000; Krämer and Scholz, 2000). The 4D version is in more
detail described in Section 3.2.1.
Data analysis
To focus on the motion and motion mitigation dependent differences between POS and FULL
dose deviations in comparison to POS are reported. Direct access to these dose differences is
provided by the ionization chamber measurements that have been analyzed separately for over-
and underdose by determining the mean and standard deviations, respectively. Analysis has
been restricted to ionization chambers that are positioned inside the respective VOIs. As the
mean dose differences for FULL as well as POS is expected to be close to zero the distributions
have been analyzed not for different mean values but for significant variance changes using the
Bartlett test (Bartlett, 1937).
Data from dose reconstructions are complementing the direct dose measurements as they
provide the dose deposition at any location inside the target volume. To compare measurements
and dose reconstructions, reconstructed dose values were extracted at the nominal ionization
chamber positions inside the target volumes. Measured as well as reconstructed dose values
have been grouped into three subsamples (REF, POS, and FULL). Correlation analysis has been
performed to assess the validity of dose reconstruction.
The reconstructed dose difference distributions were compared by means of histograms. χ2-
analysis has been applied to test if the differences between the POS and the FULL histogram
distributions are significant.
Robustness of dose compensation
It is well known that interplay patterns are very sensitive to the motion state at irradiation
start (Bert et al., 2008). In the context of robust planning a motion mitigation technique is
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favorable when the dependence of the resulting dose distributions on the motion starting phase
is small. Simulations covering a larger parameter space and thus complementing the performed
measurements were performed with TRiP4D. The goal of these simulations was to investigate
the influence of the motion starting phase on BT and RDBT, respectively. Dose calculation is
performed in a similar way like in the dose reconstructions described above but using simulated
rather than measured input data.
The BOX and SPHERE treatment plans used for the experiments were used for this simulation.
For better comparability one measured motion trajectory was used for all simulations. Ten
different starting phases, evenly distributed over the whole motion cycle (≈ 3.8 s) were defined
by introducing a time offset on the motion trajectory. Dose delivery was simulated using the
same 4DCTs the experiments were based on. Dose-volume-histograms (DVH) were calculated
from the resulting dose distributions.
2.3 Results
2.3.1 Measurements
Dosimetric results are assessed by calculating the dose differences obtained in the motion af-
fected setups (POS and FULL) and the static setup (REF). To assess the benefit of RDBT the
variances of the distributions have been compared. The Bartlett test (Bartlett, 1937) indicates
significant variance changes for the BOX (20 measurement positions) as well as SPHERE plan
(12 measurement positions) for the measured as well as the reconstructed distributions. The
2BOX plan did not show significant variance changes but at the same time only provides four
measurement positions. For further analysis under- and overdoses are considered separately.
The average under- and overdoses measured by the ionization chambers positioned inside
the VOI and their standard deviations are reported in Table 2.1. RDBT could in all cases re-
Table 2.1.: Average (± 1 standard deviation) measured under- as well as overdoses in POS and
FULL compared to REF with dose values in mGy. Nominal dose was 1000mGy. Only
ionization chambers (ICs) inside the VOI are considered. The number of ICs for each
geometry is listed.
geometry # ICs
underdose overdose
BT RDBT BT RDBT
BOX 20 52 (±36) 12 (±14) 53 (±30) 37 (±32)
SPHERE 12 30 (±30) 24 (±13) 27 (±33) 13 (±26)
2BOX 4 68 (±91) 25 (±13) 45 (±35) 25 (±16)
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duce the average under- as well as overdoses. In most of the measurements, especially for the
underdoses, also the standard deviations could be considerably reduced.
Dose values from measurement as well as reconstruction were grouped in REF, POS, and FULL.
Correlation has been investigated for all groups separately. The squared correlation coefficient
r2 was 0.98 for all groups. The respective slope was between 0.95 and 0.98. These results
show that measurements and reconstructions are well correlated and the correlation is virtually
independent on the motion mitigation technique applied. It could thus be concluded that the
reconstructed dose difference distributions can also be used to compare BT and RDBT.
Histograms of the reconstructed dose difference distributions inside the VOIs for POS as well
as FULL are shown in Figure 2.8 on the following page for all geometries. χ2-analysis at 5% sig-
nificance level showed that the dose difference distributions obtained in FULL are significantly
different compared to the distributions obtained in POS. These reconstructed distributions offer
better statistics as every CT voxel inside the VOI could be evaluated compared to the above an-
alyzed distributions that consider measurement positions only. Tests on the reconstructed dose
difference distributions show a significant distribution difference also for the 2BOX geometry.
Cuts through the central plane of the reconstructed dose difference distributions are shown in
Figure 2.8 on the next page for all geometries. While the dose differences outside the VOIs are
comparable in BT and RDBT, inside the VOIs the dose differences are clearly reduced in case of
RDBT. It is striking that the global dose change pattern for BT expands also into the VOI but for
RDBT at the VOI border there is a sudden drop in the amount of dose change. For BT areas of
under- as well as overdose exceeding 100mGy are visible (brown and pink areas) representing
cold and hot spots in the dose distribution. RDBT shows virtually no misdoses of that extent.
Even under- and overdoses in the range between 50mGy and 100mGy (blue and red voxels)
only appear rarely.
2.3.2 Starting phase dependence
The DVHs from simulations for BT as well as RDBT can be seen in Figure 2.9 on page 65 for the
BOX geometry as well as the SPHERE geometry, respectively. Each DVH is representing a different
starting phase of the motion. In each figure the 10 DVHs for BT are drawn in red while the 10
DVHs representing RDBT are presented in blue. In both figures the RDBT DVHs are superior
to the BT DVHs. Under- and overdoses are clearly reduced. Moreover, the spread of the RDBT
DVHs is smaller than the spread of the BT DVHs meaning that the dose distributions are more
robust against varying motion starting phases when RDBT is used. Comparing both geometries,
it is interesting to see that although the spread in the BT DVHs is reduced for the SPHERE plan
compared to the BOX plan the average maximum over- and underdose is virtually unchanged.
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Figure 2.8.: Differences between the dose reconstructions for BOX (top row), SPHERE (middle
row), and 2BOX (bottom row). Shown is a cut in the x-z plane through the iso-
centre. Dose reconstructions have been based on logged beam delivery data from
experiments. Ionization chamber positions are marked by white crosses. x is beam
direction, z is the lateral plane (left right in beam’s eye view). To assess the dose
differences not only in the iso-centre plane but in the complete VOI, additionally his-
tograms of the dose difference distribution within the VOIs are shown (blue solid
lines for RDBT, red dashed lines for BT). The under- as well as the overdose inside the
VOI (marked in black) could substantially be reduced in RDBT compared to BT.
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Figure 2.9.: DVHs for BT (red dashed lines) and RDBT (blue solid lines). The stationary DVH is
drawn in black as reference. Simulations have been performed for the BOX as well
as the SPHERE treatment plan. For both moving cases ten different starting phases,
evenly distributed over the motion cycle, have been analyzed. The RDBT cases are
much closer to the reference showing much smaller under- as well as overdoses com-
pared to BT. In addition, RDBT seems to be more robust against varying starting
phases as the spread of the DVHs is much smaller.
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2.4 Discussion
The general task of treatment planning is to determine delivery parameters that ensure delivery
of a predefined dose to a patient represented by imaging data, e.g., a CT. By moving to tumor
sites showing considerable intrafractional motion, additional knowledge concerning the motion
trajectory is essential for treatment planning. Obtaining a motion data set before treatment that
is still valid at time of therapy seems challenging, especially if patient motion is irregular. Even if
the validity of the 4DCT itself can be assumed, uncertainty about the respiratory trace determin-
ing the temporal sequence of the single 4DCT states remains. One approach to overcome this
problem is to implement a real-time closed-loop system. Such a system accounts for the dose
deviations between planned and deposited dose distribution in real-time and feeds them back
to the ongoing dose delivery process. Based on this information, the dose delivery parameters
are adapted to minimize the dose deviations.
The proposed RDBT method is such a closed-loop method. Based on measured motion in-
formation obtained during beam delivery, the motion impact on dose delivery is calculated and
used to change nominal particle numbers of future beam positions (see Figure 2.2 on page 54).
In this way, the delivered dose distribution gets closer to the planned dose distribution. While
changes in the motion trajectory (e.g. respiratory frequency) can be handled, it is still assumed
that the planning 4DCT represents the patient’s anatomy at treatment time. For the performed
experiments this was obviously the case but for patient data the validity of the 4DCT will among
other factors depend on the time between imaging and treatment delivery. Thus, the delay
between imaging and treatment should be reduced as far as possible.
The quantitative benefit of RDBT for patient treatments can only be evaluated in dedicated
treatment planning studies (see Chapter 3). Some qualitative trends can already be anticipated.
All motion mitigation techniques rely on the validity of patient information. While, e.g., gating
only relies on imaging, image registration and motion data concerning a subset of the whole
motion cycle, i.e., the gating window, BT and RDBT require valid information during the whole
motion cycle. The quality and reliability of imaging and registration data might thus be more
crucial for BT and RDBT than for other motion mitigation techniques. Artifacts impairing the
4DCT quality have been reported among others by Persson et al. (Persson et al., 2010). However,
methods to mitigate artifacts are reported (Mori et al., 2006) and further improvements in this
field can be anticipated.
Several groups investigated reproducibility of respiratory motion and found that the motion
itself is often reproducible (Sonke et al., 2008; Michalski et al., 2008). In a large multi-
institutional study Brock et al. report that the accuracy of deformable image registration al-
gorithms is within the CT voxel resolution especially for lung tumors (Brock, 2010).
Thus, sufficient data quality for at least a subgroup of patients seems achievable. Real-time
motion monitoring is employed to deduce the 4DCT state representing the current motion state
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best. Motion monitoring could be based on the methods used for the Cyberknife Synchrony
system (Ozhasoglu et al., 2008; Seppenwoolde et al., 2007).
Taking into account these considerations, the patient predestinated for the application of
RDBT would be a patient with good 4DCT and image registration quality, a reproducible motion
with a large amplitude containing nontranslational components. The overall benefit of RDBT
over BT in such a patient is expected to increase if the number of treatment fields or fractions
is reduced, since it is known that a larger number of fields or fractions leads to an averaging of
dose deviations and thus improves dose homogeneity (Phillips et al., 1992; Knopf et al., 2010).
As already stated above, the concept of RDBT shows some similarities to real-time motion-
adaptive-optimization (MAO) proposed by Lu et al. for TomoTherapy (Lu et al., 2009). Both
methods adapt the amount of dose delivered in the next basic dose delivery unit in real-time.
While this basic unit for TomoTherapy is a projection and the according leaf-open time is
changed, in RDBT the basic unit is a beam position and its nominal particle number is changed.
Both methods also accumulate the already delivered dose based on real-time motion measure-
ments and feed that information into the dose adaptation process. That makes both methods
closed-loop approaches. While MAO also includes the future dose estimation into the optimiza-
tion process in RDBT currently only the already deposited dose is considered. RDBT might also
profit from future dose estimation, this will be discussed later in this section.
Reconstructed dose distributions show for the large rotational target motion used that the
dose patterns deposited using RDBT are significantly closer to the ones deposited in the station-
ary reference irradiation than the dose distributions deposited using BT are. While for BT global
dose change patterns expand into the VOI, RDBT dose distributions show clearly reduced dose
deviations inside the VOI. Patterns outside the VOI are comparable. It is important to realize
that RDBT can only accumulate and compensate dose changes for beam positions. beam posi-
tions are per definition within the VOI and not outside the VOI. Nevertheless, experiments give a
hint that also motion and BT induced dose changes outside the VOI might be of importance. Es-
pecially if organs at risk (OARs) are concerned, methods to monitor and, if necessary, minimize
these dose changes (at least the overdoses) might be needed. An implementation is possible
by introducing virtual raster points in OARs which enter the RDBT process with maximal dose
levels rather than nominal ones. This question can only be addressed by careful analysis of
dedicated treatment planning studies.
Dose measurements and dose reconstructions have been shown to be highly correlated, indi-
cating that analysis based on reconstructed dose distributions are suited as well to assess the
performance of RDBT in comparison to BT.
Measured and reconstructed dose differences compared to the stationary reference irradia-
tion could be significantly reduced if RDBT was used instead of BT alone. The occurrence of
underdoses per se in RDBT is assigned to the fact that the currently implemented method only
takes into account dose changes of already irradiated beam positions. Hence the contribution of
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future beam positions, i.e., mainly beam positions in the same IES due to their lateral overlap,
is assumed to be the nominal one, i.e., as in treatment planning. Depending on the motion state
and the particle number correction applied to future beam positions their contribution to the
current position might be different from their nominal contribution. Motion prediction would
allow consideration of dose changes caused by the next beam positions. Their contribution to
the current beam position is relatively large due to the lateral overlap of pencil beams. It is
expected that underdoses can be further reduced if not even eliminated using motion predic-
tion. Such a method presumably also reduces the remaining overdoses. Overdoses might, as
discussed earlier, not be avoidable in every case because the minimum particle number appli-
cable to a beam position equals zero. In contrast to photons, the majority of dose deposited by
charged particles is delivered at the Bragg-Peak position. Therefore, it is expected that already
a short term prediction of dose changes covering the beam positions in the direct surrounding
of the actual Bragg peak position might be sufficient for a reasonable improvement. That would
of course considerably facilitate the process of motion prediction. Considering irregularities in
patient motion, its prediction gets harder the longer the relevant time span is.
Simulations showed that RDBT has the potential to substantially improve the outcome of an
irradiation on a moving target. RDBT proved itself to be more robust than BT and to decrease
the under- and overdoses introduced by target motion. However, also the simulations are based
on the artificial experimental situation and are not easily transferrable to clinical situations. One
might speculate that a RDBT irradiation is also for other clinically more typical motion patterns
more robust against changing irradiation and motion parameters. The possible quantitative gain
and the robustness against other factors have to be assessed in treatment planning studies that
are currently ongoing.
It seems plausible that due to the large rotations the effects on dose distributions both inside
as well as outside the VOI are larger in these experiments and simulations compared to those
one should expect for a typical clinical case. However, the motion type does not influence the
technical workflow. Thus, the current implementation is transferable to situations where also
translations and deformations are present.
2.5 Conclusions
A method for real-time compensation of dose changes introduced in BT irradiations by non-
translational motion components has been implemented in the GSI therapy control system and
verified for large rotational motion. A transfer to more complex motions, especially measured
patient motion, seems feasible if 4DCT data and registration data are provided. As the method
uses already delivered dose as a feedback for adapting future dose deposition it is considered as
a closed-loop approach. Experiments and complementary simulations comparing BT and RDBT
showed significantly better coverage of the target volume of the latter method.
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In the previous chapter the implementation of the real-time dose compensation functionality
extending beam tracking (BT) has been verified. However, the experimentally used motion
parameters were not meant to resemble typical motion parameters but rather to cover a worst-
case scenario. Therefore, this chapter will focus on the assessment of the clinical benefit of
real-time dose compensation combined with beam tracking (RDBT). Time resolved computed
tomography (4DCT) data from lung cancer patients have been used to simulate scanned carbon
ion dose delivery. Different techniques have been simulated: Beam application without motion
mitigation (i.e., interplay), with lateral beam tracking (LBT)1, with BT, and with RDBT.
The following sections will first shortly review the clinical experience for particle treatments
of lung tumors. Subsequently the methods used for the simulation as well as the results are
presented and discussed.
3.1 Clinical particle therapy for lung cancer
Most of the current particle therapy experience for lung tumors comes from irradiations per-
formed at National Institute of Radiological Sciences (NIRS) in Chiba, Japan (Tsujii et al.,
2007). Treatments have been conducted using a passive carbon beam delivery system. Recently
the first lung tumor treatments with scanned proton beams have been performed. However,
tumor sites showing comparably low motion (e.g., upper lung) were chosen (such treatments
have been performed at MD Anderson Cancer Center (MDACC)) or patients were under anes-
thesia (such treatments are conducted at Rinecker Proton Therapy Centre (RPTC) (Eckermann
1 For LBT beam positions are only adapted in the lateral plane (∆x i , ∆yi).
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et al., 2011)). In both cases, the intrafractional motion has been very low such that treatments
could be performed quasi-static.
The treatment planning studies performed in this work are based on a clinical protocol used
at NIRS for non-small cell lung cancer (NSCLC). In a phase I/II clinical study the optimal
dosage for stage I NSCLC had been found to be 90Gy (RBE) in 18 fractions over six weeks and
72Gy (RBE) in nine fractions over three weeks (Miyamoto et al., 2003).
After this initial dose finding study, the efficacy of hypofractionation has been explored. There-
fore the number of fractions has been reduced. This work is based on the second of these hy-
pofractionation studies employing four fractions (Miyamoto et al., 2007). Instead of a passive
beam delivery, active raster scanning has been simulated.
3.2 Material & methods
3.2.1 4D treatment planning framework
Treatment planning for the scanned carbon beam treatments at GSI Helmholtzzentrum für
Schwerionenforschung GmbH (GSI) has been performed using TReatment planning for Parti-
cles (TRiP) (Krämer et al., 2000). TRiP was originally developed for stationary tumor treat-
ments but has been extended to 4D functionality based on the work of Bert and Rietzel (Bert
and Rietzel, 2007). For clarity in the following if a specific version of TRiP is meant the 3D and
the 4D version will be distinguished by their name. The extended 4D version of TRiP will be
referred to as TRiP4D while the 3D version will be called TRiP98. TRiP will be used if general
aspects are described.
The existing structures in TRiP98, like computed tomography (CT) and treatment plan, were
extended from 3D to 4D by introducing a one dimensional array of structures. The number of
array members is given by the number of CT states. Other structures are only needed in case
of intrafractional motion and thus do not exist for TRiP98. They had to be added. The most
important among these new structures are:
Motion In the motion structure the shape of the underlying target motion as well as option-
ally the motion of surrogate signals is defined. The amplitudes of target and signals are
recorded versus time. The signals can be one or multi dimensional.
Spill The spill structure describes the accelerator behavior. For 4D calculations, not only the
target motion but also the scanner progress governed by the delivered particle intensity
is needed to establish a correlation between beam position and motion state. The spill
structure comprises time stamps of different relevant beam delivery events, e.g., beam
positions, begin and end of spill extraction, begin and end of iso-energy slices.
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MLUT The BT lookup table (MLUT) contains beam adaptation parameters for the lateral as
well as the longitudinal direction. For each beam position and each possible motion state
defined by the 4DCT adaptation parameters have to be defined.
NLUT The dose compensation lookup table (NLUT) contains base data enabling the calculation
of target motion induced dose changes to a beam position. One NLUT implementation
has already been described in detail in Section 2.2.1. As already pointed out earlier, the
memory requirement of that implementation is rapidly increasing with the number of beam
positions. As patient treatment plans can easily comprise thousands or ten thousands of
beam positions the NLUT format experimentally used was not usable. Thus, another format
had to be implemented. It will be described more thoroughly in Section 3.2.1.
Different functions have been implemented to TRiP4D. The main functional extensions include
the distribution of beam positions to the different states of a four dimensional treatment plan
according to the particle number, motion, and spill information as well as the dose calculation
on all 4DCT states and the subsequent accumulation in the reference CT state. TRiP4D has been
implemented by Richter et al. (Richter et al., 2011). BT and RDBT as well as the corresponding
calculation and handling of MLUT and NLUT has been implemented in this work.
Optimization of multiple fields
A treatment plan with multiple fields can be optimized in two different modes. Either each field
is optimized separately or all fields are optimized simultaneously. In the former case each single
field exhibits a homogeneous dose in the target area while in the latter case the single fields
might have inhomogeneous dose distributions that only result in a homogeneous cumulative
fraction dose if all fields are summed up. For clarity, relative biological effectiveness (RBE)
weighted doses in this section are always used with the index "RBE" while the index "absorbed"
will be assigned to absorbed doses. If fields are optimized separately, a field dose has to be
defined from the fraction dose. For protons, for which a constant RBE of 1.1 is clinically used,
the field dose Diproton can be calculated from the fraction dose D
fraction
proton by dividing the latter by
the number of fields n:
Diproton =
Dfractionproton
n
. (3.1)
Thus, the division of a proton fraction dose in field doses can be done by dividing the fraction
dose by the number of fields. Applying the same formalism to situations where heavy ions, e.g.,
carbon ions are used, does not work. Because of the dose dependence of the RBE (compare
Figure 1.9 on page 23) n superimposed fields with an RBE weighted dose of DiRBE will not result
in a total RBE weighted dose of n · DiRBE. In this case the calculation of field doses is more
complex.
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Instead of trying to find an adequate RBE weighted field dose for optimization, the fraction
dose can be used for the optimization of n single fields with doses DfractionRBE . Thus, n fields,
typically with different beam angles, are obtained, each optimized to deliver the total fraction
dose. This fraction dose is connected to the absorbed dose Diabsorbed via the respective RBE
i (see
Equation 1.13 on page 22):
DiRBE = D
fraction
RBE = RBE
i Diabsorbed. (3.2)
In the next step, particle numbers of the resulting fields are then scaled with 1/n leading to a
scaling of the absorbed field doses Di,scaledabsorbed = D
i
absorbed/n. In the following it is shown that the
overlay of these n scaled fields yields the desired RBE weighted fraction dose if the overall RBE
of the treatment fraction (consisting of the n scaled fields) is sufficiently close to the harmonic
mean of the RBEi of all single fields before scaling. The following equations have to hold for
all points of the target volume. Assuming the overlay of all scaled fields yields the fraction dose
one can write:
DfractionRBE
!
= RBEfraction
n∑
i=1
Diabsorbed
n
. (3.3)
The absorbed field doses can be substituted by the ratio of the RBE weighted dose and the
respective RBE: Diabsorbed = D
fraction
RBE /RBE
i. Thus, Equation 3.3 can be written as:
DfractionRBE
!
= RBEfraction
DfractionRBE
n
n∑
i=1
1
RBEi
(3.4)
⇔ RBEfraction
!
=
n∑n
i=1
1
RBEi
. (3.5)
n/
∑n
i=1
 
1/x i

is known as the harmonic mean of all x i. In these treatment planning studies
the above dose scaling method has been used. The resulting overall dose of all scaled fields has
been calculated by TRiP without motion influence and showed excellent target coverage for all
investigated patients. Thus, at least for the investigated patient cohort in conjunction with the
chosen dose levels and local effect model (LEM) tables, the overall RBE seems to be sufficiently
well represented by the harmonic mean of the unscaled field’s RBEs.
Calculation of beam tracking parameters
Calculation of BT parameters has been done according to the method described by Bert and
Rietzel (Bert and Rietzel, 2007). Beam adaptation parameters are calculated based on image
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registration. While the lateral compensation parameters ∆x and ∆y are purely geometrical,
the longitudinal compensation parameter ∆z has to be provided as water-equivalent distance.
Thus, for its calculation the geometrical image registration vector has to be combined with the
CT information to obtain water-equivalent depth compensation parameters.
One potential issue in calculating BT parameters is the type of registration that is used. Rigid
as well as non-rigid registration algorithms exist. Rigid registration algorithms rotate and shift
one image to match the other image (e.g., to match an arbitrary CT phase image CTi to the
reference CT image CTref. As the whole image is transformed (one transformation for all image
points) the shape of objects remains unchanged while the position and orientation of objects
might change. That means that the distance between two points in the transformed image is
exactly identical to the distance between these points in the original image. In contrast, in non-
rigid transformations each image point has a different transformation. Thus, deformations can
be described. Consequently, the distance of two image points in the transformed image might
differ from the distance of these image points in the original image. The difference is illustrated
in Figure 3.1.
X0
X1
(a) Original image. (b) Image after rigid registration.
X0
X1
(c) Original image.
X0
X1
(d) Image after non-rigid registration.
Figure 3.1.: Illustration of rigid and non-rigid image registration. While rigid registration con-
serves shape and point to point distances, in case of non-rigid registration the shape
of objects can change and point to point distances are not conserved.
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Treatment plans in scanned particle therapy are optimized for a homogeneous dose distri-
bution assuming a predefined beam position spacing. If non-rigid registrations are used to
calculate BT parameters, the distance between beam positions is not preserved. Rigid registra-
tions, in contrast, preserve the distance between image positions and thus the distance between
beam positions is preserved. In Figure 3.2 this effect is shown in one dimension. Grid spacing
is 2mm and full width at half maximum (FWHM) of the Gaussian shaped spots is 6mm. A
ratio of about three between FWHM and grid spacing is typically chosen in TRiP (Krämer and
Scholz, 2000). For the rigid transformation, nominal raster position distances are preserved
while small deviations are introduced in case of the non-rigid registration. The overall dose in
case of the non-rigid registration shows inhomogeneities that are not present in case of the rigid
registration.
(a) Rigid registration. (b) Non-rigid registration.
Figure 3.2.: Illustration of dose distribution in case of rigid and non-rigid image registration.
While rigid registration conserves point to point distances, in case of non-rigid regis-
tration the point to point distances are not conserved. This can result in dose inho-
mogeneities due to changing overlap parameters compared to treatment planning.
The single spot contributions as well as the overall dose are shown in both cases.
The tumor motion is in many cases best represented by non-rigid registration. But even if
the BT parameters are calculated using rigid registration, the 4D dose calculation can still be
based on a potentially more accurate non-rigid registration. Beam position distances are only
conserved within one motion state. But as the number of motion state changes typically is small
against the number of beam positions, the effect from changing motion states is expected to be
comparably low.
A low memory consumption NLUT
The main requirement for the new NLUT format was to achieve reasonable file sizes, even if
treatment plans with ten thousands of beam positions have to be dealt with. To be independent
of the number of beam positions, no direct dose contributions from one beam position to an-
74
other beam position are stored. Instead, base data are provided that allow calculation of dose
contributions in real-time.
In the analytical beam model used in TRiP dose deposition of a given particle beam can be
calculated at any position knowing the beam’s depth dose distribution (E, z), its radial shape,
here parameterized with a Gaussian distribution with variance σ, and the delivered number of
particles N (Krämer et al., 2000):
D (E, r, z) [Gy] = 1.6 · 10−8d (E, z)

MeVcm2
g

N
2πσ2

mm2
exp− r2
2σ2

, (3.6)
where z and r denote the positions water-equivalent depth and the radial distance from the
beam axis, respectively.
The new NLUT implementation contains for each iso-energy slice (IES) the corresponding
focus setting of that IES and the depth dose distribution normalized to one particle. The latter
has been interpolated to avoid the necessity for interpolation during beam application. The
central task of dose compensation is calculation of dose differences between actual and nominal
dose deposition (see Equation 2.1 on page 55). The actual dose deposition is influenced by
target motion, BT, and particle number adaptation. Provided with the depth dose distribution
for each beam the dose deposition normalized to one particle Dnorm (E, r, z) can be calculated at
any position. The actual dose difference ∆d ik
m(i)
can then be calculated during beam delivery:
∆d ik
m(i)
= Dnorm

E i, rk
m
, zk
m

~x im+∆~x
i
m
· N iadapt− Dnorm

E i, rkref, zref

~x im
· N inom, (3.7)
where rk
m
and zk
m
are the radial distance and water-equivalent depth of beam position k in
motion state m, the index term is a reminder that the relative position of beam position k has
to be calculated with respect to a beam position ~x i
m
, taking into account the position adaptation
vector ∆~x im from BT. Dnorm (E, r, z) is the dose normalized to delivery of one particle and is
calculable from the parameters provided in the new NLUT format. The nominal particle number
N inom is derived from the treatment plan, while the actually delivered particle number N
i
adapt can
be calculated during beam delivery according to Equation 2.5 on page 56.
As pointed out in Section 2.2.2, in the old NLUT format the size of the table was below
448MB for treatment plans up to 3064 beam positions when 25 motion states were used. The
new implementation produces NLUT tables with a size around 1MB if the resolution for the
depth dose distribution is set to 0.1mm. Furthermore, the NLUT size no longer depends on the
number of beam positions or motion states. Thus, the table size does not increase if, e.g., a finer
grid spacing or more motion states are used. Besides resolution, the size only depends on the
number of IESs, used in the treatment plan. On the other hand, the computational load for the
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real-time calculation of dose differences is increased as dose distributions are not provided in a
precalculated table but have to be calculated from the base data.
Spill simulation
Important parameters entering the spill simulation are the spill’s length, its shape, and the parti-
cle intensity. All these parameters have been based on the GSI accelerator parameters. The spill
length is 2.2 s, spill pause is 3.2 s when an energy change is required and 2.2 s without energy
change. The spill shape has been approximated by a Gaussian function. 15 different particle in-
tensity steps are available providing between 2× 106 particles/spill and 2× 108 particles/spill.
The intensity step is automatically chosen from the treatment plan. If beam positions with a
low particle number are present in an IES, a lower intensity is chosen for that IES to guarantee
technical applicability of the treatment plan.
3.2.2 Simulation input data
4DCT data
Five lung cancer patients entered this study. 4DCT data have been recorded at MDACC in Hous-
ton, Texas, USA. The clinical target volumes (CTVs) covered a range from 45 cm3 to 236 cm3.
The motion amplitudes in the direction of the largest motion component were from
1mm to 25mm. The 4DCTs consist of ten motion states each. Time based state definition
has been used. Thus, all CT states represent an equally long time span. Contours of the gross
tumor volume (GTV), the CTV, and several organs at risk (OARs) are drawn on the reference
motion state CT image. Patient data are summarized in Table 3.1.
Table 3.1.: CTV size, motion in the direction of the largest motion component, and contoured
OARs for all investigated patients.
patient no CTV size largest motion contoured OARs
1 236 cm3 5mm carina, esophagus, heart, spinal cord, vertebral bodies
2 160 cm3 20mm esophagus, heart, spinal cord
3 123 cm3 1mm carina, esophagus, heart, spinal cord
4 45 cm3 5mm esophagus, heart, spinal cord
5 125 cm3 25mm carina, esophagus, heart, spinal cord
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Image registration
Rigid as well as non-rigid image registrations have been performed. Rigid registration has
been performed by an in-house tool. Non-rigid registration has been performed applying the
Plastimatch code (Shackleford et al., 2010).
Treatment plan parameters
Like in the clinical setup used at NIRS, four beam entrance portals have been used. In contrast
to the NIRS treatments where one portal has been used per fraction in this study all four portals
are used for every fraction. At NIRS a horizontal and a vertical beam is used. For both beams
the couch is tilted by +20° and by −20°, respectively, resulting in four treatment portals in total.
A horizontal beam is represented by a gantry angle of 0° in TRiP while a gantry angle of -90°
represents a vertical beam. Thus, in TRiP the clinical entrance portals are realized by gantry
angles of +20°, −20°, −70°, and −110°. For patient 2 a gantry angle of −110° would result in a
treatment field partly traversing the heart. Besides elevated dose delivery to the heart this beam
portal is also technically very unfavorable as it implies the need for very large beam energy
adaptation. They are caused by the large density gradient between heart and lung tissue. The
resulting difference in water equivalent path length has to be compensated by the BT system.
For patient 2 a gantry angle of −50° has been used instead of −110°.
For the simulations the RBE weighted dose has been evaluated. It is calculated with TRiP
according to LEM (see Section 1.2.1). The most recent version of LEM has been used (Elsässer
et al., 2010; Friedrich et al., 2012). As introduced in Section 1.2.2, tumor cells and normal
tissue typically exhibit a differential α/β ratio. As input
 
α/β

CTV = 6Gy (α = 0.021Gy
−1,
β = 0.0035Gy−2, Dt = 10Gy) has been chosen for the CTV tissue (Friedrich, 2011). This
value is close to the α/β ratio of 5.585Gy used by Kanai et al. for NSCLC (Kanai et al., 2006).
Normal tissue typically has a lower α/β ratio (see Section 1.2.2). In this work
 
α/β

norm = 2Gy
(α = 0.3Gy−1, β = 0.0015Gy−2, Dt = 22Gy) has been assigned to all tissues but the CTV. This
value has been based on results from carbon irradiation of the spinal cord of rats (Karger et al.,
2006).
Treatment plans have been optimized to homogeneously cover the CTVs. The TRiP "all points"
algorithm has been used for calculation of absorbed dose, while the low dose approxima-
tion (Krämer and Scholz, 2006) was used for biological dose calculation. Grid spacing of
the treatment plans has been chosen to be 3mm in x- as well as in y-direction. Spacing be-
tween IESs has been set to 3mm|H2O and a 3mm ripple filter (Weber and Kraft, 1999) has been
used. Energy adaptation systems comparable to those installed at GSI (Saito et al., 2009) in-
troduce material proximal to the patient. As the investigated techniques BT and RDBT require
energy adaptation, a bolus of 56.8mm|H2O has been inserted proximal to the patient.
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Fractionation scheme
The NIRS fractionation scheme employing four fractions has been chosen (Miyamoto et al.,
2007). At NIRS the fraction dose was 13.2Gy (RBE) for Ia staged tumors and 15Gy (RBE) for
Ib staged tumors. It is known that the approach for RBE calculation used for carbon therapy
at NIRS and the LEM based approach used at GSI yield different results (Steinsträter et al.,
2011). Thus, for this study the fraction dose has been derived from tumor control probability
curves calculated from the data reported from NIRS. For four fractions a RBE weighted dose of
8.2Gy (RBE) per fraction has been obtained (Friedrich, 2011). This value has been used in this
study for all patients. Single treatment fields have been optimized using the method described
in Section 3.2.1. Thus, all four fields have been optimized for a target dose of 8.2Gy (RBE) each
and particle numbers have subsequently been divided by four. Nominal dose distributions for
all patients are shown in Figure 3.3 on the facing page.
Motion trajectory
A sinusoidal motion trajectory has been used. Two different approaches can be employed for
motion state detection. For phase-based motion detection and perfectly periodic motion traces
the exact shape of the motion trajectory does not matter because the motion state definition is
done in the time domain. In contrast, for amplitude based motion the shape of the motion is
important for the motion state definition. An example for both state division methods comparing
a sinusoidal and a Lujan type motion (Lujan et al., 1999) is shown in Figure 3.4 on page 80.
The same state definition method used for the reconstruction of the 4DCTs should be used in
simulations. As the 4DCTs used in this study have been reconstructed based on the time domain,
phase-based motion detection has also been used for the simulations.
To account for the possible changes in patient motion patterns, different periods (2 s, 4 s, and
6 s) as well as different starting phases (0°, 90°, 180°, and 270°) have been chosen. Motion
changes within the application of one field have not been considered in this study. Within one
fraction the motion period has been kept constant while the starting phases have been changed.
Four different combination of starting phases for the four fields of one fraction (gantry angles
+20°, −20°, −70°, and −110°) have been used:
• 0°, 90°, 180°, and 270°,
• 90°, 180°, 270°, and 0°,
• 180°, 270°, 0°, and 90°, and
• 270°, 0°, 90°, and 180°.
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(a) Patient 1.
(b) Patient 2. (c) Patient 3.
(d) Patient 4. (e) Patient 5.
Figure 3.3.: Dose cuts of the nominal dose distributions for all five patients. The CTV served as
target contour and is outlined in cyan. OARs are outlined in black. For some patients
they partly overlap with the CTV. For patient 2 a gantry angle of−110° (with respect
to the horizontal axis) for the fourth field would have resulted in traversing the
heart. This has been avoided by choosing a gantry angle of −50° for the fourth
field. The tissue directly adjacent to the CTV receives a dose level above the nominal
fraction dose (pink areas). This can be explained when taking the differential α/β
ratios of CTV and normal tissue into account.
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(a) Phase based motion states. (b) Amplitude based motion states.
Figure 3.4.: Phase based (Figure 3.4a) versus amplitude based (Figure 3.4b) motion state defi-
nition. For clarity only four motion states have been defined. Two simple periodic
motions, a shifted and stretched sinus function and a Lujan type (sin4) function,
have been chosen. In the phase based approach motion state determination is done
based on the phase information (vertical lines). In the amplitude based approach
the state is determined based on the motion amplitude (horizontal dashed lines).
For clarity resulting motion state changes are again indicated by vertical lines. While
in the phase based approach for this perfectly periodic motion the state definition
over time does not depend on the shape of the motion, for the amplitude based
approach there is a difference in state definition depending on the motion shape.
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Both limitations in period and starting phases are artificial and many more combinations are
possible. But this parameter choice is thought to reasonably cover the expected parameter
space of a patient and thus be sufficient to show the range of possible dosimetric results when
applying different motion mitigation techniques.
3.2.3 Analysis
The measures Dx and Vx are used to judge a dose distribution:
Dx : x% of the volume under consideration has received a dose of at least Dx ,
Vx : A dose of at least x% of the target dose has been received by the volume Vx .
For comparison of the different motion mitigation techniques, the V95 and the V107 of the CTV
have been analyzed as a measure for target coverage and overdose of the CTV, respectively.
This choice has been based on the ICRU recommendations (ICRU, 1993a). As an indicator for
the homogeneity, the width of the dose fall-off has been assessed by evaluating the difference
D5 − D95. The evaluation of these measures is exemplary shown in Figure 3.5 on the following
page.
All measures have been evaluated for all four beam application techniques (interplay, LBT,
BT, and RDBT). For each beam technique, like mentioned in Section 3.2.2, twelve motion pa-
rameters (four starting phases and three amplitudes) are simulated. Additionally, two different
registration algorithms (rigid and non-rigid) are employed for dose calculation, while the MLUT
calculation for all cases relies on rigid registration (see Section 3.2.1). Thus, in total 96 fraction
dose distributions are simulated per patient.
For the calculation of cumulative treatment course doses four fraction doses have been added
according to the linear-quadratic-linear model (compare to Section 1.2.1). Each of the four
motion starting phases has been assigned to one fraction. Taking into account three different
motion periods a total of 34 = 81 combinations have been evaluated for each of the four beam
delivery techniques and each of the two registration methods.
For each measure mean and standard deviation over all motion parameters are calculated per
patient for fraction dose distributions as well as for cumulative treatment course dose distribu-
tions. Results for dose calculation based on the rigid and the non-rigid registration algorithm
are reported separately. The mean values of all measures have been investigated for signifi-
cant differences between different beam application techniques. The Tuckey-Kramer test at 5%
significance level has been used.
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Figure 3.5.: Example of the analysis of V95, V107, and D5 − D95 comparing two different DVHs.
The V95 and V107 are the volumes at the intersection of the vertical lines (at 95% and
107% dose level, respectiveley) and the according DVH curve. For the orange DVH
V95 = 64.7% and V107 = 4.2%, for the blue DVH V95 = 98.7% and V107 = 0.2%.
The D5 is the dose at the intersection of the horizontal line at 5% volume level and
the DVH curve. Accordingly, the D95 is the intersection of the horizontal line at 95%
volume level and the DVH curve. The difference between these dose levels is the
D5−D95. For the orange DVH D5−D95 = 39% and for the red DVH D5−D95 = 7%.
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3.3 Results
Representative dose distributions for all techniques (motion period 4 s, motion starting phases
0°, 90°, 180°, and 270°, rigid registration) for patient 5 are shown in Figure 3.6 on the next
page.
Dose distributions for the other patients are shown in Figures A.1 to A.4 in the appendix.
The results of the V95 analysis are shown in Figure 3.7 on page 85. The mean values and
standard deviations (SDs) of the V95 value for all patients are summarized in Tables A.1 to A.8
in the appendix. An overview concerning the significances in the differences of V95 for all
application techniques is also provided there.
For all investigated patients the V95 is larger if BT or RDBT are used compared to interplay
and LBT. Except for one case, when fraction doses based on non-rigid calculation are compared
for RDBT and LBT, the mean values have been significantly better. The mean V95 values for
the fraction dose were between 92.9% and 99.5% (90.5% to 97.6% for non-rigid registration)
for BT and between 94.6% and 99.2% (86.8% to 97.1% for non-rigid registration) for RDBT.
Significant differences between BT and RDBT in the V95 for the fraction doses could be observed
only for non-rigid registration where BT performed significantly better for patients 2 and 3.
For all investigated patients the mean V95 after a complete treatment course is at least at 95%
(90.5% for non-rigid registration) when BT or RDBT are used. For the patients 1 and 3 also
interplay and LBT show V95 values above that threshold. In contrast, for the patients 2, 4, and
5 the V95 drops if interplay or LBT are employed.
The V107 values for all investigated techniques are shown in Figure 3.8 on page 86. The mean
V107 values and their SDs for all patients are summarized in Tables A.9 to A.16 along with the
analysis results from significance analysis.
All application techniques show very low V107 values for patient 3. This patient shows only
little tumor motion. In most of the cases, BT and RDBT perform significantly better than the
other techniques. Especially conspicuous are the results for patient 2. V107 values for BT are
significantly worse than for all other techniques for this patient. Although RDBT relies on the
same position adaptation like BT, overdoses are significantly lower for RDBT compared to BT
and all other application techniques.
The V107 after the complete treatment course are all below 3%, often even close to 0% except
for patient 2 when treated with BT. For patients 1, 2, and 5 RDBT reaches significantly lower
V107 than BT for a full treatment course.
The D5 − D95 values for all investigated techniques are shown in Figure 3.9 on page 87.
The mean values and SDs of the D5 − D95 values are summarized in Tables A.17 to A.24 in
the appendix. Information about the significances of the differences between the investigated
delivery techniques can also be found there.
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(a) Interplay. (b) lateral beam tracking.
(c) Beam tracking. (d) RDBT.
Figure 3.6.: Dose distributions for all four application techniques in patient 5. Cuts are drawn
through iso-centre. Motion period of 4 s and motion starting phases of 0°, 90°, 180°,
and 270° have been used. Dose calculation has been based on rigid registration. An
improved homogeneity for BT and RDBT compared interplay and LBT can already be
seen in these cuts.
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Figure 3.7.: V95 value as a measure for dose coverage of the CTV for rigid registration based
dose calculation. Results for fraction dose and dose from a complete treatment
course are shown separately. Also results from dose calculation based on rigid and
non-rigid registration, respectively, are shown in different figures.
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Figure 3.8.: V107 value as a measure for overdoses of the CTV. The V107 spread for BT is compa-
rably low except for patient 2 where BT produced very pronounced overdoses. Only
RDBT shows comparably low values for all patients and motion patterns.
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Figure 3.9.: D5 − D95 value as a measure for homogeneity of the CTV dose coverage A small
D5 − D95 indicates a steep DVH fall-off and thus a homogeneous dose distribution.
The D5 − D95 for interplay and lateral BT strongly depends on the patient and its
individual motion. BT and RDBT show a greater robustness against different patient
characteristics.
87
The steepness of the dose volume histograms (DVHs), assessed by their D5−D95 value, showed
significantly lower values for RDBT than for interplay and LBT for all patients in all but one case
(patient 3, rigid registration, complete treatment course). Also BT performed significantly better
than LBT and interplay in most patients. RDBT significantly outperformed BT for patients 1, 2,
3, and 4 if doses for the complete treatment course are analyzed.
Results for the ranges of mean and maximal dose deposited to the OARs are shown in Ta-
bles A.25 to A.44.
3.4 Discussion
In this treatment planning study, the motion mitigation techniques LBT, BT, and RDBT have
been compared for the treatment of lung tumors. For comparison, beam application without
application of motion mitigation, i.e., interplay, has been simulated in addition. Rigid as well as
non-rigid registrations have been used for dose calculation. Rigid registration has in both cases
been used for the MLUT calculation to maintain the distance between beam positions after
application of position adaptation. For direct comparison of the motion mitigation techniques,
the simulations employing rigid registration are best suited as the results are not biased by
different image registration algorithms used for beam application (via the MLUT) and dose
calculation. Using the non-rigid registration for dose calculation offers some insights in the
robustness of all MLUT related techniques (i.e., LBT, BT, and RDBT). Deviations between the
rigid and the non-rigid registration algorithm impair the validity of the MLUT. This might be
comparable to a clinical scenario where imperfect registrations will be a potential concern.
However, for a direct comparison the quantitative differences between the algorithms would
have to be assessed.
Prerequisite for the application of RDBT was a substantial reduction of the NLUT file size.
Thus, a new NLUT format has been implemented. File size was dramatically reduce and is
now in the order of MB. However, while minimizing the file size, the computational load for
the real-time calculation of dose differences has been increased. The current therapy control
system (TCS) at GSI is not fast enough to reliably perform the required dose calculations for
typical irradiation speeds of some ms per beam position. However, the implementation has
been optimized for the use in TRiP where operations are not time critical. It is expected that
a dedicated implementation optimized for real-time performance can be fast enough for the
application in the TCS.
Dose levels in the healthy tissue very close to the CTV exceed the prescribed dose. This can
be understood if taking the differential α/β ratio into account.
Results after one fraction show that BT and RDBT typically exhibit superior values for V95,
V107, and D5 − D95 compared to interplay and LBT. Patient 2 showed rather large overdoses
when BT was used. The V107 was significantly worse for BT compared to all other application
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techniques. As also LBT produces less overdose than BT, the overdoses are likely to be connected
to the depth compensation. This patient exhibits two GTVs. A common CTV encompassing both
GTVs was drawn in some slices. Overdoses were mainly apparent in the area between the GTVs.
The transition between relatively dense GTV tissue and the lung tissue positioned centrally
within the CTV for this patient might be challenging to handle for BT. Van de Water et al.
simulated BT on heterogeneous phantoms and found that BT can produce dose inhomogeneities
for heterogeneous targets (van de Water et al., 2009). The question if these results would also
occur in patients could not be answered in their study. Patient 2 might be such a case due to the
density gradient within the CTV and the observed overdoses might be comparable to the results
reported by van de Water. However, as also patient 1, 3, and 4 have multiple GTVs and BT copes
much better with that patients, the density gradients do not seem to be the only reason for the
bad performance of BT. It is striking that RDBT, using the same MLUT that BT uses, copes very
well with patient 2. This emphasizes the advantages of a closed-loop system. Overdoses can
be detected by RDBT and particle numbers can be reduced for the respective beam positions.
Although further patients showing similar anatomy should be analyzed first, this might be a
hint that treatment volumes encompassing large density gradients can compromise the dose
distributions obtained by BT.
For a complete treatment course consisting of four fractions BT and RDBT yield V95 values
above 95% (above 90% for dose calculation based on non-rigid registration) for all patients. BT
tends to show higher V95 when compared to RDBT. A study by Bert also compared different
motion mitigation techniques for the treatment of lung cancer with carbon ions (Bert, 2006).
Absorbed dose has been investigated. The V95 values for BT reported by Bert are worse than the
ones obtained in this study. Mean V95 values as low as 75.7% have been reported for one patient.
RDBT has been proposed to improve target coverage. A possible explanation for these different
results might be the number of fields applied. While four fields have been used in this study
one field was used by Bert. Knopf et al. reported more favorable dose distributions when more
treatment fields were used for re-scanning (Knopf et al., 2010). It can be expected that dose
deviations from the nominal treatment dose are also reduced for other beam application tech-
niques when more fields are applied. While target coverage using BT in this study was already
very good and no additional improvement could be observed when using RDBT, improvements
from using RDBT when compared to BT were the reduction of overdoses assessed by the V107
value and the improved dose homogeneity assessed by the D5 − D95 value. When analyzing a
complete treatment course both values were for most patients (3/4 for V107, 4/5 for D5 − D95)
significantly better when RDBT was used. These values have not been explicitly assessed in the
study by Bert. However, from the DVHs shown, a clear trend to increased overdoses is apparent
in that study. This trend disagrees with the result from this work. Besides the above mentioned
differences in study design, also the differences in the implementation of RDBT itself might be
a reason for the different results obtained.
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This study also showed the importance of the energy adaptation. LBT results were often
significantly worse than BT results. On the other hand patient 3 exhibiting only very small
target motion showed comparably good results for LBT and even interplay. A subset of lung
tumors might thus be treatable without motion mitigation. Also the combination of RDBT and
LBT instead of BT might be an option worthwhile for investigation.
So far the real-time dose change calculation performed by RDBT considers absorbed doses
only. Nevertheless results are often superior to BT even if biological dose calculation is assessed,
as in this treatment planning study. This might be partly due to the fact that RDBT calculates
overall dose changes relative to the nominal dose (see Section 2.2.1). In this relative quantity
the effect of biological dosimetry is expected to partly cancel out. However, considering the
nonlinear relationship between absorbed dose and biological dose, there will be a remaining
error introduced and implementation of biological dosimetry might further improve RDBT per-
formance. If taking into account the results from the experimental assessment of RDBT (see
Chapter 2) where also underdoses could be significantly reduced, one might speculate that also
the V95 values obtained by using RDBT would be superior to the ones obtained by BT when
biological dosimetry would be included into RDBT.
Analysis of robustness of all motion mitigation techniques was not within the scope of this
work. However, the results based on non-rigid registration for dose calculation and rigid
registration for MLUT calculation might provide a glance on robustness of motion mitigation
techniques. Quantitative analysis of the differences introduced by the different registration
techniques and subsequent comparison to registration uncertainties expected in clinical radio-
therapy would be needed. However, at least with the registration uncertainties introduced in
these studies, BT and RDBT were still typically significantly better than interplay and LBT. Also
significantly better performance of RDBT compared to BT especially in the V107 and D5 − D95
was still measured when non-rigid registration was used. However, dedicated treatment plan-
ning studies taking into account realistic uncertainties are indispensable to judge the robustness
especially of very sophisticated techniques like BT and RDBT.
90
4 Dose compensated re-scanning
In the preceding chapters real-time dose compensationwas always used in conjunction with beam
tracking (BT) but this is not compulsive. In this chapter, a new method, called real-time dose
compensated re-scanning (RDRS), is proposed. Real-time dose compensation is combined with
several re-scans. Lateral or full BT can optionally be included.
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Different motion mitigation techniques are available with individual advantages and disad-
vantages. As tumor motion shows a large inter-patient variability it is likely that not only one
motion mitigation technique turns out to be the universal solution but different patient and tu-
mor characteristics demand different approaches. The introduced motion mitigation techniques
rescanning, gating, and BT (with or without real-time dose compensation) can not only be used
seperately but might be combined. Combinations of these techniques can be superior compared
to the application of one technique and some combinations have already been proposed in the
literature. Van de Water et al. simulated BT with protons and concluded that proton BT should
be combined with re-scanning to improve the method’s robustness against uncertainties (van de
Water et al., 2009). Furukawa et al. proposed a combination of gating and re-scanning for the
treatment of moving tumors (Furukawa et al., 2010a). A clinical BT implementation should be
combined with gating to trigger beam pauses in case unexpected motion, e.g., due to coughing,
is detected (Bert and Durante, 2011).
Beam delivery techniques including re-scans are known to improve robustness (van de Water
et al., 2009). But the application of RDRS possibly offers advantages beyond increased robust-
ness. If employed without full BT, RDRS can be used to compensate also for dose changes that
occur due to the lack of full BT. In this case, dose deposition is not only altered by nontransla-
tional motion components but also by a lack of full Bragg peak position adaptation.
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While lateral beam tracking (LBT), i.e., beam position adaptation only in the lateral plane
(∆x i, ∆yi), can be technically realized using the existing scanner magnets and a dedicated con-
trol software, longitudinal BT is technically more challenging and currently requires additional
hardware, e.g., the double wedge system employed at GSI Helmholtzzentrum für Schwerionen-
forschung GmbH (GSI) (Saito et al., 2009). This in-room device is due to the need for additional
hardware in the treatment room and the introduction of passive material in the beam proximal
to the patient no a favorable clinical solution. Alternative solutions adapt the beam energy in-
side the beam line (Chaudhri et al., 2010). RDRS can be used together with LBT. The main
motion direction should be in the lateral plane thus LBT can cover most of the motion influ-
ence. The missing depth compensation including the influence of nontranslational motion is
compensated by RDRS.
RDRS functionality has been implemented at the GSI therapy control system (TCS) as well
as in TRiP4D. Film measurements assessing RDRS in two dimensions as well as simulations
for three dimensional treatment plans have been conducted and are described in the following
sections.
4.1 Material & methods
4.1.1 Methodology
RDRS relies, like real-time dose compensation combined with beam tracking (RDBT), on real-time
calculation of dose deviations between nominal dose and actually delivered dose. Thus, also for
RDRS base parameters for the calculation of dose changes need to be precalculated. Calculation
of dose compensation parameters Dik
m
for RDRS is with some adaptations done according to the
method outlined in Section 2.2.1. For RDBT the dose contributions Dik
m
from a beam position i to
another beam position k in a motion state m are calculated taking the target in motion state m
as well as BT position adaptations ∆x i, ∆yi, ∆zi for beam position i into account. RDRS can be
used with full BT but might also be used with LBT or without BT at all. Thus, for Dik
m
calculations
in RDRS the beam position i is only affected by (lateral) BT parameters if the respective method
is applied during beam delivery.
For RDBT it is sufficient to calculate only dose contributions concerning later irradiated raster
positions k > i. In RDRS, also dose changes to beam positions k < i are accumulated as they
are relevant for future re-scans. Consequently, the regarding dose compensation parameters are
additionally calculated. It should be stated here that these additional parameters increase the
NLUT size only if the initial implementation (see Section 2.2.1) is used. The size of the low
memory NLUT introduced in Section 3.2.1 is not increased as its size does not depend on the
number of beam positions in the treatment plan.
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The possible lack of (lateral) BT in RDRS also implies that the Bragg peak position ~x iBP might
not coincide with the anatomical position ~x iana the Bragg peak is applied to in the reference
state. Moreover, the Bragg peak might be closer to the anatomical position ~x lana of another beam
position l. This is especially likely if RDRS is used without BT at all. In this case the corrected
particle number N ladapt (see Equation 2.5 on page 56) of beam position l should be delivered
(see Figure 4.1). Therefore, for the use without BT the NLUT is extended by a correlation table
~x lana/~x
l
BP ~x
i
ana/~x
i
BP
~x lana ~x
i
ana
~x lBP ~x
i
BP
Figure 4.1.: Illustration of the necessity for the correlation table. Anatomical position ~x iana and
according Bragg peak position ~x iBP coincide for the reference motion state. Due to
organ motion and the lack of BT in motion state m, the anatomical position ~x lana
of beam position l is closer to the Bragg peak position ~x iBP than the anatomical
position ~x iana. Accordingly, if beam position i is to be irradiated in motion state m,
the adapted particle number of beam position l, N l
adapt
, will be used for irradiation.
For each beam position, the motion state dependent closest anatomical position is
stored in the correlation table for all motion states.
from that the motion state dependent closest beam position can be obtained in real-time. This
correlation table is currently implemented only in the TCS. Thus, for the presented experiments
this correlation table has been used while the simulations have been performed without this
correlation table.
In some cases the Bragg peak might be positioned outside the target volume due to the lack
of full BT. In this case the minimal applicable particle number Nmin is applied. Ideally beam
positions can be skipped, but depending on the delivery system a certain minimal number of
particles might have to be applied (see Section 2.2.1).
93
4.1.2 Measurements
Film measurements have been performed to verify the working principle of RDRS. RDRS mea-
surements have been compared to re-scanning measurements. In these two dimensional film
measurements the energy adaptation can not be assessed. RDRS combined with LBT is not an
option since in two dimensions LBT results in complete motion compensation. Thus, for the
film measurements RDRS has been applied without BT at all. RDRS has been used to account
for dose changes from the current and from earlier re-scans and to lower the dose deposition
to areas outside the target area. In comparison to re-scanning, there is no need to construct an
internal target volume (ITV) despite the lack of BT. Also, in contrast to, e.g., gating, the full
motion cycle is used for irradiation.
The target area (TA) has been a square of 6× 6 cm2. Grid spacing was 2mm in both direc-
tions with up-down-up scan path. Nominal particle number was 3× 105 particles/beam position
delivered in two target scans. 2 cm peak-to-peak motion in horizontal direction has been intro-
duced by mounting the films on a motion table. Accordingly, a planning target area (PTA) has
been constructed for re-scanning irradiations by adding internal margins (IM) encompassing the
motion amplitude to the TA. The size of the re-scanning treatment plan thus was 8× 6 cm2. No
internal margins need to be applied for RDRS as the method compensates the lack of BT by the
adaptation of particle numbers. The motion has been divided into 21 motion states and dose
compensation parameters Dik
m
as well as a correlation table have been calculated. For re-scanning
as well as RDRS 1, 3, 5, 7, 9, 11, and 15 re-scans have been measured. Target motion for all
measurements was started in the same motion state for better comparability of the results.
Homogeneity as well as dose conformity of the films optical density (OD) have been assessed.
To minimize the influence of setup uncertainties a 1 cm margin of the TA has been excluded
from homogeneity analysis. The region of interest thus was 4× 4 cm2. Homogeneity H has been
calculated from the standard deviation OD|SD and mean value OD|mean of the OD distribution:
H= 1−
OD|SD
OD|mean
. (4.1)
The conformity of the distributions has been assessed by evaluating the integral OD in the TA
(6× 6 cm2), ODTA, and the integral OD of the complete irradiated area, ODall. The conformity
index (CI) is used for conformity assessment:
CI=
ODTA
ODall
. (4.2)
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The resulting mean CIs for RDRS and re-scanning from all measurements with different num-
ber of re-scans are tested by a two-sided t-test. Mean CIs and the p value are reported.
4.1.3 Simulations
Delivery of a treatment plan covering a three dimensional target volume with RDRS has been
simulated using TRiP4D. RDRS has been used in conjunction with LBT. This combination,
as described above, is considered to have the potential to supersede the energy compensation
system needed for full BT as well as RDBT. Five re-scans have been used. In contrast to the
TCS, the correlation table is not implemented in TRiP4D. Thus, particle number correction of
the nominal beam position is applied.
For easier comparability with other motion mitigation techniques, simulations have been
based on the time resolved computed tomography (4DCT) and setup used for the simulations
in Section 2.2.3 that is shortly summarized:
• SPHERE treatment plan: spherical target volume with 22mm radius,
• water phantom 4DCT with 25 motion states,
• target dose 1Gy
• rotational motion between −14° and 10°,
• 3.8 s motion period,
• ten different motion starting phases.
As all simulation input parameters were identical to those in the simulation of BT and RDBT
conducted in Section 2.2.3, results can be directly compared. Dose cuts for one exemplary
motion starting phase (0°) from static as well as BT, RDBT, and RDRS are presented. The
dose volume histograms (DVHs) for all ten motion starting phases are compared for all investi-
gated motion mitigation techniques with respect to over- and underdoses compared to the static
irradiation.
4.2 Results
4.2.1 Measurements
The optical density distributions for all re-scanning and RDRS measurements as well as the
static measurements are shown in Figure 4.2 on the next page and 4.3 on page 97. An increase
in homogeneity for both methods can be seen. Also, the increasing mean OD of the RDRS
measurements that is attributed to the compulsive delivery of a minimum number of particles
can be seen.
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Figure 4.2.:Measured ODs represented by grayscale images. The target area is drawn in blue
solid lines. Dashed lines indicate the internal margins that had to be added for re-
scanning . In this figure, the static distributions as well as the distributions for 1, 3,
and 5 re-scans are shown. The distributions for 7, 9, 11, and 15 re-scans can be found
in Figure 4.3 on the facing page.
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Figure 4.3.:Measured ODs represented by grayscale images. The target area is drawn in blue
solid lines. Dashed lines indicate the internal margins that had to be added for re-
scanning . In this figure, the distributions for 7, 9, 11, and 15 re-scans are shown. The
static distributions as well as the distributions for 1, 3, and 5 re-scans can be found
in Figure 4.2 on the facing page.
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Figure 4.4.: Film homogeneity depending on the number of re-scans for RDRS as well as re-
scanning. The homogeneity level of the static irradiation is given for both techniques
as a dashed line.
Results of the homogeneity analysis are shown in Figure 4.4. Both methods show an increase
of homogeneity with increasing number of re-scans. The homogeneity level of the respective
static irradiation is achieved after seven re-scans for re-scanning and after 15 re-scans for RDRS.
The homogeneity for re-scanning saturates at seven re-scans. As not more than 15 re-scans have
been measured the saturation behavior for RDRS could not be investigated.
Conformity has been assessed by the CI. The result is presented in Table 4.1. The irradiations
Table 4.1.: Conformity of re-scanning and RDRS using the conformity index (CI). For both tech-
niques the mean conformity from all seven measurements using different number of
re-scans is given. The two-sided t-test has been used to assess the significance of the
obtained mean conformity differences.
mean CIre-scanning (SD) mean CIRDRS (SD) p-value
59.7 (3.0) 90.6 (2.9) 1.1× 10−7
using RDRS have been significantly more conformal compared to the re-scanning irradiations.
While on average only 59.7% of the integral OD have been measured within the TA in case
of re-scanning, this number could be increased to 90.6% when RDRS has been used for dose
delivery.
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Figure 4.5.: Dose cuts through iso-centre. Static delivery as well as the motion mitigation tech-
niques BT, RDBT, and RDRS are shown. For the motion mitigation techniques the
cuts are from the simulation with motion starting phase at 0°.
4.2.2 Simulations
In Figure 4.5 dose cuts through the isocentre are shown. For BT, RDBT as well as RDRS the
dose cuts with starting phase 0° are shown. Only BT shows in these cuts areas with doses below
800mGy. RDRS shows less underdoses than BT. They are only apparent at the very distal part
of the target volume. RDBT performs best in avoiding overdoses.
Figure 4.6 on the following page shows DVHs from simulations for different motion mitigation
techniques. The SPHERE treatment plan introduced in Section 2.2.3 has been used. RDRS is
preventing underdose for all starting phases very well. The prevention of underdoses for this
setup is superior to BT and even RDBT. Overdoses are most effectively prevented using RDBT.
But despite its lack of energy compensation, RDRS outperforms BT in preventing overdoses in
the target volume.
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Figure 4.6.: DVHs for 10 different starting phases using RDRS. For comparison the earlier investi-
gated techniques BT and RDBT are also shown (compare Section 2.3.2). RDRS in this
setup exhibits the best prevention of underdoses for all techniques. Overdoses can
be reduced compared to BT but are higher than in RDBT.
4.3 Discussion
Intrafractional tumor motion introduces a large variety of characteristics relevant for radio-
therapy treatment of affected tumors. Tumor motion e.g., differs in amplitude, period, and
reproducibility. As e.g., in the therapy of stationary tumors beam angles can be chosen for best
organ at risk (OAR) sparing in the treatment of moving tumors the choice of a motion mitigation
technique best suited to the actual tumor and it’s motion characteristic can improve e.g., target
coverage, OAR sparing, and treatment time. The choice of a motion mitigation technique will
not only be governed by the motion parameters. Additional hardware required by some of the
most sophisticated motion mitigation techniques might not be available at all therapy centers.
BT and RDBT require real-time energy adaptation systems. Currently no such system is clinically
available. The motion mitigation technique RDRS introduced in this chapter does not rely on
real-time energy adaptation. It’s a pure software implementation and could thus in principle be
implemented in any clinical center using scanned ion beam therapy. The only additional hard-
ware requirement compared to irradiations of stationary tumors is a motion monitoring system.
All introduced motion mitigation techniques but re-scanning explicitly rely on motion monitor-
ing. Also for re-scanning a clinical implementation is very likely to include a motion monitoring
system, e.g., for beam pausing in case of unexpected motion. Also more elaborate methods of
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re-scanning have been proposed that rely on motion monitoring, e.g., to avoid synchronization
between motion period and iso-energy slice (IES) irradiation time (Furukawa et al., 2007; Seco
et al., 2009).
RDRS has been implemented into the GSI TCS as well as into TReatment planning for Particles
(TRiP). At the moment the correlation table in only implemented into the TCS. As in the
simulations performed in TRiP RDRS has been used in conjunction with LBT the need for this
correlation table is expected to be lower.
In film measurements RDRS has been compared to re-scanning. In the OD distributions dark
spots can be seen already in the static irradiations. They are thus not caused by the motion
mitigation techniques. Possible causes for these dark spots are the intensity control system of the
TCS. These spots compromise the homogeneity values. Both techniques showed an increasing
homogeneity with increasing number of re-scans. In case of re-scanning the homogeneity is even
better than in the static case if the re-scan number is seven or larger. This can be explained when
taking into account that also the influence of the dark spots is averaged with increasing re-scan
number. The homogeneity of RDRS is biased by the need of delivering a minimal number of
particles at each spot.
RDRS has proven to be very advantageous in terms of conformity. The CI could significantly
be improved from 59.7% when re-scanning was used to 90.6% when RDRS was used. The con-
formity of a treatment technique in case of a clinical application is directly connected to healthy
tissue sparing. An ITV needs to be constructed when re-scanning is used what intrinsically im-
plies dose delivery to surrounding areas. The relative fraction of dose delivered to the target
depends among other factors on the relation between target size and motion amplitude.
Besides affecting the films homogeneity the additional dose delivery also increased the mean
dose with increasing number of re-scans for RDRS. This is because the current beam delivery
system at GSI is not capable of skipping single beam positions. Thus, a minimal fraction of 10%
had to be applied even if the current beam position already received enough dose or was even
not within the TA. Thus, also the dose delivered to areas outside the TA is increased by this
effect. Functionality to skip beam positions can in principle be implemented to the TCS. It is
anticipated that this would further improve homogeneity, mean dose, and dose conformity of
RDRS.
Simulations for a three dimensional treatment plan showed that the RDRS technique com-
bined with LBT has the potential to improve dose coverage of the target volume compared to
BT and at the same time reduce the hardware requirements for beam application compared to
BT as no real-time energy compensation is needed.
The proposed RDRS technique would be especially advantageous for a tumor exhibiting a
large target motion. Especially if no real-time energy adaptation is available and thus BT and
RDBT can not be used, RDRS could be used. It could provide a higher tumor conformity com-
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pared to re-scanning and at the same time use the full accelerator duty cycle in contrast to
gating.
For the assessment of the efficacy of RDRS for clinical treatments, treatment planning studies
are indispensable.
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5 Discussion and perspectives
After the implementation of real-time dose compensation has been assessed in experiments and
simulations, this chapter is intended to provide a summarizing discussion. Also, possible direc-
tions of future research will be outlined.
Modern radiotherapy methods like intensity modulated radiotherapy (IMRT) and scanned
particle techniques allow one to shape the treatment field very conformally to the tumor. Dose
to healthy tissue and, especially, organs at risk (OARs) can be kept very low. Both techniques use
an overlay of many small beams, called beamlets in IMRT and pencil beams in scanned particle
therapy. Thus, the treatment field for these intensity modulation techniques is not constant over
the treatment time. When transferring these techniques to the therapy of intrafractionally mov-
ing tumors, interference effects occur if the treatment field changes on a time scale comparable
to the time scale of tumor motion. These interference effects are known as interplay. To avoid
or reduce the dose deteriorations introduced by these interferences two principle approaches in
beam delivery are conceivable:
• beam application speed is changed to another time scale compared to tumor motion,
• motion mitigation techniques are applied to mitigate the perturbing effect of motion on
the dose distribution.
In principle, the irradiation speed could be dramatically reduced. This would not only have
the disadvantage of a prolonged treatment time but also smear out the dose distribution to an
area encompassing the entire motion trajectory. Dose homogeneity would only be reached by
abandoning tumor conformity. Hence, deceleration of the application speed is not an acceptable
solution. A dramatic increase of the application speed, on the other hand, would lead to a quasi-
static irradiation of the tumor, as intrafractional tumor motion within the irradiation time would
become negligible. Up to now, no beam delivery system is able to deliver typical treatment
doses precisely to a tumor volume on a time scale where organ motion is negligible. However,
technical development towards accelerated dose delivery has been reported in the literature.
Furukawa et al. report that a physical dose of 1Gy could be delivered to a sphere with 60mm
radius within 20 s (Furukawa et al., 2010b). Pedroni et al. estimate a treatment time of 6.5 s
for dose delivery to a volume of one liter comprising 21 iso-energy slices (IESs) in continuous
scanning mode (Pedroni et al., 2004). Although these treatment times are much shorter than
typical current treatment times, they are still on the same time scale as tumor motion. Thus,
currently, the application of motion mitigation techniques is the only feasible option to treat
intrafractionally moving tumors with intensity modulation techniques.
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Various motion mitigation techniques have been proposed. Some of them are already in clin-
ical use. Re-scanning relies on statistical averaging of different interplay patterns leading to a
homogeneous overall dose by repeated delivery of treatment fields. This method is relatively
robust against uncertainties if synchronization effects between target motion and beam delivery
can be avoided. Methods to address the problem of synchronization have been proposed (Fu-
rukawa et al., 2007; Seco et al., 2009). Re-scanning compromises tumor conformity, as margins
covering the whole motion trajectory need to be used. Gating restricts dose delivery to a subset
of the tumor trajectory and, thus, achieves reduction of the target motion occurring during beam
delivery. Beam tracking (BT) adapts the beam positions to the tumor motion and can, thus, in
principle, maintain full tumor conformity.
Knowing the specific advantages and drawbacks of each motion mitigation technique, treat-
ments of moving tumors could be tailored to individual patient characteristics. Re-scanning
might be the method of choice if a tumor exhibits only small or hardly-reproducible motion
because re-scanning is very robust and the severity of its main disadvantage, loss of tumor con-
formity, scales with the tumor motion amplitude. Gating is currently already used in IMRT
treatments (Keall et al., 2006) as well as in passive particle beam delivery (Miyamoto et al.,
2003). The tumor motion during beam application is reduced to the residual motion within
the gating window. Accordingly, the severity of interplay patterns is reduced. It can be further
reduced by combining gating with re-scanning (Furukawa et al., 2010a). BT techniques have so
far only been applied clinically in photon therapy (Ozhasoglu et al., 2008). BT in photon ther-
apy is realized by adapting the lateral beam position to the tumor motion. The application of BT
in scanned particle therapy involves additional complexity as the range sensitivity of ion beams
is much larger compared to photon beams. This sensitivity necessitates the implementation
of a fast beam energy adaptation system for three dimensional adaptation of the Bragg peak
position. Even if fast energy adaptation is available, dose distributions can be compromised
if non-translational motion occurs. Non-translational motion can change the tumor geometry
relative to the pathway of the beam even if three dimensional BT is applied. These dose deterio-
rations are not predictable due to the limited accuracy of a priori knowledge concerning patient
motion. A real-time dose compensation functionality can be implemented to assess, based on
measured motion, and compensate dose changes occurring during beam application by adapt-
ing the nominal particle numbers applied at each beam position. Such a method is considered to
be a closed-loop method as the results of the ongoing dose delivery are fed back to the therapy
control system (TCS) and are used to adapt the ongoing delivery process. Such an approach
has been proposed by Bert (Bert, 2006) but has not been implemented into the TCS prior to
this work. A closed-loop approach for real-time dose adaptation in photon therapy has been
proposed by Lu et al. (Lu et al., 2009). Their implementation is based on the TomoTherapy
system (see Section 1.3 on page 28) and adapts dose deposition based on accumulated dose
delivery and estimation of future dose delivery.
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Within the scope of this work, real-time dose compensation combined with beam tracking
(RDBT) has been implemented into the GSI Helmholtzzentrum für Schwerionenforschung
GmbH (GSI) TCS. Its functionality has been experimentally verified in water phantom mea-
surements (see Chapter 2). Rotational motion was introduced (total rotation angle of −24°)
by a dedicated motion table. Nominal dose was 1Gy, and different simple geometric shapes
were used as target volumes. Average under- and overdoses in BT for the different target
volumes have been measured to be between 27mGy and 68mGy. These could be reduced to
12mGy to 37mGy by using RDBT. The efficacy of RDBT was thus experimentally verified. How-
ever, the experimental conditions are not easily transferrable to a clinical scenario. A relatively
large rotation was used that covers a worst case scenario rather than a typical tumor motion.
The heterogeneous density distribution of a patient, especially in the lung region, was also not
adequately represented by the employed water phantom. While relative biological effective-
ness (RBE) weighted dose needs to be used for radiotherapy, measurements could only assess
absorbed dose. Therefore, treatment planning studies were conducted in Chapter 3.
Treatment planning studies, based on time resolved computed tomography (4DCT) data from
five lung cancer patients, were conducted as a first step to answer the question which tumor
characteristics require which level of BT complexity. Therefore, the techniques lateral beam
tracking (LBT), BT and RDBT have been compared for scanned carbon therapy. For comparison,
beam application without motion mitigation has additionally been simulated. The study was
based on a fractionation scheme applied in passive carbon radiotherapy at the National Insti-
tute of Radiological Sciences (NIRS) (Miyamoto et al., 2007). Different measures were used
to evaluate the dose distributions for all application techniques. Dose coverage of the clinical
target volume (CTV) was assessed by V95
1, the overdose level was assessed by the V107 value and
the D5− D95
2 value has been used as a measure for dose homogeneity. BT and RDBT have typi-
cally delivered significantly superior dose distributions compared to LBT and beam application
without motion mitigation. RDBT typically outperformed BT when the V107 and the D5 − D95
value were measured. The V95 values for both techniques were on average above 95% for all
patients. These results are different from the results reported by Bert (Bert, 2006). Bert found
unacceptably low V95 values for some patients when BT was applied. While the RDBT results
reported by Bert typically offered excellent V95 the over-dose level was increased when using
RDBT. The patients in the current study covered a tumor motion range from 1mm to 25mm.
Patient 3 exhibiting a motion amplitude of only 1mm showed good target coverage even when
treated without motion mitigation. For such patients treatment without motion mitigation can
be justified. At MD Anderson Cancer Center (MDACC) lung cancer patients with very low tu-
mor motion have already been treated with scanned proton beams without application of one
of the introduced motion mitigation techniques. Dose coverage in patients with larger motion
1 V95: The volume that receives at least 95% of the prescribed dose.
2 D5: 5% of the volume received a dose of at least D5.
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amplitude was not satisfying if interplay or LBT were used. Thus, at least for the applied frac-
tionation scheme and field setup there are lung cancer patients whose motion characteristics
suggest the necessity for energy compensation if BT methods are supposed to be used. In one
case, patient 2, BT produced a high level of over-doses that was not measured when RDBT was
used. These over-doses in BT might be connected to density gradients apparent within the CTV
of this patient. Similar effects for heterogeneous phantoms have been reported by van de Water
et al. (van de Water et al., 2009).
In Chapter 4, a new motion mitigation technique, called real-time dose compensated re-
scanning (RDRS), is proposed. It combines real-time dose compensation with several re-scans. BT
can be optionally used with this method. Also, the application of BT in less than three dimen-
sions, e.g., LBT, can be used with this method. Besides increased robustness due to the effect of
the re-scans, this method also compensates for dose changes introduced by missing or limited
BT. Thus, this method might supersede the technically challenging implementation of real-time
energy adaptation in a clinical environment. Film irradiations for twodimensional treatment
plans as well as simulations using threedimensional treatment plans have been performed. For
the film irradiations, the mean conformity to the target area (TA) could be increased from 59.7
when re-scanning was used to 90.6 when RDRS without BT was used. Homogeneity compara-
ble to the static irradiation could be obtained with less re-scans by re-scanning than by RDRS.
Simulations using a water phantom showed a substantial reduction of under-doses when RDRS
combined with LBT was used compared to BT and even compared to RDBT. Over-dose level has
been reduced in comparison to BT but was not as low as the over-dose level obtained applying
RDBT. It should be emphasized that among these three methods only RDRS did not rely on
real-time energy adaptation. Installation of a real-time energy adaptation system is expected
to be one of the most critical steps in transferring BT into a clinical environment. However,
only an initial assessment of RDRS could be presented in this work. Further measurements and
simulations are needed to assess the clinical efficacy of RDRS. Especially, treatment planning
studies like those conducted in this work comparing LBT, BT, and RDBT would be desirable.
In order to transfer any of the introduced motion mitigation techniques to a clinical environ-
ment several steps are needed. They encompass hardware and software upgrades as well as
workflow changes. Some of the required steps are outlined here:
Motion monitoring: In a clinical environment, all motion mitigation techniques will require
monitoring of the tumor motion. Several techniques are available. A review has been
published by Evans et al. (Evans, 2008). A comparison of the correlation of different
surrogate signals with tumor motion has been investigated by Steidl (Steidl, 2011).
4D treatment planning: In order to treat mobile tumors, dedicated 4D treatment planning is
necessary. Methods have been proposed for photon (Keall, 2004; Keall et al., 2005) as well
as for particle treatments (Rietzel et al., 2005a; Bert and Rietzel, 2007).
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TCS: The TCS needs to be extended. For BT and related techniques, the ability for real-time
adaptation of the Bragg peak position needs to be implemented. The interlock system
needs to be upgraded, e.g., to cover irregular patient motion.
Quality assurance: Quality assurance for moving tumors is more complex than for stationary
tumors. The application of motion phantoms might be considered (Serban et al., 2008;
Steidl, 2011). A method for BT quality assurance has been proposed by Saito et al. (Saito
et al., 2010).
The implementations to the TCS and to TReatment planning for Particles (TRiP) presented
in this work show a possible way towards clinical 4D treatment planning and 4D treatment
delivery. The treatment planning studies are important to assess the necessity of motion mitiga-
tion for different motion characteristics. They should, in the future, be extended by robustness
analysis.
However, 4D treatment planning, especially for scanned particle beams, is a relatively new
field and many developments can be expected in the future. So far, 4D treatment planning
typically encompasses the optimization of a 3D treatment plan. In case of BT as well as RDBT,
compensation parameters aiming to preserve the 3D optimized dose distribution are precalcu-
lated. That means that the motion and the anatomic information of the other 4DCT states is
not exploited in the optimization process. This has already been stated by Bert et al. (Bert
and Durante, 2011). In photon therapy, methods incorporating the full 4DCT information
into the optimization process have been proposed, e.g., by Nohadani et al. (Nohadani et al.,
2010). A real 4D optimization might also improve scanned particle delivery for moving tumors.
One method for 4D optimization and beam delivery is proposed here. It is called motion syn-
chronized delivery (MSD). For photon therapy dose-rate regulated tracking (DRRT) has been
proposed (Yi et al., 2008). The basic ideas of both approaches are comparable.
One of the major problems in treatment plan optimization for moving targets is the missing a
priori knowledge concerning the patient’s motion trajectory. Even in the case where the 4DCT
information is still valid at time of treatment delivery the exact breathing trajectory, i.e., the
exact time sequence of the motion states is in general not known. Thus, the correlation between
a beam position and the motion state it will be irradiated in is unknown.
For MSD, a treatment plan is optimized taking a nominal patient motion trajectory, e.g., ob-
tained during the imaging session, into account. At the time of treatment delivery, the assumed
correlation between beam positions and motion states is likely not to be valid any more. In-
stead of trying to adapt the patient motion to the treatment plan, in MSD, the beam delivery
is adapted to the patient motion. This can be achieved by incorporating multiple beam pauses
into the nominal 4D treatment plan. At the end of each nominal motion state a beam pause is
scheduled. Thus in each motion state mi a fraction t
p
i
of the nominal length t i is reserved for a
beam pause while the remaining time t b
i
= t i − t
p
i
is used for irradiation of Ni beam positions.
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Figure 5.1.: Sketch of the working principle of motion synchronized delivery. Beam-on time (t b
i
,
red) as well as one nominal pause (t
p
i
, light blue) per motion state are scheduled
in treatment planning. At time of treatment delivery the pause duration et p
i
is pro-
longed in case of slower breathing or shortened in case of faster breathing. In both
cases the beam-on time t b
i
can be kept constant and thus delivery of the nominal
amount of beam positions in that motion state can be achieved and the nominal
correlation between beam positions and motion state can thus be maintained. Al-
though not explicitly shown here, frequency changes within one treatment session
can also be handled.
During beam delivery, the length of this beam pause is adapted to the patient motion. It is likely
that the time et i spent in the motion state mi during therapy differs from t i assumed in treatment
planning. In case et i > t i the beam pause is prolonged et pi > t pi . Vice versa the beam pause is
shortened et p
i
< t
p
i
if the patient spends less time in the motion state mi, i.e., et i < t i. In both
cases, et i = t bi + et pi is valid, and the nominal number of beam positions Ni can be irradiated in
the motion state mi. Thus, the correlation between motion state and beam positions can be pre-
served. DRRT also relies on real-time adaptation of the beam delivery to maintain correlations.
Instead of introducing beam pauses, the dose rate is adapted.
A sketch of the working principle of MSD is shown in Figure 5.1. Although not shown in that
figure, changes of the breathing speed during therapy can also be handled as the length of each
pause is adapted separately. Some issues need to be solved before such a method could be ap-
plied. While frequency changes within certain limits can easily be dealt with, amplitude changes
are more difficult to handle. Optimization including all motion states is not yet implemented for
scanned particle therapy but seems achievable for the proposed method, since the basic routines
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for 3D optimization can be applied due to the preserved correlation between motion state and
beam positions.
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6 Conclusions
Scanned particle therapy provides very conformal irradiations of stationary tumors. With this
technique, the tumor is covered with thousands or even ten thousands of beam positions. An
optimized amount of particles is delivered to each of these beam positions employing a narrow
pencil beam. By using heavier ions, an elevated biological effectiveness can be exploited in
addition to physical advantages of ions compared to photons. An increasing number of clinical
centers use scanned particle radiotherapy. Irradiations have so far been restricted to tumor
locations not exhibiting considerable intrafractional motion, as interference effects between
dynamic beam application and tumor motion deteriorate resulting dose distributions.
Several motion mitigation techniques to overcome these dose deteriorations are currently
investigated. Beam tracking (BT) is one of these methods. The idea of BT is to adapt the
pencil beam positions to the changing tumor position. A dose distribution optimized for a static
tumor can, in principle, be preserved if target motion is purely translational. In the case of
nontranslational motion, e.g., rotations and deformations, the tumor geometry with respect to
the pencil beam’s path is altered. This leads to changes in the overall dose distribution, even if
each pencil beam position is adapted to the changed target position.
Real-time dose compensation combined with beam tracking (RDBT) was proposed to mitigate
these dose changes in real-time during dose delivery. In this work such a functionality has
been implemented into the therapy control system (TCS) at GSI Helmholtzzentrum für Schw-
erionenforschung GmbH (GSI) as well as into the GSI treatment planning software TReatment
planning for Particles (TRiP). The implemented functionality has been verified in dedicated
experiments. A significant reduction of dose changes compared to a static reference irradiation
has been measured when RDBT was used for motion mitigation compared to BT. Dose distribu-
tions were reconstructed using a 4D extension of TRiP. Reconstructed dose differences were in
good agreement with those experimentally obtained.
The clinical benefit of RDBT has been assessed in treatment planning studies. Scanned carbon
ion therapy courses, comprising four fractions with four treatment fields each, have been sim-
ulated based on time resolved computed tomography (4DCT) data of five lung cancer patients.
A range of different tumor motion parameters has been used. For most patients, overdose (3
out of 5 patients) was significantly reduced and dose homogeneity (4 out of 5 patients) was
significantly improved when RDBT was used compared to all other techniques. BT and RDBT
were superior to lateral beam tracking (LBT) and beam application without motion mitigation.
Differences between the investigated motion mitigation techniques were small for one patient
exhibiting only a very small tumor motion.
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A method combining real-time dose compensation with several re-scans, called real-time dose
compensated re-scanning (RDRS), has been proposed. In conjunction with LBT this method
should have the potential to supersede the technically complex real-time energy adaptation
needed for BT. Film experiments comparing RDRS and re-scanning, i.e., a motion mitigation
technique using repeated dose delivery to average under- and overdoses, as well as simulations
comparing RDRS, RDBT and BT have been performed. The RDRS film measurements showed a
significantly improved sparing of areas surrounding the target area compared to re-scanning. In
simulations, RDRS showed a better prevention of underdoses when compared to BT and RDBT.
The level of overdose was reduced using RDRS compared to BT but not as low as achieved by
RDBT. Further assessment of this technique, preferably using patient data, will be needed to
explore the clinical efficacy of RDRS.
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A Results treatment planning studies
Results of the treatment planning studies that were not presented in the text are shown here.
(a) Interplay. (b) lateral beam tracking.
(c) Beam tracking. (d) RDBT.
Figure A.1.: Dose distributions for all four application techniques in patient 1. Cuts are drawn
through iso-centre. The line connecting the CTVs is a display artifact. Motion pe-
riod of 4 s and motion starting phases of 0°, 90°, 180°, and 270° have been used.
Dose calculation has been based on rigid registration. BT and RDBT deliver a more
homogeneous dose distribution than interplay and LBT.
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(a) Interplay. (b) lateral beam tracking.
(c) Beam tracking. (d) RDBT.
Figure A.2.: Dose distributions for all four application techniques in patient 2. Cuts are drawn
through iso-centre. Motion period of 4 s andmotion starting phases of 0°, 90°, 180°,
and 270° have been used. Dose calculation has been based on rigid registration. BT
and RDBT deliver a more homogeneous dose distribution than interplay and LBT.
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(a) Interplay. (b) lateral beam tracking.
(c) Beam tracking. (d) RDBT.
Figure A.3.: Dose distributions for all four application techniques in patient 3. Cuts are drawn
through iso-centre. Motion period of 4 s andmotion starting phases of 0°, 90°, 180°,
and 270° have been used. Dose calculation has been based on rigid registration.
Tumor motion for patient 3 was very small. Differences in dose distributions can
hardly be seen.
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(a) Interplay. (b) lateral beam tracking.
(c) Beam tracking. (d) RDBT.
Figure A.4.: Dose distributions for all four application techniques in patient 4. Cuts are drawn
through iso-centre. Motion period of 4 s andmotion starting phases of 0°, 90°, 180°,
and 270° have been used. Dose calculation has been based on rigid registration. BT
and RDBT deliver a more homogeneous dose distribution than interplay and LBT.
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Table A.1.:Mean and standard deviations of V95 for all patients when rigid registration is used
for dose calculation. Results of the fraction doses are shown here.
patient no
V95 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 90.9 (2.1) 92.0 (1.7) 98.8 (0.3) 97.8 (0.3)
2 66.1 (7.1) 80.5 (2.3) 98.0 (0.4) 97.9 (0.5)
3 97.5 (0.8) 97.3 (0.8) 99.7 (0.0) 99.2 (0.2)
4 82.3 (3.4) 81.7 (2.4) 92.9 (1.1) 94.6 (1.0)
5 49.4 (12.5) 86.6 (3.6) 99.5 (0.2) 98.8 (0.3)
Table A.2.: Overview of the significance of V95 differences between the application techniques
using rigid registration. Results are for the treatment of one fraction. The V95 results
of two techniques showed significant differences for the patients whose numbers is
given in the corresponding cell while a "-" indicates no significant differences for that
patient.
interplay LBT BT RDBT
interplay - -/2/-/-/5 1/2/3/4/5 1/2/3/4/5
LBT -/2/-/-/5 - 1/2/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/2/3/4/5 - -/-/-/-/-
RDBT 1/2/3/4/5 1/2/3/4/5 -/-/-/-/- -
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Table A.3.:Mean and standard deviations of V95 for all patients when rigid registration is used
for dose calculation. Results for the complete treatment course are shown.
patient no
V95 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 97.2 (0.7) 97.4 (0.7) 99.5 (0.1) 98.7 (0.1)
2 71.5 (3.6) 85.8 (1.4) 98.8 (0.2) 98.7 (0.3)
3 99.4 (0.1) 99.3 (0.2) 99.8 (0.0) 99.3 (0.1)
4 89.8 (1.1) 89.9 (1.2) 95.0 (0.9) 96.3 (0.6)
5 53.2 (9.3) 92.7 (1.2) 99.8 (0.1) 98.9 (0.2)
Table A.4.: Overview of the significance of V95 differences between the application techniques
using rigid registration. Results for the complete treatment course are shown. The
Tuckey-Kramer test at 5% significance level has been used. The V95 results of two
techniques showed significant differences for the patients whose numbers is given in
the corresponding cell while a "-" indicates no significant differences for that patient.
interplay LBT BT RDBT
interplay - 1/2/-/-/5 1/2/3/4/5 1/2/3/4/5
LBT 1/2/-/-/5 - 1/2/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/2/3/4/5 - 1/-/3/4/-
RDBT 1/2/3/4/5 1/2/3/4/5 1/-/3/4/- -
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Table A.5.:Mean and standard deviations of V95 for all patients when non-rigid registration is
used for dose calculation while MLUT calculation is done using the rigid registration.
Results are for the treatment of one fraction.
patient no
V95 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 91.3 (2.2) 91.9 (2.1) 97.6 (0.9) 95.8 (1.2)
2 71.0 (5.0) 77.1 (2.0) 90.5 (1.5) 86.8 (1.6)
3 95.1 (0.8) 94.7 (0.9) 98.7 (0.3) 97.1 (0.6)
4 82.7 (2.7) 81.2 (1.9) 91.8 (1.1) 93.0 (0.8)
5 54.5 (12.3) 83.2 (3.8) 94.1 (3.0) 90.6 (3.8)
Table A.6.: Overview of the significance of V95 differences between the application techniques
using non-rigid registration for dose calculation. MLUT calculation has been per-
formed based on rigid registration. Results are for the treatment of one fraction.
The Tuckey-Kramer test at 5% significance level has been used. The V95 results of two
techniques showed significant differences for the patients whose numbers is given in
the corresponding cell while a "-" indicates no significant differences for that patient.
interplay LBT BT RDBT
interplay - -/2/-/-/5 1/2/3/4/5 1/2/3/4/5
LBT -/2/-/-/5 - 1/2/3/4/5 1/2/3/4/-
BT 1/2/3/4/5 1/2/3/4/5 - -/2/3/-/-
RDBT 1/2/3/4/5 1/2/3/4/- -/2/3/-/- -
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Table A.7.:Mean and standard deviations of V95 for all patients when non-rigid registration is
used for dose calculation while MLUT calculation is done using the rigid registration.
Results for the complete treatment course are shown here.
patient no
V95 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 96.7 (0.7) 97.2 (0.7) 99.1 (0.2) 97.8 (0.3)
2 75.1 (2.7) 82.3 (1.1) 92.3 (0.6) 90.5 (1.1)
3 98.6 (0.3) 98.4 (0.4) 99.5 (0.1) 98.3 (0.3)
4 90.4 (1.3) 89.1 (1.4) 93.5 (0.8) 94.4 (0.7)
5 58.6 (8.7) 87.7 (1.7) 95.8 (0.8) 93.6 (1.2)
Table A.8.: Overview of the significance of V95 differences between the application techniques
using non-rigid registration for dose calculation. MLUT calculation has been per-
formed based on rigid registration. Results for the complete treatment course are
shown here. The Tuckey-Kramer test at 5% significance level has been used. The V95
results of two techniques showed significant differences for the patients whose num-
bers is given in the corresponding cell while a "-" indicates no significant differences
for that patient.
interplay LBT BT RDBT
interplay - 1/2/3/4/5 1/2/3/4/5 1/2/3/4/5
LBT 1/2/3/4/5 - 1/2/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/2/3/4/5 - 1/2/3/4/5
RDBT 1/2/3/4/5 1/2/3/4/5 1/2/3/4/5 -
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Table A.9.:Mean and standard deviations of V107 for all patients when rigid registration is used
for dose calculation. Results are for the treatment of one fraction.
patient no
V107 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 2.0 (0.8) 2.3 (0.7) 0.6 (0.2) 0.1 (0.0)
2 6.0 (3.0) 3.9 (0.8) 15.8 (1.0) 1.3 (0.3)
3 0.2 (0.1) 0.2 (0.1) 0.0 (0.0) 0.0 (0.0)
4 4.1 (1.8) 3.1 (1.3) 0.4 (0.2) 0.3 (0.2)
5 7.9 (13.0) 7.5 (2.9) 2.0 (0.6) 0.4 (0.4)
Table A.10.: Overview of the significance of V107 differences between the application techniques
using rigid registration. Results are for the treatment of one fraction. The Tuckey-
Kramer test at 5% significance level has been used. The V107 results of two tech-
niques showed significant differences for the patients whose numbers is given in
the corresponding cell while a "-" indicates no significant differences for that pa-
tient.
interplay LBT BT RDBT
interplay - -/2/-/-/- 1/2/3/4/- 1/2/3/4/5
LBT -/2/-/-/- - 1/2/3/4/- 1/2/3/4/-
BT 1/2/3/4/- 1/2/3/4/- - -/2/-/-/-
RDBT 1/2/3/4/5 1/2/3/4/- -/2/-/-/- -
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Table A.11.:Mean and standard deviations of V107 for all patients when rigid registration is used
for dose calculation. Results for the complete treatment course are shown.
patient no
V107 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 0.1 (0.1) 0.3 (0.1) 0.5 (0.1) 0.0 (0.0)
2 0.7 (0.6) 0.4 (0.2) 23.5 (0.5) 1.2 (0.3)
3 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
4 0.3 (0.2) 0.2 (0.2) 0.0 (0.0) 0.0 (0.0)
5 3.2 (5.7) 2.6 (1.1) 1.9 (0.6) 0.2 (0.2)
Table A.12.: Overview of the significance of V107 differences between the application techniques
using rigid registration. Results for the complete treatment course are shown. The
Tuckey-Kramer test at 5% significance level has been used. The V107 results of two
techniques showed significant differences for the patients whose numbers is given
in the corresponding cell while a "-" indicates no significant differences for that pa-
tient.
interplay LBT BT RDBT
interplay - 1/2/-/4/- 1/2/3/4/5 1/2/3/4/5
LBT 1/2/-/4/- - 1/2/-/4/- 1/2/-/4/5
BT 1/2/3/4/5 1/2/-/4/- - 1/2/-/-/5
RDBT 1/2/3/4/5 1/2/-/4/5 1/2/-/-/5 -
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Table A.13.:Mean and standard deviations of V107 for all patients when non-rigid registration
is used for dose calculation. The MLUTs are calculated based on rigid registration.
Results are for the treatment of one fraction.
patient no
V107 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 1.7 (0.9) 2.1 (0.7) 0.9 (0.3) 0.4 (0.6)
2 4.7 (2.3) 4.4 (1.1) 11.6 (2.4) 3.7 (1.0)
3 0.8 (0.3) 0.7 (0.3) 0.4 (0.2) 0.1 (0.1)
4 3.9 (1.7) 3.1 (1.3) 0.3 (0.2) 0.3 (0.2)
5 7.3 (11.7) 7.2 (2.7) 4.2 (2.2) 2.0 (1.4)
Table A.14.: Overview of the significance of V107 differences between the application techniques
using non-rigid registration for dose calculation. MLUTs are calculated according to
rigid registration. Results are for the treatment of one fraction. The Tuckey-Kramer
test at 5% significance level has been used. The V107 results of two techniques
showed significant differences for the patients whose numbers is given in the cor-
responding cell while a "-" indicates no significant differences for that patient.
interplay LBT BT RDBT
interplay - -/-/-/-/- 1/2/3/4/- 1/-/3/4/-
LBT -/-/-/-/- - 1/2/3/4/- 1/-/3/4/-
BT 1/2/3/4/- 1/2/3/4/- - -/2/3/-/-
RDBT 1/-/3/4/- 1/-/3/4/- -/2/3/-/- -
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Table A.15.:Mean and standard deviations of V107 for all patients when non-rigid registration
is used for dose calculation. The MLUTs are calculated based on rigid registration.
Results for the complete treatment course are shown here.
patient no
V107 mean (standard deviation) [% CTV volume]
interplay lateral BT BT RDBT
1 0.1 (0.1) 0.3 (0.2) 0.7 (0.2) 0.0 (0.1)
2 0.5 (0.4) 0.4 (0.2) 14.3 (1.1) 2.2 (0.7)
3 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0)
4 0.3 (0.2) 0.2 (0.2) 0.0 (0.0) 0.0 (0.0)
5 2.5 (4.6) 2.3 (0.9) 2.2 (1.0) 0.5 (0.4)
Table A.16.: Overview of the significance of V107 differences between the application techniques
using non-rigid registration for dose calculation. MLUTs are calculated according
to rigid registration. Results for the complete treatment course are shown here.
The Tuckey-Kramer test at 5% significance level has been used. The V107 results of
two techniques showed significant differences for the patients whose numbers is
given in the corresponding cell while a "-" indicates no significant differences for
that patient.
interplay LBT BT RDBT
interplay - 1/-/-/4/- 1/2/3/4/- -/2/3/4/5
LBT 1/-/-/4/- - 1/2/3/4/- 1/2/3/4/5
BT 1/2/3/4/- 1/2/3/4/- - 1/2/3/-/5
RDBT -/2/3/4/5 1/2/3/4/5 1/2/3/-/5 -
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Table A.17.:Mean and standard deviations of D5− D95 for all patients when rigid registration is
used for dose calculation. Results are for the treatment of one fraction.
patient no
D5 − D95 mean (standard deviation) [% prescribed dose]
interplay lateral BT BT RDBT
1 11.4 (0.7) 11.6 (0.9) 7.8 (0.5) 6.8 (0.6)
2 26.9 (3.6) 15.6 (0.9) 13.6 (0.5) 8.7 (0.5)
3 7.3 (0.9) 7.2 (1.0) 5.8 (0.4) 5.2 (0.4)
4 15.2 (1.1) 14.5 (1.2) 9.1 (0.3) 8.4 (0.8)
5 40.8 (10.4) 15.8 (2.2) 7.7 (0.8) 7.2 (0.6)
Table A.18.: Overview of the significance of D5 − D95 differences between the application tech-
niques using rigid registration. Results are for the treatment of one fraction. The
Tuckey-Kramer test at 5% significance level has been used. The D5 − D95 results
of two techniques showed significant differences for the patients whose numbers
is given in the corresponding cell while a "-" indicates no significant differences for
that patient.
interplay LBT BT RDBT
interplay - -/2/-/-/5 1/2/3/4/5 1/2/3/4/5
LBT -/2/-/-/5 - 1/-/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/-/3/4/5 - 1/2/-/-/-
RDBT 1/2/3/4/5 1/2/3/4/5 1/2/-/-/- -
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Table A.19.:Mean and standard deviations of D5− D95 for all patients when rigid registration is
used for dose calculation. Results for the complete treatment course are shown.
patient no
D5 − D95 mean (standard deviation) [% prescribed dose]
interplay lateral BT BT RDBT
1 7.1 (0.8) 7.9 (0.7) 6.0 (0.2) 5.1 (0.3)
2 26.1 (2.1) 11.9 (0.8) 15.9 (0.5) 8.8 (0.4)
3 4.5 (0.7) 4.8 (0.9) 5.0 (0.2) 4.4 (0.6)
4 10.2 (0.8) 9.2 (0.8) 7.3 (0.8) 6.3 (0.5)
5 41.1 (5.3) 11.7 (0.9) 7.2 (0.6) 6.5 (0.5)
Table A.20.: Overview of the significance of D5 − D95 differences between the application tech-
niques using rigid registration. Results for the complete treatment course are
shown. The Tuckey-Kramer test at 5% significance level has been used. The D5−D95
results of two techniques showed significant differences for the patients whose
numbers is given in the corresponding cell while a "-" indicates no significant dif-
ferences for that patient.
interplay LBT BT RDBT
interplay - 1/2/-/4/5 1/2/3/4/5 1/2/-/4/5
LBT 1/2/-/4/5 - 1/2/-/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/2/-/4/5 - 1/2/3/4/-
RDBT 1/2/-/4/5 1/2/3/4/5 1/2/3/4/- -
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Table A.21.:Mean and SDs of D5 − D95 for all patients when non-rigid registration is used for
dose calculation. MLUT calculation was based on rigid registration. Results are for
the treatment of one fraction.
patient no
D5 − D95 mean (standard deviation) [% prescribed dose]
interplay lateral BT BT RDBT
1 11.1 (0.9) 11.2 (1.1) 8.6 (0.5) 8.2 (0.7)
2 23.2 (2.6) 17.2 (1.0) 16.8 (1.5) 14.8 (1.4)
3 9.2 (0.8) 9.5 (0.7) 7.5 (0.5) 6.9 (0.3)
4 15.1 (1.2) 14.3 (1.2) 9.2 (0.8) 9.1 (0.5)
5 39.4 (9.9) 18.1 (2.1) 12.0 (2.2) 11.8 (1.4)
Table A.22.: Overview of the significance of D5 − D95 differences between the application tech-
niques using non-rigid registration for dose calculation and rigid registration for
MLUT calculation. Results are for the treatment of one fraction. The Tuckey-Kramer
test at 5% significance level has been used. The D5 − D95 results of two techniques
showed significant differences for the patients whose numbers is given in the cor-
responding cell while a "-" indicates no significant differences for that patient.
interplay LBT BT RDBT
interplay - -/2/-/-/5 1/2/3/4/5 1/2/3/4/5
LBT -/2/-/-/5 - 1/-/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/-/3/4/5 - -/2/-/-/-
RDBT 1/2/3/4/5 1/2/3/4/5 -/2/-/-/- -
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Table A.23.:Mean and SDs of D5 − D95 for all patients when non-rigid registration is used for
dose calculation. MLUT calculation was based on rigid registration. Results for the
complete treatment course are shown here.
patient no
D5 − D95 mean (standard deviation) [% prescribed dose]
interplay lateral BT BT RDBT
1 7.0 (0.7) 8.0 (0.7) 6.6 (0.5) 6.3 (0.6)
2 21.1 (1.3) 14.0 (0.6) 17.7 (0.8) 12.5 (0.9)
3 5.7 (0.6) 5.8 (0.5) 6.0 (0.2) 5.0 (0.2)
4 9.9 (0.7) 9.4 (0.7) 7.6 (0.5) 7.0 (0.6)
5 40.1 (4.6) 14.7 (1.0) 9.9 (0.9) 9.2 (0.6)
Table A.24.: Overview of the significance of D5 − D95 differences between the application tech-
niques using non-rigid registration for dose calculation and rigid registration for
MLUT calculation. Results for the complete treatment course are shown here. The
Tuckey-Kramer test at 5% significance level has been used. The D5 − D95 results
of two techniques showed significant differences for the patients whose numbers
is given in the corresponding cell while a "-" indicates no significant differences for
that patient.
interplay LBT BT RDBT
interplay - 1/2/-/4/5 1/2/3/4/5 1/2/3/4/5
LBT 1/2/-/4/5 - 1/2/3/4/5 1/2/3/4/5
BT 1/2/3/4/5 1/2/3/4/5 - 1/2/3/4/-
RDBT 1/2/3/4/5 1/2/3/4/5 1/2/3/4/- -
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Table A.25.:Minimum and maximum of the mean as well as the maximum fraction OAR doses
for patient 1 with rigid registration based dose calculation. Results are for the treat-
ment of one fraction.
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.5Gy (RBE) 7.8Gy (RBE) 12.0Gy (RBE) 12.9Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 2.0Gy (RBE) 2.8Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 11.5Gy (RBE) 12.9Gy (RBE)
heart 1.0Gy (RBE) 1.1Gy (RBE) 11.3Gy (RBE) 12.2Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.7Gy (RBE) 10.1Gy (RBE) 11.7Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.7Gy (RBE) 7.9Gy (RBE) 11.9Gy (RBE) 13.0Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.6Gy (RBE) 2.7Gy (RBE)
esophagus 2.9Gy (RBE) 3.0Gy (RBE) 11.5Gy (RBE) 12.6Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 11.5Gy (RBE) 12.4Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.7Gy (RBE) 10.2Gy (RBE) 11.5Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.8Gy (RBE) 7.9Gy (RBE) 11.5Gy (RBE) 12.4Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.6Gy (RBE) 2.2Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 11.1Gy (RBE) 11.6Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 10.9Gy (RBE) 11.2Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.6Gy (RBE) 9.9Gy (RBE) 10.6Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.7Gy (RBE) 7.8Gy (RBE) 11.0Gy (RBE) 12.0Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.7Gy (RBE) 2.6Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 10.8Gy (RBE) 11.8Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 10.6Gy (RBE) 11.1Gy (RBE)
vertebral bodies 1.7Gy (RBE) 1.7Gy (RBE) 10.0Gy (RBE) 10.7Gy (RBE)
(d) RDBT
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Table A.26.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 2 when dose calcu-
lation was based on rigid registration. Interplay, lateral BT, BT and RDBT have been
used for Tables A.27a, A.27b, A.27c and A.27d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.8Gy (RBE) 3.6Gy (RBE) 5.9Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 2.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 4.4Gy (RBE) 5.4Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.9Gy (RBE) 3.8Gy (RBE) 5.8Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.1Gy (RBE) 1.2Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.7Gy (RBE) 5.7Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.5Gy (RBE) 2.7Gy (RBE) 3.8Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 1.0Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.3Gy (RBE) 5.3Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.5Gy (RBE) 2.9Gy (RBE) 4.1Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 1.0Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.2Gy (RBE) 4.9Gy (RBE)
(d) RDBT
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Table A.27.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 3 when dose calcu-
lation was based on rigid registration. Interplay, lateral BT, BT and RDBT have been
used for Tables A.28a, A.28b, A.28c, and A.28d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.3Gy (RBE) 5.7Gy (RBE)
esophagus 3.3Gy (RBE) 3.3Gy (RBE) 11.7Gy (RBE) 13.0Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.3Gy (RBE) 5.7Gy (RBE)
esophagus 3.2Gy (RBE) 3.3Gy (RBE) 11.8Gy (RBE) 13.0Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.4Gy (RBE) 4.7Gy (RBE)
esophagus 3.2Gy (RBE) 3.3Gy (RBE) 11.4Gy (RBE) 11.8Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.4Gy (RBE) 5.0Gy (RBE)
esophagus 3.2Gy (RBE) 3.3Gy (RBE) 11.4Gy (RBE) 11.9Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.28.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 4 when dose calcu-
lation was based on rigid registration. Interplay, lateral BT, BT and RDBT have been
used for Tables A.29a, A.29b, A.29c, and A.29d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 5.9Gy (RBE) 7.8Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.2Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 6.2Gy (RBE) 8.1Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 5.1Gy (RBE) 5.8Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 5.4Gy (RBE) 6.4Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
132
Table A.29.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 5 when dose calcu-
lation was based on rigid registration. Interplay, lateral BT, BT and RDBT have been
used for Tables A.30a, A.30b, A.30c, and A.30d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.5Gy (RBE) 3.5Gy (RBE) 6.1Gy (RBE)
esophagus 1.2Gy (RBE) 1.9Gy (RBE) 8.2Gy (RBE) 10.5Gy (RBE)
heart 2.1Gy (RBE) 2.2Gy (RBE) 10.7Gy (RBE) 13.3Gy (RBE)
carina 0.7Gy (RBE) 1.7Gy (RBE) 7.5Gy (RBE) 10.3Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 3.0Gy (RBE) 4.3Gy (RBE)
esophagus 1.1Gy (RBE) 1.3Gy (RBE) 8.7Gy (RBE) 9.8Gy (RBE)
heart 2.4Gy (RBE) 2.5Gy (RBE) 11.3Gy (RBE) 13.6Gy (RBE)
carina 0.2Gy (RBE) 0.3Gy (RBE) 4.6Gy (RBE) 6.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 2.2Gy (RBE) 2.8Gy (RBE)
esophagus 1.0Gy (RBE) 1.0Gy (RBE) 7.4Gy (RBE) 8.1Gy (RBE)
heart 2.4Gy (RBE) 2.4Gy (RBE) 10.6Gy (RBE) 11.4Gy (RBE)
carina 0.1Gy (RBE) 0.2Gy (RBE) 3.7Gy (RBE) 4.7Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 2.2Gy (RBE) 3.3Gy (RBE)
esophagus 1.0Gy (RBE) 1.1Gy (RBE) 7.6Gy (RBE) 8.5Gy (RBE)
heart 2.4Gy (RBE) 2.4Gy (RBE) 10.4Gy (RBE) 11.4Gy (RBE)
carina 0.2Gy (RBE) 0.2Gy (RBE) 3.8Gy (RBE) 4.6Gy (RBE)
(d) RDBT
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Table A.30.:Minimum and maximum of the mean as well as the maximum fraction dose for var-
ious OARs for patient 1 when dose calculation was based on non-rigid registration.
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.5Gy (RBE) 7.8Gy (RBE) 12.0Gy (RBE) 12.9Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 2.0Gy (RBE) 2.8Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 11.5Gy (RBE) 12.9Gy (RBE)
heart 1.0Gy (RBE) 1.1Gy (RBE) 11.3Gy (RBE) 12.2Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.7Gy (RBE) 10.1Gy (RBE) 11.7Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.7Gy (RBE) 7.9Gy (RBE) 11.9Gy (RBE) 13.0Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.6Gy (RBE) 2.7Gy (RBE)
esophagus 2.9Gy (RBE) 3.0Gy (RBE) 11.5Gy (RBE) 12.6Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 11.5Gy (RBE) 12.4Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.7Gy (RBE) 10.2Gy (RBE) 11.5Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.8Gy (RBE) 7.9Gy (RBE) 11.5Gy (RBE) 12.4Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.6Gy (RBE) 2.2Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 11.1Gy (RBE) 11.6Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 10.9Gy (RBE) 11.2Gy (RBE)
vertebral bodies 1.6Gy (RBE) 1.6Gy (RBE) 9.9Gy (RBE) 10.6Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 7.7Gy (RBE) 7.8Gy (RBE) 11.0Gy (RBE) 12.0Gy (RBE)
spinal cord 0.2Gy (RBE) 0.2Gy (RBE) 1.7Gy (RBE) 2.6Gy (RBE)
esophagus 3.0Gy (RBE) 3.0Gy (RBE) 10.8Gy (RBE) 11.8Gy (RBE)
heart 1.1Gy (RBE) 1.1Gy (RBE) 10.6Gy (RBE) 11.1Gy (RBE)
vertebral bodies 1.7Gy (RBE) 1.7Gy (RBE) 10.0Gy (RBE) 10.7Gy (RBE)
(d) RDBT
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Table A.31.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 2 when dose calcu-
lation was based on non-rigid registration. Interplay, lateral BT, BT and RDBT have
been used for Tables A.32a, A.32b, A.32c, and A.32d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.7Gy (RBE) 3.4Gy (RBE) 5.0Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.1Gy (RBE) 2.5Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 3.6Gy (RBE) 4.5Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.5Gy (RBE) 0.7Gy (RBE) 3.4Gy (RBE) 5.1Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 2.4Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.7Gy (RBE) 5.5Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.5Gy (RBE) 2.2Gy (RBE) 3.8Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 1.2Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.1Gy (RBE) 4.7Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.5Gy (RBE) 2.4Gy (RBE) 4.0Gy (RBE)
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 1.0Gy (RBE) 1.5Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 4.0Gy (RBE) 4.5Gy (RBE)
(d) RDBT
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Table A.32.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 3 when dose calcu-
lation was based on non-rigid registration. Interplay, lateral BT, BT and RDBT have
been used for Tables A.33a, A.33b, A.33c, and A.33d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.4Gy (RBE) 5.7Gy (RBE)
esophagus 3.3Gy (RBE) 3.3Gy (RBE) 12.1Gy (RBE) 13.0Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.4Gy (RBE) 5.7Gy (RBE)
esophagus 3.3Gy (RBE) 3.4Gy (RBE) 12.1Gy (RBE) 12.9Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.3Gy (RBE) 4.8Gy (RBE)
esophagus 3.3Gy (RBE) 3.3Gy (RBE) 11.6Gy (RBE) 12.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 4.2Gy (RBE) 5.0Gy (RBE)
esophagus 3.2Gy (RBE) 3.3Gy (RBE) 11.4Gy (RBE) 11.9Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.33.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 4 when dose calcu-
lation was based on non-rigid registration. Interplay, lateral BT, BT and RDBT have
been used for Tables A.34a, A.34b, A.34c, and A.34d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.2Gy (RBE) 0.2Gy (RBE) 5.8Gy (RBE) 8.1Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 5.5Gy (RBE) 8.3Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 5.0Gy (RBE) 6.5Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.3Gy (RBE) 0.3Gy (RBE) 5.3Gy (RBE) 6.8Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.1Gy (RBE) 0.1Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.34.:Minimum and maximum of the fraction mean dose as well as minimum and maxi-
mum of the maximal fraction dose for various OARs for patient 5 when dose calcu-
lation was based on non-rigid registration. Interplay, lateral BT, BT and RDBT have
been used for Tables A.35a, A.35b, A.35c, and A.35d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 2.6Gy (RBE) 5.6Gy (RBE)
esophagus 1.2Gy (RBE) 1.8Gy (RBE) 8.8Gy (RBE) 10.5Gy (RBE)
heart 2.1Gy (RBE) 2.2Gy (RBE) 10.2Gy (RBE) 12.9Gy (RBE)
carina 0.4Gy (RBE) 0.9Gy (RBE) 5.9Gy (RBE) 7.9Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.4Gy (RBE) 0.4Gy (RBE) 2.5Gy (RBE) 4.2Gy (RBE)
esophagus 1.0Gy (RBE) 1.2Gy (RBE) 8.0Gy (RBE) 11.5Gy (RBE)
heart 2.3Gy (RBE) 2.4Gy (RBE) 11.1Gy (RBE) 12.5Gy (RBE)
carina 0.0Gy (RBE) 0.1Gy (RBE) 1.0Gy (RBE) 4.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.3Gy (RBE) 0.4Gy (RBE) 1.9Gy (RBE) 2.8Gy (RBE)
esophagus 0.9Gy (RBE) 1.0Gy (RBE) 7.2Gy (RBE) 9.4Gy (RBE)
heart 2.3Gy (RBE) 2.3Gy (RBE) 10.7Gy (RBE) 12.1Gy (RBE)
carina 0.0Gy (RBE) 0.1Gy (RBE) 1.1Gy (RBE) 3.7Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.3Gy (RBE) 0.4Gy (RBE) 2.0Gy (RBE) 2.9Gy (RBE)
esophagus 0.9Gy (RBE) 1.1Gy (RBE) 7.4Gy (RBE) 9.8Gy (RBE)
heart 2.2Gy (RBE) 2.3Gy (RBE) 10.6Gy (RBE) 12.4Gy (RBE)
carina 0.0Gy (RBE) 0.1Gy (RBE) 0.9Gy (RBE) 3.7Gy (RBE)
(d) RDBT
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Table A.35.:Minimum and maximum of the mean as well as the maximum total OAR doses
for patient 1 with rigid registration based dose calculation. Results for the total
treatment course are shown here.
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 19.7Gy (RBE) 20.3Gy (RBE) 29.9Gy (RBE) 33.6Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.2Gy (RBE) 5.3Gy (RBE)
esophagus 7.7Gy (RBE) 7.8Gy (RBE) 29.8Gy (RBE) 33.2Gy (RBE)
heart 2.5Gy (RBE) 2.5Gy (RBE) 28.2Gy (RBE) 31.2Gy (RBE)
vertebral bodies 3.9Gy (RBE) 4.0Gy (RBE) 25.9Gy (RBE) 28.7Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.3Gy (RBE) 20.6Gy (RBE) 30.2Gy (RBE) 33.8Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.1Gy (RBE) 5.4Gy (RBE)
esophagus 7.6Gy (RBE) 7.6Gy (RBE) 29.4Gy (RBE) 32.0Gy (RBE)
heart 2.7Gy (RBE) 2.7Gy (RBE) 28.7Gy (RBE) 31.7Gy (RBE)
vertebral bodies 4.0Gy (RBE) 4.0Gy (RBE) 26.2Gy (RBE) 29.3Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.6Gy (RBE) 20.7Gy (RBE) 30.8Gy (RBE) 33.6Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 3.9Gy (RBE) 4.8Gy (RBE)
esophagus 7.6Gy (RBE) 7.6Gy (RBE) 29.6Gy (RBE) 31.6Gy (RBE)
heart 2.7Gy (RBE) 2.7Gy (RBE) 28.2Gy (RBE) 29.7Gy (RBE)
vertebral bodies 3.9Gy (RBE) 3.9Gy (RBE) 26.5Gy (RBE) 27.6Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.2Gy (RBE) 20.3Gy (RBE) 29.4Gy (RBE) 32.0Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.0Gy (RBE) 5.1Gy (RBE)
esophagus 7.6Gy (RBE) 7.7Gy (RBE) 28.6Gy (RBE) 31.3Gy (RBE)
heart 2.6Gy (RBE) 2.7Gy (RBE) 27.6Gy (RBE) 29.3Gy (RBE)
vertebral bodies 4.1Gy (RBE) 4.1Gy (RBE) 26.6Gy (RBE) 28.3Gy (RBE)
(d) RDBT
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Table A.36.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 2 when dose cal-
culation was based on rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for
Tables A.37a, A.37b, A.37c, and A.37d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.5Gy (RBE) 1.8Gy (RBE) 8.1Gy (RBE) 10.2Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.8Gy (RBE) 3.6Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 8.2Gy (RBE) 10.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.5Gy (RBE) 1.8Gy (RBE) 8.3Gy (RBE) 10.4Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.8Gy (RBE) 2.8Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 9.4Gy (RBE) 11.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.2Gy (RBE) 1.3Gy (RBE) 6.5Gy (RBE) 7.9Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.6Gy (RBE) 2.6Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 9.1Gy (RBE) 10.3Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.3Gy (RBE) 1.3Gy (RBE) 6.8Gy (RBE) 8.0Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.6Gy (RBE) 2.7Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 9.1Gy (RBE) 10.1Gy (RBE)
(d) RDBT
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Table A.37.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 3 when dose cal-
culation was based on rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for
Tables A.38a, A.38b, A.38c, and A.38d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 9.2Gy (RBE) 10.8Gy (RBE)
esophagus 8.2Gy (RBE) 8.3Gy (RBE) 30.9Gy (RBE) 34.0Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 9.3Gy (RBE) 10.9Gy (RBE)
esophagus 8.3Gy (RBE) 8.4Gy (RBE) 31.1Gy (RBE) 34.0Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.9Gy (RBE) 0.9Gy (RBE) 9.4Gy (RBE) 9.9Gy (RBE)
esophagus 8.1Gy (RBE) 8.1Gy (RBE) 30.7Gy (RBE) 32.2Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.9Gy (RBE) 0.9Gy (RBE) 9.3Gy (RBE) 10.2Gy (RBE)
esophagus 8.1Gy (RBE) 8.1Gy (RBE) 30.2Gy (RBE) 32.2Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.38.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 4 when dose cal-
culation was based on rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for
Tables A.39a, A.39b, A.39c, and A.39d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 11.0Gy (RBE) 14.2Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.5Gy (RBE) 0.5Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 11.1Gy (RBE) 13.7Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.4Gy (RBE) 0.5Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 10.2Gy (RBE) 11.4Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.4Gy (RBE) 0.4Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 10.5Gy (RBE) 12.2Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.4Gy (RBE) 0.5Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.39.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 5 when dose cal-
culation was based on rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for
Tables A.40a, A.40b, A.40c, and A.40d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.1Gy (RBE) 1.2Gy (RBE) 6.9Gy (RBE) 11.5Gy (RBE)
esophagus 3.4Gy (RBE) 3.9Gy (RBE) 19.8Gy (RBE) 25.5Gy (RBE)
heart 5.0Gy (RBE) 5.3Gy (RBE) 26.8Gy (RBE) 33.1Gy (RBE)
carina 2.5Gy (RBE) 3.5Gy (RBE) 17.7Gy (RBE) 23.3Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.1Gy (RBE) 6.4Gy (RBE) 7.7Gy (RBE)
esophagus 2.7Gy (RBE) 3.0Gy (RBE) 18.5Gy (RBE) 23.9Gy (RBE)
heart 5.9Gy (RBE) 6.0Gy (RBE) 28.8Gy (RBE) 33.2Gy (RBE)
carina 0.5Gy (RBE) 0.6Gy (RBE) 10.1Gy (RBE) 12.1Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.9Gy (RBE) 1.0Gy (RBE) 5.4Gy (RBE) 6.2Gy (RBE)
esophagus 2.4Gy (RBE) 2.4Gy (RBE) 17.4Gy (RBE) 18.9Gy (RBE)
heart 5.8Gy (RBE) 5.8Gy (RBE) 29.1Gy (RBE) 30.3Gy (RBE)
carina 0.4Gy (RBE) 0.4Gy (RBE) 8.3Gy (RBE) 10.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 5.7Gy (RBE) 6.8Gy (RBE)
esophagus 2.5Gy (RBE) 2.5Gy (RBE) 17.9Gy (RBE) 19.9Gy (RBE)
heart 5.7Gy (RBE) 5.7Gy (RBE) 28.2Gy (RBE) 29.6Gy (RBE)
carina 0.4Gy (RBE) 0.4Gy (RBE) 8.5Gy (RBE) 9.8Gy (RBE)
(d) RDBT
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Table A.40.:Minimum and maximum of the mean as well as the maximum total dose for vari-
ous OARs for patient 1 when dose calculation was based on non-rigid registration.
Results for the complete treatment course are shown here.
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 19.7Gy (RBE) 20.3Gy (RBE) 29.9Gy (RBE) 33.6Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.2Gy (RBE) 5.3Gy (RBE)
esophagus 7.7Gy (RBE) 7.8Gy (RBE) 29.8Gy (RBE) 33.2Gy (RBE)
heart 2.5Gy (RBE) 2.5Gy (RBE) 28.2Gy (RBE) 31.2Gy (RBE)
vertebral bodies 3.9Gy (RBE) 4.0Gy (RBE) 25.9Gy (RBE) 28.7Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.3Gy (RBE) 20.6Gy (RBE) 30.2Gy (RBE) 33.8Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.1Gy (RBE) 5.4Gy (RBE)
esophagus 7.6Gy (RBE) 7.6Gy (RBE) 29.4Gy (RBE) 32.0Gy (RBE)
heart 2.7Gy (RBE) 2.7Gy (RBE) 28.7Gy (RBE) 31.7Gy (RBE)
vertebral bodies 4.0Gy (RBE) 4.0Gy (RBE) 26.2Gy (RBE) 29.3Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.6Gy (RBE) 20.7Gy (RBE) 30.8Gy (RBE) 33.6Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 3.9Gy (RBE) 4.8Gy (RBE)
esophagus 7.6Gy (RBE) 7.6Gy (RBE) 29.6Gy (RBE) 31.6Gy (RBE)
heart 2.7Gy (RBE) 2.7Gy (RBE) 28.2Gy (RBE) 29.7Gy (RBE)
vertebral bodies 3.9Gy (RBE) 3.9Gy (RBE) 26.5Gy (RBE) 27.6Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
carina 20.2Gy (RBE) 20.3Gy (RBE) 29.4Gy (RBE) 32.0Gy (RBE)
spinal cord 0.6Gy (RBE) 0.6Gy (RBE) 4.0Gy (RBE) 5.1Gy (RBE)
esophagus 7.6Gy (RBE) 7.7Gy (RBE) 28.6Gy (RBE) 31.3Gy (RBE)
heart 2.6Gy (RBE) 2.7Gy (RBE) 27.6Gy (RBE) 29.3Gy (RBE)
vertebral bodies 4.1Gy (RBE) 4.1Gy (RBE) 26.6Gy (RBE) 28.3Gy (RBE)
(d) RDBT
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Table A.41.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 2 when dose cal-
culation was based on non-rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for Ta-
bles A.42a, A.42b, A.42c, and A.42d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.4Gy (RBE) 1.5Gy (RBE) 7.6Gy (RBE) 9.3Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.8Gy (RBE) 4.0Gy (RBE)
heart 0.1Gy (RBE) 0.1Gy (RBE) 7.4Gy (RBE) 8.7Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.4Gy (RBE) 1.6Gy (RBE) 7.6Gy (RBE) 9.4Gy (RBE)
esophagus 0.6Gy (RBE) 0.7Gy (RBE) 2.8Gy (RBE) 4.2Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 9.0Gy (RBE) 10.5Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.2Gy (RBE) 1.2Gy (RBE) 5.0Gy (RBE) 7.5Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.5Gy (RBE) 2.7Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 8.3Gy (RBE) 9.3Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.2Gy (RBE) 1.2Gy (RBE) 5.1Gy (RBE) 7.6Gy (RBE)
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 2.5Gy (RBE) 2.9Gy (RBE)
heart 0.2Gy (RBE) 0.2Gy (RBE) 8.4Gy (RBE) 9.2Gy (RBE)
(d) RDBT
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Table A.42.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 3 when dose cal-
culation was based on non-rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for Ta-
bles A.43a, A.43b, A.43c, and A.43d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 9.2Gy (RBE) 10.9Gy (RBE)
esophagus 8.3Gy (RBE) 8.4Gy (RBE) 30.9Gy (RBE) 33.6Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 9.3Gy (RBE) 10.9Gy (RBE)
esophagus 8.3Gy (RBE) 8.4Gy (RBE) 31.0Gy (RBE) 33.6Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.9Gy (RBE) 1.0Gy (RBE) 9.2Gy (RBE) 9.9Gy (RBE)
esophagus 8.2Gy (RBE) 8.2Gy (RBE) 30.7Gy (RBE) 32.6Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 0.9Gy (RBE) 1.0Gy (RBE) 9.1Gy (RBE) 10.2Gy (RBE)
esophagus 8.1Gy (RBE) 8.2Gy (RBE) 30.1Gy (RBE) 32.5Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
carina 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.43.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 4 when dose cal-
culation was based on non-rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for Ta-
bles A.44a, A.44b, A.44c, and A.44d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.6Gy (RBE) 0.6Gy (RBE) 10.5Gy (RBE) 14.0Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.4Gy (RBE) 0.4Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 10.9Gy (RBE) 14.9Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.3Gy (RBE) 0.3Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 9.9Gy (RBE) 12.6Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.3Gy (RBE) 0.3Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
esophagus 0.7Gy (RBE) 0.7Gy (RBE) 10.3Gy (RBE) 13.8Gy (RBE)
spinal cord 0.0Gy (RBE) 0.0Gy (RBE) 0.2Gy (RBE) 0.3Gy (RBE)
heart 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE) 0.0Gy (RBE)
(d) RDBT
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Table A.44.:Minimum and maximum of the total mean dose as well as minimum and maxi-
mum of the maximal total dose for various OARs for patient 5 when dose cal-
culation was based on non-rigid registration. Results for the complete treatment
course are shown here. Interplay, lateral BT, BT and RDBT have been used for Ta-
bles A.45a, A.45b, A.45c, and A.45d, respectively.
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.1Gy (RBE) 7.6Gy (RBE) 11.4Gy (RBE)
esophagus 3.1Gy (RBE) 3.7Gy (RBE) 19.9Gy (RBE) 23.5Gy (RBE)
heart 5.1Gy (RBE) 5.3Gy (RBE) 27.0Gy (RBE) 32.6Gy (RBE)
carina 1.2Gy (RBE) 1.8Gy (RBE) 14.9Gy (RBE) 18.1Gy (RBE)
(a) Interplay
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.1Gy (RBE) 5.8Gy (RBE) 7.8Gy (RBE)
esophagus 2.5Gy (RBE) 2.7Gy (RBE) 17.3Gy (RBE) 23.9Gy (RBE)
heart 5.7Gy (RBE) 5.7Gy (RBE) 28.7Gy (RBE) 32.8Gy (RBE)
carina 0.2Gy (RBE) 0.3Gy (RBE) 4.8Gy (RBE) 7.9Gy (RBE)
(b) lateral BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 4.7Gy (RBE) 5.6Gy (RBE)
esophagus 2.2Gy (RBE) 2.3Gy (RBE) 16.1Gy (RBE) 21.0Gy (RBE)
heart 5.5Gy (RBE) 5.5Gy (RBE) 28.6Gy (RBE) 30.7Gy (RBE)
carina 0.2Gy (RBE) 0.3Gy (RBE) 4.4Gy (RBE) 7.4Gy (RBE)
(c) BT
OAR mean dose|min mean dose|max max dose|min max dose|max
spinal cord 1.0Gy (RBE) 1.0Gy (RBE) 5.1Gy (RBE) 6.2Gy (RBE)
esophagus 2.3Gy (RBE) 2.4Gy (RBE) 16.8Gy (RBE) 22.2Gy (RBE)
heart 5.4Gy (RBE) 5.4Gy (RBE) 27.6Gy (RBE) 31.2Gy (RBE)
carina 0.2Gy (RBE) 0.3Gy (RBE) 4.4Gy (RBE) 7.0Gy (RBE)
(d) RDBT
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